


**CUMULATIVE
SUPPLEMENT 6
JUNE 2022**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2022

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**Cumulative Supplement 6
June 2022**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**CUMULATIVE SUPPLEMENT 6
JUNE 2022**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
DAIICHI SANKYO INC (DAIICHI SANKYO)	COSETTE PHARMACEUTICALS INC (COSETTE PHARMS)
DAIICHI SANKYO INC (DAIICHI SANKYO INC)	COSETTE PHARMACEUTICALS INC (COSETTE PHARMS)
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)
LANNETT CO INC (LANNETT)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)

LANNETT CO INC (LANNETT CO INC)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
MERCK AND CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK AND CO INC (MERCK AND CO INC)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK RESEARCH LABORATORIES DIV MERCK CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP (MERCK SHARP DOHME)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC (MSD MERCK CO)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
SANDOZ INC (SANDOZ)	EPIC PHARMA INC (EPIC PHARMA)
TELIGENT OU (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
TELIGENT PHARMA INC (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter,

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2021</u>	<u>MAR</u> <u>2022</u>	<u>JUN</u> <u>2022</u>	<u>SEP</u> <u>2022</u>	<u>DEC</u> <u>2022</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	21133 2701 (12.8%)	21339 2716 (12.7%)	21640 2748 (12.7%)		
MULTISOURCE	18432 (87.2%)	18623 (87.3%)	18892 (87.3%)		
THERAPEUTICALLY EQUIVALENT	18298 (86.6%)	18493 (86.7%)	18762 (86.7%)		
NOT THERAPEUTICALLY EQUIVALENT	134 (0.6%)	130 (0.6%)	130 (.6%)		
EXCEPTIONS ⁴	54 (0.3%)	53 (0.2%)	53 (.2%)		
NEW MOLECULAR ENTITIES APPROVED	13	11	23		
NUMBER OF APPLICANTS	1190	1204	1219		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET, FOR SUSPENSION;ORAL
TRIUMEQ PD

+! VIIV HLTHCARE EQ 60MG BASE;EQ 5MG BASE;30MG N215413 001 Mar 30, 2022 Mar NEWA

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL
ABACAVIR SULFATE AND LAMIVUDINE

>D> AB AUROBINDO PHARMA LTD EQ 600MG BASE;300MG A206151 001 Mar 28, 2017 Jun DISC
>A> @ EQ 600MG BASE;300MG A206151 001 Mar 28, 2017 Jun DISC

ABIRATERONE ACETATE

TABLET;ORAL
ABIRATERONE ACETATE

AB GLENMARK PHARMS 500MG A209227 002 May 19, 2022 May NEWA
>A> AB TEVA PHARMS USA 125MG A212206 001 Jun 24, 2022 Jun NFTG
YONSA
>D> +! SUN PHARM 125MG N210308 001 May 22, 2018 Jun CFTG
>A> AB +! 125MG N210308 001 May 22, 2018 Jun CFTG
+! 125MG N210308 001 May 22, 2018 Feb CAHN

ABROCITINIB

TABLET;ORAL
CIBINQO

+ PFIZER 50MG N213871 001 Jan 14, 2022 Jan NEWA
+ 100MG N213871 002 Jan 14, 2022 Jan NEWA
+! 200MG N213871 003 Jan 14, 2022 Jan NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE

! AMNEAL PHARM EQ 200MG BASE A075047 001 Dec 30, 1999 Apr CTEC
! EQ 400MG BASE A075047 002 Dec 30, 1999 Apr CTEC
@ MYLAN EQ 200MG BASE A074288 001 Apr 24, 1995 Apr DISC
AB EQ 200MG BASE A074288 001 Apr 24, 1995 Apr CAHN
@ EQ 400MG BASE A074288 002 Apr 24, 1995 Apr DISC
AB EQ 400MG BASE A074288 002 Apr 24, 1995 Apr CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS
ACETAMINOPHEN

>A> +! HIKMA 1GM/100ML (10MG/ML) N206968 001 Jun 03, 2022 Jun CAHN
AP ! SANDOZ INC 1GM/100ML (10MG/ML) A204052 001 Mar 22, 2016 Feb CHRS
OFIRMEV
+ @ MALLINCKRODT HOSP 1GM/100ML (10MG/ML) N022450 001 Nov 02, 2010 Feb DISC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL
ALLZITAL

AA ! LARKEN LABS INC 325MG;25MG A203484 001 Dec 04, 2015 Apr CTEC
BUTALBITAL AND ACETAMINOPHEN
>D> AA HAVIX 300MG;50MG A214088 001 Apr 07, 2022 Jun CAHN
AA 300MG;50MG A214088 001 Apr 07, 2022 Apr NEWA
>D> AA 325MG;25MG A214088 002 Apr 07, 2022 Jun CAHN
AA 325MG;25MG A214088 002 Apr 07, 2022 Apr NEWA
>D> AA 325MG;50MG A214088 003 Apr 07, 2022 Jun CAHN
AA 325MG;50MG A214088 003 Apr 07, 2022 Apr NEWA
>A> AA SENORES PHARMS 300MG;50MG A214088 001 Apr 07, 2022 Jun CAHN
>A> AA 325MG;25MG A214088 002 Apr 07, 2022 Jun CAHN
>A> AA 325MG;50MG A214088 003 Apr 07, 2022 Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA HIKMA 300MG;50MG;40MG A215135 001 Mar 25, 2022 Mar NEWA
AA 325MG;50MG;40MG A215135 002 Mar 25, 2022 Mar NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB	HIKMA	300MG; 50MG; 40MG; 30MG	A 215138	002	Jan 26, 2022	Jan	NEWA
AB		325MG; 50MG; 40MG; 30MG	A 215138	001	Jan 26, 2022	Jan	NEWA
AB	LGM PHARMA	300MG; 50MG; 40MG; 30MG	A 076560	002	Jul 19, 2012	Jan	CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	CHARTWELL	120MG/5ML; 12MG/5ML	A 089450	001	Oct 27, 1992	Apr	CAHN
AA	MIKART	120MG/5ML; 12MG/5ML	A 089450	001	Oct 27, 1992	Mar	CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ CHARTWELL

300MG; 15MG

A 089997 001 Dec 28, 1994 Feb CAHN

@

300MG; 30MG

A 089998 001 Dec 28, 1994 Feb CAHN

@

300MG; 60MG

A 089999 001 Dec 28, 1994 Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	!	CHARTWELL	325MG/15ML; 7.5MG/15ML	A 040482	001	Sep 25, 2003	Apr	CAHN
	!	MIKART	300MG/15ML; 10MG/15ML	A 040881	001	Feb 25, 2010	Apr	CTEC
AA	!		325MG/15ML; 7.5MG/15ML	A 040482	001	Sep 25, 2003	Mar	CAHN
	@	TRIS PHARMA INC	300MG/15ML; 10MG/15ML	A 201295	002	Dec 30, 2021	Apr	DISC
	@		325MG/15ML; 7.5MG/15ML	A 201295	001	Dec 30, 2021	Apr	DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ANDA REPOSITORY

325MG; 2.5MG

A 040846 001 Jun 09, 2010 May DISC

! ASCENT PHARMS INC

325MG; 2.5MG

A 211487 001 Nov 07, 2018 May CHRS

325MG; 2.5MG

A 211487 001 Nov 07, 2018 May CTEC

AA	!	CHARTWELL	300MG; 5MG	A 040658	001	Jan 19, 2006	Apr	CAHN
AA	!		300MG; 7.5MG	A 040658	002	Mar 24, 2006	Apr	CAHN
AA	!		300MG; 10MG	A 040658	003	Jun 23, 2004	Apr	CAHN
	@		325MG; 7.5MG	A 040248	001	Apr 28, 2000	Feb	CAHN
AA			325MG; 7.5MG	A 040432	001	Jan 22, 2003	Apr	CAHN
	@		325MG; 10MG	A 040248	002	Apr 28, 2000	Feb	CAHN
AA		MIKART	325MG; 7.5MG	A 040432	001	Jan 22, 2003	Mar	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

MIKART

300MG/5ML; 10MG/5ML

A 202142 001 Nov 27, 2018 Mar CAHN

TABLET; ORAL

OXYCODONE 5/APAP 500

>D>	+	@	BRISTOL MYERS SQUIBB	500MG; 5MG	A 085911	001		Jun	CRLD
>A>		@		500MG; 5MG	A 085911	001		Jun	CRLD

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

AB	!	CADILA	500MG	A 205301	001	Jan 16, 2019	May	CHRS
	@	INDICUS PHARMA	500MG	A 090779	001	Jul 14, 2011	May	DISC

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

>D>	AT	!	WOCKHARDT BIO AG	2%	A 040166	001	Jul 26, 1996	Jun	DISC
>A>		@		2%	A 040166	001	Jul 26, 1996	Jun	DISC
			VOSOL						
>D>	AT		AKORN	2%	N 012179	001		Jun	CHRS
>A>	AT	!		2%	N 012179	001		Jun	CHRS

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP		ASPEN	6GM/30ML (200MG/ML)	A 213693	001	Feb 03, 2022	Jan	NEWA
	@	EXELA PHARMA	6GM/30ML (200MG/ML)	A 204797	001	Apr 15, 2021	Feb	DISC
AP		INDOCO	6GM/30ML (200MG/ML)	A 215620	001	Feb 23, 2022	Feb	NEWA

ACOLIDINIUM BROMIDEPOWDER, METERED; INHALATION
TUDORZA PRESSAIR

+! COVIS 0.4MG/INH N202450 001 Jul 23, 2012 Apr CAHN

ACOLIDINIUM BROMIDE; FORMOTEROL FUMARATEPOWDER, METERED; INHALATION
DUAKLIR PRESSAIR

+! COVIS 0.4MG/INH; 0.012MG/INH N210595 001 Mar 29, 2019 Apr CAHN

ACYCLOVIROINTMENT; TOPICAL
ACYCLOVIR

@ PRINSTON INC 5% A212202 001 Nov 15, 2021 Mar DISC

SUSPENSION; ORAL
ACYCLOVIRAB AUROBINDO PHARMA LTD 200MG/5ML A216331 001 Mar 31, 2022 Mar NEWA
>A> AB HETERO LABS LTD III 200MG/5ML A215669 001 Jul 01, 2022 Jun NEWAACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUMAP AM INJECTABLES EQ 50MG BASE/ML A207919 001 Jun 17, 2020 Apr CAHN
@ CHARTWELL INJECTABLE EQ 500MG BASE/VIAL A074596 002 Apr 22, 1997 Mar CAHN
@ EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Mar CAHNADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

>A> AB ACTAVIS LABS UT INC 0.3%; 2.5% A209641 001 Jun 22, 2022 Jun NEWA
AB PADAGIS ISRAEL 0.3%; 2.5% A212464 001 May 31, 2022 May NEWA
AB ZYDUS PHARMS 0.3%; 2.5% A214553 001 Jun 03, 2022 May NEWA
AT 0.3%; 2.5% A214553 001 Jun 03, 2022 May NEWAALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

>D> AB DR REDDYS 200MG A211034 001 Jan 26, 2021 Jun CHRS
>A> AB ! 200MG A211034 001 Jan 26, 2021 Jun CHRS
ALBENZA
>D> AB +! IMPAX LABS INC 200MG N020666 001 Jun 11, 1996 Jun DISC
>A> + @ 200MG N020666 001 Jun 11, 1996 Jun DISCALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>A> @ BAUSCH EQ 0.083% BASE A075358 001 Mar 29, 2000 Jun CAHN
>A> @ EQ 0.5% BASE A075050 001 Jun 18, 1998 Jun CAHN
>D> @ BAUSCH AND LOMB EQ 0.083% BASE A075358 001 Mar 29, 2000 Jun CAHN
>D> @ EQ 0.5% BASE A075050 001 Jun 18, 1998 Jun CAHN

SYRUP; ORAL

ALBUTEROL SULFATE

AA CHARTWELL RX EQ 2MG BASE/5ML A077788 001 Jun 26, 2007 May CMFD

TABLET; ORAL

ALBUTEROL SULFATE

@ CHARTWELL RX EQ 4MG BASE A072151 002 Dec 05, 1989 Feb CMS1

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

@ ATLANTIDE 10MG A090221 001 Aug 10, 2012 Apr CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTRUNA HCT

+ @ NODEN PHARMA EQ 300MG BASE; 12.5MG N022107 003 Jan 18, 2008 May DISC
+ @ EQ 300MG BASE; 25MG N022107 004 Jan 18, 2008 May DISC

ALLOPURINOL

		INJECTABLE; INJECTION							
		ALLOPURINOL							
AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Jan	NEWA	
		TABLET; ORAL							
		ALLOPURINOL							
AB	!	ACCORD HLTHCARE	300MG	A203154	002	May 06, 2013	Apr	CHRS	
AB		HARMAN FINOCHEM	100MG	A214443	001	Mar 07, 2022	Feb	NEWA	
AB			300MG	A214443	002	Mar 07, 2022	Feb	NEWA	
		ZYLOPRIM							
AB	+	CASPER PHARMA LLC	300MG	N016084	002		Apr	CHRS	

ALLOPURINOL SODIUM

		INJECTABLE; INJECTION							
		ALLOPRIM							
AP	+!	MYLAN	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Apr	CAHN	

ALLOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

		TABLET; ORAL							
		OSENİ							
	+	@ TAKEDA PHARMS USA	EQ 12.5MG BASE; EQ 15MG BASE	N022426	004	Jan 25, 2013	Mar	DISC	
	+	@	EQ 12.5MG BASE; EQ 45MG BASE	N022426	006	Jan 25, 2013	Mar	DISC	

ALOSETRON HYDROCHLORIDE

		TABLET; ORAL							
		ALOSETRON HYDROCHLORIDE							
	@	PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Apr	DISC	
	@		EQ 1MG BASE	A206113	002	Feb 23, 2018	Apr	DISC	

ALPELISIB

		TABLET; ORAL							
		VIJOICE							
	+	NOVARTIS	50MG	N215039	001	Apr 05, 2022	Apr	NEWA	
	+		125MG	N215039	002	Apr 05, 2022	Apr	NEWA	
	+!		200MG	N215039	003	Apr 05, 2022	Apr	NEWA	

AMANTADINE HYDROCHLORIDE

		CAPSULE; ORAL							
		AMANTADINE HYDROCHLORIDE							
AB		STRIDES PHARMA	100MG	A211354	001	Feb 18, 2022	Feb	NEWA	
		SYRUP; ORAL							
		AMANTADINE HYDROCHLORIDE							
AA	!	CHARTWELL RX	50MG/5ML	A074028	001	Jun 28, 1993	Mar	CAHN	
		TABLET; ORAL							
		AMANTADINE HYDROCHLORIDE							
AB		EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022	May	NEWA	
	@	JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	May	DISC	

AMBRISENTAN

		TABLET; ORAL							
		AMBRISENTAN							
AB		APOTEX	5MG	A210701	001	May 19, 2022	May	NEWA	
AB			10MG	A210701	002	May 19, 2022	May	NEWA	

AMIFOSTINE

		INJECTABLE; INJECTION							
		AMIFOSTINE							
	@	EUGIA PHARMA SPECLTS	500MG/VIAL	A204363	001	Jul 17, 2017	Mar	CAHN	

AMILORIDE HYDROCHLORIDE

		TABLET; ORAL							
		AMILORIDE HYDROCHLORIDE							
	@	USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	May	DISC	

AMINO ACIDS

		INJECTABLE; INJECTION							
		NEPHRAMINE 5.4%							
	@	B BRAUN	5.4% (5.4GM/100ML)	N017766	001		Mar	DISC	

AMINOCAPROIC ACID

SOLUTION;ORAL

AMINOCAPROIC ACID

AA	AGENIX	0.25GM/ML	A215510	001	Mar 23, 2022	Mar	NEWA
>A>	AA	CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Jun CAHN
>D>	AA	LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26, 2021	Jun CAHN

TABLET;ORAL

AMINOCAPROIC ACID

>A>	AB	CARNEGIE	500MG	A213928	001	Feb 12, 2021	Jun CAHN
>A>	AB		1GM	A213928	002	Feb 12, 2021	Jun CAHN
>D>	AB	LEADING PHARMA LLC	500MG	A213928	001	Feb 12, 2021	Jun CAHN
>D>	AB		1GM	A213928	002	Feb 12, 2021	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	May	NEWA
AB		25MG	A216243	002	Jun 06, 2022	May	NEWA
AB		50MG	A216243	003	Jun 06, 2022	May	NEWA
AB		75MG	A216243	004	Jun 06, 2022	May	NEWA
AB		100MG	A216243	005	Jun 06, 2022	May	NEWA
AB		150MG	A216243	006	Jun 06, 2022	May	NEWA
	@ UPSHER SMITH LABS	10MG	A212654	002	Sep 29, 2021	May	DISC
	@	25MG	A212654	001	Apr 07, 2020	May	DISC
	@	50MG	A212654	003	Sep 29, 2021	May	DISC
	@	75MG	A212654	004	Sep 29, 2021	May	DISC
	@	100MG	A212654	005	Sep 29, 2021	May	DISC
	@	150MG	A212654	006	Sep 29, 2021	May	DISC
>D>	AB	VINTAGE PHARMS	10MG	A040218	001	Sep 11, 1997	Jun DISC
>A>	@		10MG	A040218	001	Sep 11, 1997	Jun DISC
>D>	AB		25MG	A040218	002	Sep 11, 1997	Jun DISC
>A>	@		25MG	A040218	002	Sep 11, 1997	Jun DISC
>D>	AB		50MG	A040218	003	Sep 11, 1997	Jun DISC
>A>	@		50MG	A040218	003	Sep 11, 1997	Jun DISC
>D>	AB		75MG	A040218	004	Sep 11, 1997	Jun DISC
>A>	@		75MG	A040218	004	Sep 11, 1997	Jun DISC
>D>	AB		100MG	A040218	005	Sep 11, 1997	Jun DISC
>A>	@		100MG	A040218	005	Sep 11, 1997	Jun DISC
>D>	AB		150MG	A040218	006	Sep 11, 1997	Jun DISC
>A>	@		150MG	A040218	006	Sep 11, 1997	Jun DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Jan	NEWA
AB		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Jan	NEWA
AB	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Jan	CTEC
AB	!	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Jan	CTEC
	@ UNITED RES LABS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Apr	CAHN
	@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Apr	CAHN

AMLODIPINE BESYLATE

SOLUTION;ORAL

NORLIQVA

+!	CMP DEV LLC	EQ 1MG BASE/ML	N214439	001	Feb 24, 2022	Feb	NEWA
----	-------------	----------------	---------	-----	--------------	-----	------

TABLET;ORAL

AMLODIPINE BESYLATE

	@ CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan	CAHN
	@	EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan	CAHN
	@	EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan	CAHN
AB	TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Mar	CMFD
AB		EQ 5MG BASE	A076846	002	Jun 28, 2007	Mar	CMFD
AB		EQ 10MG BASE	A076846	003	Jun 28, 2007	Mar	CMFD
	NORVASC						
AB	+ VIATRIS	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jan	CAHN
AB	+	EQ 5MG BASE	N019787	002	Jul 31, 1992	Jan	CAHN
AB	+!	EQ 10MG BASE	N019787	003	Jul 31, 1992	Jan	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>D>	@	STRIDES PHARMA	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Jun	CMFD
>A>	AB		EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Jun	CMFD
>D>	@		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Jun	CMFD
>A>	AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Jun	CMFD
>D>	@		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Jun	CMFD
>A>	AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Jun	CMFD
>D>	@		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Jun	CMFD
>A>	AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Jun	CMFD
>D>	@		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Jun	CMFD
>A>	AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Jun	CMFD

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

@	TORRENT	EQ 5MG BASE;40MG	A202517	001	Jan 08, 2014	Mar	DISC
@		EQ 5MG BASE;80MG	A202517	003	Jan 08, 2014	Mar	DISC
@		EQ 10MG BASE;40MG	A202517	002	Jan 08, 2014	Mar	DISC
@		EQ 10MG BASE;80MG	A202517	004	Jan 08, 2014	Mar	DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>D>	@	STRIDES PHARMA	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun	CMFD
>A>	AB		EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun	CMFD
>D>	@		EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun	CMFD
>A>	AB		EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun	CMFD
>D>	@		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun	CMFD
>A>	AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun	CMFD
>D>	@		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun	CMFD
>A>	AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun	CMFD

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

>A>	AB	MICRO LABS	250MG	A207471	001	Jun 24, 2022	Jun	NEWA
>A>	AB		500MG	A207471	002	Jun 24, 2022	Jun	NEWA

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PACK

+	!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May	NEWA
+	!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May	CMS1

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEZNA DUAL PACK

+	!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May	NEWA
+	!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May	CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DETRIOAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	May	DISC
@		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	May	DISC
@		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	May	DISC
@		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	May	DISC
@		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	May	DISC
@		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	May	DISC
AB	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	NEWA
AB		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	NEWA
AB		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	NEWA

TABLET;ORAL

DETRIOAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jun	NEWA
-----	----	--------------	-----------------------------	---------	-----	--------------	-----	------

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jun NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jun NEWA
>A>	AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jun NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jun NEWA
	AB	ZYDUS PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Mar CAHN
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Mar CAHN
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Mar CAHN
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Mar CAHN
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Mar CAHN
	AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Mar CAHN
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Mar CAHN

AMPHETAMINE SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	@	AZURITY	2.5MG	N209905	005	Apr 16, 2021	Apr CAHN
+			5MG	N209905	001	Jan 30, 2019	Apr CAHN
+			10MG	N209905	002	Jan 30, 2019	Apr CAHN
+			15MG	N209905	003	Jan 30, 2019	Apr CAHN
+	!		20MG	N209905	004	Jan 30, 2019	Apr CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@	AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	May DISC
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	May DISC

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

AP	+	!	MDD US	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Feb CFTG
AP			SAGE CHEMS	30MG/3ML (10MG/ML)	A212025	001	Feb 23, 2022	Feb NFTG

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

IOPIDINE

>A>	AT	+	!	IMPRIMIS PHARMS USA	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Jun CAHN
>A>					EQ 1% BASE	N019779	001	Dec 31, 1987	Jun CAHN
>D>	AT	+	!	NOVARTIS	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Jun CAHN
>D>					EQ 1% BASE	N019779	001	Dec 31, 1987	Jun CAHN

APREMILAST

TABLET;ORAL

APREMILAST

@	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jan DISC
@		20MG	A211782	002	Jun 30, 2021	Jan DISC
@		30MG	A211782	003	Jun 30, 2021	Jan DISC

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN			ALEMBIC PHARMS LTD	EQ 0.015MG BASE/2ML	A214779	001	May 10, 2022	Apr NEWA
>D>	AN		GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021	Jun DISC
>A>		@		EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021	Jun DISC
AN			LUPIN	EQ 0.015MG BASE/2ML	A213068	001	Feb 07, 2022	Jan NEWA
AN			SUN PHARM	EQ 0.015MG BASE/2ML	A215385	001	May 26, 2022	May NEWA
AN			TAP	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Apr CAHN
AN			VISTAPHARM	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb NEWA

ARGATROBAN

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

+	@	CIPLA	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Apr CAHN
---	---	-------	--------------------	---------	-----	--------------	----------

ARSENIC TRIOXIDE

	INJECTABLE; INJECTION							
	ARSENIC TRIOXIDE							
AP	!	FRESENIUS KABI USA	1MG/ML	A208231	001	Aug 31, 2018	Apr	CHRS
AP		GLAND PHARMA LTD	1MG/ML	A215059	002	Apr 22, 2022	Apr	NEWA

ARTESUNATE

	POWDER; INTRAVENOUS							
	ARTESUNATE							
+	!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020	Feb	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

	FOR SOLUTION; INTRAVENOUS							
	M.V.I. PEDIATRIC							
+	@	HOSPIRA	80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL	N018920	001	Sep 21, 2000	Jan	DISC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

	INJECTABLE; INTRAVENOUS							
	M.V.I. ADULT							
+	@	HOSPIRA	200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL	N021625	001	Jan 30, 2004	Jan	DISC
	M.V.I. ADULT (PHARMACY BULK PACKAGE)							
+	@	HOSPIRA	200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML	N021643	001	Feb 18, 2004	Jan	DISC

ASENAPINE

	SYSTEM; TRANSDERMAL							
	SECUADO							
+	!	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019	Mar	CHRS
+			7.6MG/24HR	N212268	003	Oct 11, 2019	Mar	CHRS

ASPIRIN; BUTALBITAL; CAFFEINE

	CAPSULE; ORAL							
	BUTALBITAL, ASPIRIN AND CAFFEINE							
	@	LGM PHARMA	500MG; 50MG; 40MG	A205230	001	Oct 18, 2021	Apr	DISC
AA		NOSTRUM LABS INC	325MG; 50MG; 40MG	A078149	001	Jun 13, 2007	Apr	CMFD
>D>		FIORINAL						
>D>	AA	+	ALLERGAN	N017534	005	Apr 16, 1986	Jun	DISC
>A>		@		N017534	005	Apr 16, 1986	Jun	DISC
AA		+		N017534	005	Apr 16, 1986	Apr	CHRS
	LANORINAL							
AA	!	LANNETT	325MG; 50MG; 40MG	A086996	002	Oct 11, 1985	Apr	CHRS
	TABLET; ORAL							
	BUTALBITAL, ASPIRIN AND CAFFEINE							
+	@	HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162	002	Feb 16, 1984	Mar	CRLD

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

	CAPSULE; ORAL							
	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE							
	@	MAYNE PHARMA INC	325MG; 50MG; 40MG; 30MG	A203335	001	Oct 30, 2015	Jan	DISC
AB	!	STEVENS J	325MG; 50MG; 40MG; 30MG	A074951	001	Aug 31, 1998	May	CHRS
	FIORINAL W/CODEINE							
+	@	ALLERGAN	325MG; 50MG; 40MG; 30MG	N019429	003	Oct 26, 1990	May	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

GALT PHARMS

385MG;30MG;25MG

A075141 001 May 29, 1998 Mar CMFD

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB HETERO LABS LTD III

EQ 150MG BASE

A212278 001 Feb 02, 2022 Jan NEWA

AB EQ 200MG BASE

A212278 002 Feb 02, 2022 Jan NEWA

AB EQ 300MG BASE

A212278 003 Feb 02, 2022 Jan NEWA

REYATAZ

+ @ BRISTOL MYERS SQUIBB EQ 150MG BASE

N021567 002 Jun 20, 2003 Apr DISC

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPEN

+! MMT EQ 0.25MG SULFATE/0.3ML

N017106 004 Sep 17, 2004 May CAHN

+! EQ 0.5MG SULFATE/0.7ML

N017106 003 Jun 19, 2003 May CAHN

+! EQ 1MG SULFATE/0.7ML

N017106 002 Jun 19, 2003 May CAHN

+! EQ 2MG SULFATE/0.7ML

N017106 001 May CAHN

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP +! ACCORD HLTHCARE 0.4MG/ML (0.4MG/ML)

N214652 001 Sep 29, 2020 May CFTG

AP +! 1MG/ML (1MG/ML)

N214652 002 Sep 29, 2020 May CFTG

AP AM REGENT 0.4MG/ML (0.4MG/ML)

A216120 001 May 26, 2022 May NFTG

AP 1MG/ML (1MG/ML)

A216120 002 May 26, 2022 May NFTG

AP AMNEAL 0.5MG/5ML (0.1MG/ML)

A215342 001 Jan 26, 2022 Jan NEWA

AP +! HOSPIRA 0.5MG/5ML (0.1MG/ML)

N021146 001 Jul 09, 2001 Jan CMFD

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>A> AA CHARTWELL RX 0.025MG;2.5MG

A207128 001 Oct 21, 2020 Jun CAHN

@ MAYNE PHARMA INC 0.025MG;2.5MG

A210789 001 Jun 03, 2020 Jan DISC

>D> AA PHARMA LIFE 0.025MG;2.5MG

A207128 001 Oct 21, 2020 Jun CAHN

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+! MMT 2.1MG/0.7ML;600MG/2ML

N021983 001 Sep 28, 2006 Jan CAHN

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP AMNEAL 100MG/VIAL

A211549 001 Feb 03, 2022 Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

@ APOTEX INC 0.2055MG/SPRAY

A201846 001 Aug 31, 2012 May DISC

@ AUROBINDO PHARMA LTD 0.2055MG/SPRAY

A212775 001 Nov 12, 2020 May DISC

@ HIKMA 0.2055MG/SPRAY

A207243 001 Sep 22, 2017 May DISC

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

+ AZURITY EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Mar CAHN

+! EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Mar CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

+ AZURITY EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011 Mar CAHN

+! EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011 Mar CAHN

AZITHROMYCIN

SOLUTION/DROPS;OPHTHALMIC

AZASITE

+! THEA PHARMA 1% N050810 001 Apr 27, 2007 Apr CAHN

TABLET;ORAL

AZITHROMYCIN

AB ATLANTIDE EQ 250MG BASE A065404 001 Feb 11, 2008 Apr CAHN

AB EQ 500MG BASE A065405 001 Feb 11, 2008 Apr CAHN

AB EQ 600MG BASE A065302 003 Feb 11, 2008 Apr CAHN

BACLOFEN

GRANULES;ORAL

LYVISPAH

+ AMNEAL 5MG/PACKET N215422 001 Nov 22, 2021 Feb CAHN

+ 10MG/PACKET N215422 002 Nov 22, 2021 Feb CAHN

+! 20MG/PACKET N215422 003 Nov 22, 2021 Feb CAHN

INJECTABLE;INTRATHECAL

BACLOFEN

>A> AP AMNEAL 0.05MG/ML A091193 001 May 03, 2016 Jun CAHN

>A> AP 0.5MG/ML A091193 002 May 03, 2016 Jun CAHN

>A> AP 2MG/ML A091193 003 May 03, 2016 Jun CAHN

>D> AP EMERALD INTL LTD 0.05MG/ML A091193 001 May 03, 2016 Jun CAHN

>D> AP 0.5MG/ML A091193 002 May 03, 2016 Jun CAHN

>D> AP 2MG/ML A091193 003 May 03, 2016 Jun CAHN

LIORESAL

AP +! AMNEAL 0.05MG/ML N020075 003 Nov 07, 1996 Feb CAHN

AP +! 0.5MG/ML N020075 001 Jun 17, 1992 Feb CAHN

AP +! 2MG/ML N020075 002 Jun 17, 1992 Feb CAHN

SUSPENSION;ORAL

FLEQSUVY

+! AZURITY 25MG/5ML N215602 001 Feb 04, 2022 Feb NEWA

TABLET;ORAL

BACLOFEN

AB MANKIND PHARMA 5MG A215885 001 Jan 25, 2022 Jan NEWA

AB 10MG A215885 002 Jan 25, 2022 Jan NEWA

AB 20MG A215885 003 Jan 25, 2022 Jan NEWA

BARICITINIB

TABLET;ORAL

OLUMIANT

+ ELI LILLY AND CO 4MG N207924 003 May 10, 2022 May NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

LOTENSIN

>D> AB + VALIDUS PHARMS 5MG N019851 001 Jun 25, 1991 Jun DISC

>A> + @ 5MG N019851 001 Jun 25, 1991 Jun DISC

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA ACELLA 100MG A091310 001 Jan 16, 2015 Jan CAHN

AA 200MG A091310 002 Jan 16, 2015 Jan CAHN

@ MIKART 100MG A040851 001 Nov 09, 2009 May DISC

@ 150MG A040851 002 Nov 09, 2009 May DISC

@ 200MG A040851 003 Nov 09, 2009 May DISC

AA ! THEPHARMANETWORK LLC 100MG A040627 002 Mar 30, 2007 Jan CMS1

AA ! 150MG A040627 003 Sep 24, 2014 Jan CMS1

AA ! 200MG A040627 002 Jul 25, 2007 Mar CMS1

BENZOYL PEROXIDE

CREAM;TOPICAL

EPSOLAY

>A> +! GALDERMA LABS LP 5% N214510 001 Apr 22, 2022 Jun CAHN

>D> +! SOL GEL TECHNOLOGIES 5% N214510 001 Apr 22, 2022 Jun CAHN

+! 5% N214510 001 Apr 22, 2022 Apr NEWA

<u>BENZOYL PEROXIDE; TRETINOIN</u>								
CREAM; TOPICAL								
TWYNEO								
	+	!	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	Mar CMFD
	+	@		3%;0.1%	N214902	001	Jul 26, 2021	Feb CAHN
	+	@	SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021	Jan DISC
<u>BENZPHETAMINE HYDROCHLORIDE</u>								
TABLET; ORAL								
BENZPHETAMINE HYDROCHLORIDE								
			CHARTWELL	25MG	A090473	001	Sep 15, 2010	Apr CAHN
AA				50MG	A090473	002	Sep 15, 2010	Apr CAHN
			MIKART	25MG	A090473	001	Sep 15, 2010	Mar CAHN
AA				50MG	A090473	002	Sep 15, 2010	Mar CAHN
<u>BENZTROPINE MESYLATE</u>								
INJECTABLE; INJECTION								
BENZTROPINE MESYLATE								
AP	!		HIKMA FARMACEUTICA	1MG/ML	A090287	001	Aug 31, 2009	Mar CHRS
			COGENTIN					
	+	@	AKORN	1MG/ML	N012015	001		Mar DISC
<u>BETAINE</u>								
FOR SOLUTION; ORAL								
BETAINE								
AB			LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Jan NEWA
<u>BETAMETHASONE DIPROPIONATE</u>								
OINTMENT; TOPICAL								
BETAMETHASONE DIPROPIONATE								
AB			PADAGIS ISRAEL	EQ 0.05% BASE	A215847	001	Apr 12, 2022	Apr NEWA
AB			TASMAN PHARMA	EQ 0.05% BASE	A215186	001	Feb 18, 2022	Feb NEWA
<u>BEXAROTENE</u>								
GEL; TOPICAL								
BEXAROTENE								
AB			AMNEAL	1%	A215398	001	Apr 27, 2022	Apr NFTG
			TARGRETIN					
AB	+	!	BAUSCH	1%	N021056	001	Jun 28, 2000	Apr CFTG
<u>BISOPROLOL FUMARATE</u>								
TABLET; ORAL								
BISOPROLOL FUMARATE								
AB			UNITED RES LABS	5MG	A075474	001	Oct 25, 2002	Apr CAHN
AB				10MG	A075474	002	Oct 25, 2002	Apr CAHN
<u>BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE</u>								
TABLET; ORAL								
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE								
AB			GLENMARK PHARMS LTD	2.5MG; 6.25MG	A215995	001	Jan 26, 2022	Jan NEWA
AB				5MG; 6.25MG	A215995	002	Jan 26, 2022	Jan NEWA
AB				10MG; 6.25MG	A215995	003	Jan 26, 2022	Jan NEWA
<u>BIVALIRUDIN</u>								
INJECTABLE; INTRAVENOUS								
BIVALIRUDIN								
AP			MEITHEAL	250MG/VIAL	A091602	001	Jul 16, 2018	Apr CAHN
<u>BORTEZOMIB</u>								
INJECTABLE; INTRAVENOUS, SUBCUTANEOUS								
BORTEZOMIB								
AP			APOTEX	3.5MG/VIAL	A205533	001	May 02, 2022	Apr NFTG
AP			BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	Apr NFTG
AP			EUGIA PHARMA	3.5MG/VIAL	A212825	001	May 02, 2022	Apr NFTG
AP			FRESENIUS KABI USA	3.5MG/VIAL	A209659	001	May 02, 2022	Apr NFTG
AP			PHARMASCIENCE INC	3.5MG/VIAL	A208392	001	May 02, 2022	Apr NFTG
AP			QILU PHARM HAINAN	3.5MG/VIAL	A210824	001	May 02, 2022	Apr NFTG
AP			TEVA PHARMS USA	3.5MG/VIAL	A205857	001	May 02, 2022	Apr NFTG
AP			ZYDUS PHARMS	3.5MG/VIAL	A210204	001	May 02, 2022	Apr NFTG

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL
BUDESONIDE

@ NATCO 3MG A206724 001 Nov 23, 2016 Jan CAHN

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

AB MYLAN 0.08MG/INH;0.0045MG/INH A211699 001 Mar 15, 2022 Mar NFTG

AB 0.16MG/INH;0.0045MG/INH A211699 002 Mar 15, 2022 Mar NFTG

SYMBICORT

AB +! ASTRAZENECA 0.08MG/INH;0.0045MG/INH N021929 001 Jul 21, 2006 Mar CFTG

AB +! 0.16MG/INH;0.0045MG/INH N021929 002 Jul 21, 2006 Mar CFTG

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP ATHENEX INC 0.25MG/ML A074441 001 Jan 27, 1995 Feb CMFD

AP GLAND PHARMA LTD 0.25MG/ML A216434 001 May 26, 2022 May NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE; INFILTRATION

POSIMIR

+! DURECT 660MG/5ML (132MG/ML) N204803 001 Feb 01, 2021 May CMFD

+! INNOCOLL 660MG/5ML (132MG/ML) N204803 001 Feb 01, 2021 May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

@ CIVICA 0.5% A211096 001 Feb 19, 2019 Apr CAHN

@ NOVOCOL PHARM 0.5% A211096 001 Feb 19, 2019 Mar CAHN

@ STERISCIENCE 0.25% A091503 001 Oct 18, 2011 Feb CAHN

@ 0.5% A091503 002 Oct 18, 2011 Feb CAHN

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

@ STERISCIENCE 0.25% A091487 002 Oct 18, 2011 Feb CAHN

@ 0.5% A091487 001 Oct 18, 2011 Feb CAHN

@ 0.75% A091487 003 Oct 18, 2011 Feb CAHN

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE; PERIARTICULAR

ZYNRELEF KIT

+ @ HERON THERAPS INC 60MG/2.3ML N211988 001 May 12, 2021 Apr DISC

+ @ (29.25MG/ML); 1.8MG/2.3ML N211988 003 May 12, 2021 Apr DISC

+ @ 300MG/10.5ML N211988 003 May 12, 2021 Apr DISC

+ @ (29.25MG/ML); 9MG/10.5ML N211988 003 May 12, 2021 Apr DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

AB ALVOGEN 5MCG/HR A207490 001 May 17, 2022 May CAHN

AB 10MCG/HR A207490 002 May 17, 2022 May CAHN

AB 15MCG/HR A207490 003 May 17, 2022 May CAHN

AB 20MCG/HR A207490 004 May 17, 2022 May CAHN

AB ALVOGEN PINE BROOK 5MCG/HR A207490 001 May 17, 2022 May NEWA

AB 10MCG/HR A207490 002 May 17, 2022 May NEWA

AB 15MCG/HR A207490 003 May 17, 2022 May NEWA

AB 20MCG/HR A207490 004 May 17, 2022 May NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

+ BDSI EQ 0.075MG BASE N207932 001 Oct 23, 2015 Jan CTEC

+ EQ 0.15MG BASE N207932 002 Oct 23, 2015 Jan CTEC

+ EQ 0.3MG BASE N207932 003 Oct 23, 2015 Jan CTEC

+ EQ 0.45MG BASE N207932 004 Oct 23, 2015 Jan CTEC

+ EQ 0.6MG BASE N207932 005 Oct 23, 2015 Jan CTEC

+ EQ 0.75MG BASE N207932 006 Oct 23, 2015 Jan CTEC

+! EQ 0.9MG BASE N207932 007 Oct 23, 2015 Jan CTEC

BUPRENORPHINE HYDROCHLORIDE

@ ALVOGEN EQ 0.075MG BASE A211594 001 Aug 03, 2021 Jan DISC

@ EQ 0.15MG BASE A211594 002 Aug 03, 2021 Jan DISC

@ EQ 0.3MG BASE A211594 003 Aug 03, 2021 Jan DISC

FILM;BUCCAL

BUPRENORPHINE HYDROCHLORIDE

@		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jan DISC
@		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jan DISC
@		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jan DISC
@		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jan DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AVEVA	EQ 8MG BASE;EQ 2MG BASE	A212756	001	Jun 02, 2022	May NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A212756	002	Jun 02, 2022	May NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	GRANULES	150MG	A215568	001	Feb 02, 2022	Jan NEWA
AB3		300MG	A215568	002	Feb 02, 2022	Jan NEWA
AB3	WOCKHARDT LTD	300MG	A202189	002	Jan 28, 2022	Feb NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	!	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Feb CHRS
	@	MYLAN	7.5MG	A075467	002	Mar 28, 2001	Feb DISC
AB		TEVA	15MG	A075022	003	Feb 28, 2002	Feb CHRS

BUSULFAN

TABLET;ORAL

MYLERAN

	+!	WOODWARD SPECL	2MG	N009386	001		Apr CAHN
--	----	----------------	-----	---------	-----	--	----------

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

>A>	AP	BRECKENRIDGE	60MG/1.5ML (40MG/ML)	A207619	001	Jun 23, 2022	Jun NFTG
		JEVTANA KIT					
>D>	+	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jun CFTG
>A>	AP	+	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jun CFTG

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB		STRIDES PHARMA	0.5MG	A076310	001	Dec 29, 2005	Mar CMFD
----	--	----------------	-------	---------	-----	--------------	----------

CAFFEINE CITRATE

SOLUTION;ORAL

CAF CIT

	+ @	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan DISC
		CAFFEINE CITRATE					
AA	!	EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Jan CHRS

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

AP		FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;60	A210332	001	Mar 28, 2022	Mar NEWA
			0MG/100ML;310MG/100ML				
			POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER				
	@	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;179MG/100ML;6	A211428	001	Nov 09, 2021	Apr DISC
			00MG/100ML;310MG/100ML				

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		FRESENIUS KABI USA	17.6MG/100ML;325.3MG/100ML;119.3MG	A214623	001	Feb 18, 2022	Feb NEWA
			/100ML;643MG/100ML				

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	ATLANTIDE	12.5MG	A 074532	001	Mar 28, 1997	Mar CAHN
AB		25MG	A 074532	002	Mar 28, 1997	Mar CAHN
AB		50MG	A 074532	003	Mar 28, 1997	Mar CAHN
AB		100MG	A 074532	004	Mar 28, 1997	Mar CAHN

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

@ VGYAAN

200MG

A 214328 001 Aug 16, 2021 Feb DISC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	ZHEJIANG JIUZHOU	100MG	A 215591	001	Mar 31, 2022	Mar NEWA
AB		200MG	A 215591	002	Mar 31, 2022	Mar NEWA
AB		400MG	A 215591	003	Mar 31, 2022	Mar NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

>D>	AB	ANI PHARMS	25MG	A 203261	001	Mar 10, 2014	Jun DISC
>A>		@	25MG	A 203261	001	Mar 10, 2014	Jun DISC

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	RISING	12.5MG; 200MG; 50MG	A 213212	001	Jan 25, 2022	Jan NEWA
AB		18.75MG; 200MG; 75MG	A 213212	002	Jan 25, 2022	Jan NEWA
AB		25MG; 200MG; 100MG	A 213212	003	Jan 25, 2022	Jan NEWA
AB		31.25MG; 200MG; 125MG	A 213212	004	Jan 25, 2022	Jan NEWA
AB		37.5MG; 200MG; 150MG	A 213212	005	Jan 25, 2022	Jan NEWA
AB		50MG; 200MG; 200MG	A 213212	006	Jan 25, 2022	Jan NEWA
AB	STALEVO 125					
AB	+ ORION PHARMA	31.25MG; 200MG; 125MG	N 021485	006	Aug 29, 2008	Jan CTEC
AB	STALEVO 200					
AB	+! ORION PHARMA	50MG; 200MG; 200MG	N 021485	004	Aug 02, 2007	Jan CTEC
AB	STALEVO 50					
AB	+! ORION PHARMA	12.5MG; 200MG; 50MG	N 021485	001	Jun 11, 2003	Jan CTEC
AB	STALEVO 75					
AB	+ ORION PHARMA	18.75MG; 200MG; 75MG	N 021485	005	Aug 29, 2008	Jan CTEC

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

AP	TEYRO LABS	50MG/5ML (10MG/ML)	A 077861	001	Jan 18, 2007	Apr CAHN
AP		150MG/15ML (10MG/ML)	A 077861	002	Jan 18, 2007	Apr CAHN
AP		450MG/45ML (10MG/ML)	A 077861	003	Jan 18, 2007	Apr CAHN
AP		600MG/60ML (10MG/ML)	A 077861	004	Jan 18, 2007	Apr CAHN

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP	AMNEAL	EQ 0.25MG BASE/ML	A 215337	001	Jan 27, 2022	Jan NEWA
----	--------	-------------------	----------	-----	--------------	----------

CARGLUMIC ACID

TABLET, FOR SUSPENSION; ORAL

CARGLUMIC ACID

>A>	AB	NAVINTA LLC	200MG	A 213395	001	Jun 22, 2022	Jun NEWA
-----	----	-------------	-------	----------	-----	--------------	----------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

>D>	AA	FOSUN PHARMA	350MG	A 081025	001	Apr 13, 1989	Jun CAHN
>A>	AA	WANBANG BIOPHARMS	350MG	A 081025	001	Apr 13, 1989	Jun CAHN

CARMUSTINE

		IMPLANT; INTRACRANIAL							
		GLIADEL							
>D>	+	ARBOR PHARMS LLC	7.7MG		N020637	001	Sep 23, 1996	Jun	CAHN
>A>	+	AZURITY	7.7MG		N020637	001	Sep 23, 1996	Jun	CAHN
		INJECTABLE; INJECTION							
		CARMUSTINE							
>A>	AP	INGENUS PHARMS LLC	100MG/VIAL		A211011	001	Jun 21, 2022	Jun	NEWA
		POWDER; INTRAVENOUS							
		CARMUSTINE							
	+	ACCORD HLTHCARE	50MG/VIAL		N215000	001	May 16, 2022	May	NEWA
	+		300MG/VIAL		N215000	002	May 16, 2022	May	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

		TABLET; ORAL							
		CEFADROXIL							
AB	!	TEVA PHARMS	EQ 1GM BASE		A062774	001	Apr 08, 1987	Mar	CTEC

CEFAZOLIN SODIUM

		INJECTABLE; INJECTION							
		CEFAZOLIN SODIUM							
		QILU	EQ 2GM BASE/VIAL		A203661	002	Mar 11, 2022	Mar	NEWA

CEFEPIME HYDROCHLORIDE

		INJECTABLE; INJECTION							
		CEFEPIME HYDROCHLORIDE							
AP		ASTRAL	EQ 1GM BASE/VIAL		A212721	001	Jul 21, 2020	Jan	CMFD
AP			EQ 2GM BASE/VIAL		A212721	002	Jul 21, 2020	Jan	CMFD

CEFOTETAN DISODIUM

		INJECTABLE; INJECTION							
		CEFOTAN IN PLASTIC CONTAINER							
	@	PAI HOLDINGS PHARM	EQ 20MG BASE/ML		N050694	002	Jul 30, 1993	Apr	CAHN
	@		EQ 40MG BASE/ML		N050694	001	Jul 30, 1993	Apr	CAHN

CEFPODOXIME PROXETIL

		TABLET; ORAL							
		CEFPODOXIME PROXETIL							
AB		ALKEM LABS LTD	EQ 100MG BASE		A210568	001	May 18, 2022	May	NEWA
AB			EQ 200MG BASE		A210568	002	May 18, 2022	May	NEWA

CEFPROZIL

		FOR SUSPENSION; ORAL							
		CEFPROZIL							
	@	CHARTWELL RX	125MG/5ML		A065236	001	Dec 08, 2005	Mar	CAHN
	@		250MG/5ML		A065236	002	Dec 08, 2005	Mar	CAHN

CEFTAROLINE FOSAMIL

		POWDER; INTRAVENOUS							
		CEFTAROLINE FOSAMIL							
	@	APOTEX	400MG/VIAL		A208075	001	Sep 21, 2021	Mar	DISC
	@		600MG/VIAL		A208075	002	Sep 21, 2021	Mar	DISC
		TEFLARO							
	+	ALLERGAN	400MG/VIAL		N200327	001	Oct 29, 2010	Mar	CTEC
	+		600MG/VIAL		N200327	002	Oct 29, 2010	Mar	CTEC

CEFTRIAZONE SODIUM

		INJECTABLE; INJECTION							
		CEFTRIAZONE							
AP		ATLANTIDE	EQ 1GM BASE/VIAL		A065180	001	May 12, 2006	Apr	CAHN
		INJECTABLE; INTRAMUSCULAR, INTRAVENOUS							
		CEFTRIAZONE							
AP		ATLANTIDE	EQ 250MG BASE/VIAL		A065391	001	Apr 12, 2007	Apr	CAHN
AP			EQ 500MG BASE/VIAL		A065391	002	Apr 12, 2007	Apr	CAHN
AP			EQ 2GM BASE/VIAL		A065391	003	Apr 12, 2007	Apr	CAHN
	@	LUPIN	EQ 250MG BASE/VIAL		A065125	001	Sep 30, 2003	May	DISC
	@		EQ 500MG BASE/VIAL		A065125	002	Sep 30, 2003	May	DISC
	@		EQ 1GM BASE/VIAL		A065125	003	Sep 30, 2003	May	DISC
	@		EQ 2GM BASE/VIAL		A065125	004	Sep 30, 2003	May	DISC

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ATLANTIDE	EQ 125MG BASE	A065166	001	Jul 29, 2005	Mar	CAHN
AB		EQ 250MG BASE	A065166	002	Jul 29, 2005	Mar	CAHN
AB		EQ 500MG BASE	A065166	003	Jul 29, 2005	Mar	CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP	+! PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb	CAHN
AP	+!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb	CAHN
		INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
		ZINACEF					
AB	+! PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb	CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB

@ UNICHEM

50MG

A213301 001 Jan 12, 2021 Feb DISC

@

100MG

A213301 002 Jan 12, 2021 Feb DISC

@

200MG

A213301 003 Jan 12, 2021 Feb DISC

@

400MG

A213301 004 Jan 12, 2021 Feb DISC

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ ATLANTIDE

5MG/5ML

A078757 001 Aug 28, 2009 Apr CAHN

>A> AA

BAJAJ

5MG/5ML

A090191 001 Nov 12, 2009 Jun CAHN

>D> AA

MICRO LABS

5MG/5ML

A090191 001 Nov 12, 2009 Jun CAHN

>D> AA

TORRENT

5MG/5ML

A078870 001 Apr 27, 2009 Jun DISC

>A>

@

5MG/5ML

A078870 001 Apr 27, 2009 Jun DISC

AA

5MG/5ML

A078870 001 Apr 27, 2009 May CMFD

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+! WOODWARD SPECL

2MG

N010669 002 Apr CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

LIBRIUM

AB + VALEANT PHARM INTL

5MG

A085461 001 Jan CRLD

AB

+

10MG

A085472 001 Jan CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

>A> AB

CHARTWELL RX

5MG; 2.5MG

A213530 001 Oct 20, 2020 Jun CAHN

>D> AB

PHARMA LIFE

5MG; 2.5MG

A213530 001 Oct 20, 2020 Jun CAHN

>D> AB

TEVA PHARMS USA

5MG; 2.5MG

A211476 001 Nov 02, 2021 Jun DISC

>A>

@

5MG; 2.5MG

A211476 001 Nov 02, 2021 Jun DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIOGARD

@ COLGATE PALMOLIVE CO 0.12%

A073695 001 Jan 14, 1994 Apr DISC

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUZISTRA XR

>D>

+! AYTU

EQ 2.8MG BASE/5ML; EQ 14.7MG
BASE/5ML

N207768 001 Apr 30, 2015 Jun CAHN

>A>

+! TRIS PHARMA INC

EQ 2.8MG BASE/5ML; EQ 14.7MG
BASE/5ML

N207768 001 Apr 30, 2015 Jun CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREXCAPSULE, EXTENDED RELEASE;ORAL
TUSSICAPS

@	ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A 077273	002	Sep 24, 2007	Feb	DISC
@		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A 077273	001	Sep 24, 2007	Feb	DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

@	APPCO	10MG	A 213590	001	Aug 31, 2020	Mar	CAHN
@		25MG	A 213590	002	Aug 31, 2020	Mar	CAHN
@		50MG	A 213590	003	Aug 31, 2020	Mar	CAHN
@		100MG	A 213590	004	Aug 31, 2020	Mar	CAHN
@		200MG	A 213590	005	Aug 31, 2020	Mar	CAHN
AB	MSN	25MG	A 214827	001	Jan 27, 2022	Jan	NEWA
AB		50MG	A 214827	002	Jan 27, 2022	Jan	NEWA
AB		100MG	A 214827	003	Jan 27, 2022	Jan	NEWA
AB		200MG	A 214827	004	Jan 27, 2022	Jan	NEWA

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	CHARTWELL RX	25MG	A 211063	001	Feb 26, 2019	Jan	CAHN
AB		50MG	A 211063	002	Feb 26, 2019	Jan	CAHN
AB	INVENTIA	25MG	A 211320	001	Feb 09, 2022	Jan	NEWA
AB		50MG	A 211320	002	Feb 09, 2022	Jan	NEWA
	@ SUNNY	25MG	A 209068	001	Jan 25, 2022	May	DISC
AB		25MG	A 209068	001	Jan 25, 2022	Jan	NEWA
	@	50MG	A 209068	002	Jan 25, 2022	May	DISC
AB		50MG	A 209068	002	Jan 25, 2022	Jan	NEWA
AB	TAGI	25MG	A 212878	001	Feb 24, 2022	Feb	NEWA
AB		50MG	A 212875	001	Feb 24, 2022	Feb	NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

>D>	AB	GLENMARK PHARMS LTD	375MG	A 212185	001	May 26, 2020	Jun	DISC
>A>		@	375MG	A 212185	001	May 26, 2020	Jun	DISC
>D>	AB		750MG	A 212185	002	May 26, 2020	Jun	DISC
>A>		@	750MG	A 212185	002	May 26, 2020	Jun	DISC
	AB	RISING	375MG	A 213126	001	Apr 05, 2022	Mar	NEWA
	AB		500MG	A 213126	002	Apr 05, 2022	Mar	NEWA
	AB		750MG	A 213126	003	Apr 05, 2022	Mar	NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

@	UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A 214877	001	Jan 21, 2022	Mar	DISC
AB		EQ 4GM RESIN/PACKET	A 214877	001	Jan 21, 2022	Jan	NEWA
	@	EQ 4GM RESIN/SCOOPFUL	A 214877	002	Jan 21, 2022	Mar	DISC
AB		EQ 4GM RESIN/SCOOPFUL	A 214877	002	Jan 21, 2022	Jan	NEWA

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

AT	PAI HOLDINGS PHARM	1%	A 209975	001	Apr 05, 2018	Mar	CAHN
	SOLUTION;TOPICAL						
	CICLOPIROX						
AT	CHARTWELL RX	8%	A 078046	001	Sep 18, 2007	Mar	CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@	CHARTWELL RX	200MG	A 074100	001	Jan 31, 1995	Jan	CAHN
@		300MG	A 074100	002	Jan 31, 1995	Jan	CAHN
@		400MG	A 074100	003	Jan 31, 1995	Jan	CAHN
@		800MG	A 074100	004	Jan 31, 1995	Jan	CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

@	AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Feb	DISC
@		60MG	A204364	002	Dec 02, 2021	Feb	DISC
@		90MG	A204364	003	Dec 02, 2021	Feb	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan	CAHN
@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan	CAHN
@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

>A>	AP	HIKMA	EQ 10MG BASE/ML	A203078	001	Jun 28, 2022	Jun	NEWA
	AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	001	May 24, 2022	May	NEWA
	AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	May	NEWA
	AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Mar	NEWA
	AP		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Mar	NEWA
	AP	SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Mar	CMFD

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

+	!	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Jan	NEWA
---	---	----------	--------------	---------	-----	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB		ALEMBIC PHARMS LTD	250MG	A210459	001	Jan 31, 2022	Jan	NEWA
AB			500MG	A210459	002	Jan 31, 2022	Jan	NEWA

CLINDAMYCIN PHOSPHATE

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		ENCUBE	EQ 1% BASE	A215607	001	Jan 18, 2022	Jan	NEWA
----	--	--------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT		PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016	Mar	CAHN
----	--	--------------------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB1		ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Feb	CTEC
AB2		SOLARIS PHARMA CORP	1.2%;0.025%	A212845	001	Feb 10, 2022	Feb	NFTG
		VELTIN						
AB2	+	! ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb	CFTG
		ZIANA						
AB1	+	! BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006	Feb	CTEC

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

AB		AUROBINDO PHARMA LTD	2.5MG/ML	A214404	001	Mar 24, 2022	Mar	NEWA
----	--	----------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CLOBAZAM

AB		MSN	10MG	A213404	001	May 11, 2021	Feb	CMFD
AB			20MG	A213404	002	May 11, 2021	Feb	CMFD

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEOR DERMACEUTICALS	0.05%	A215838	001	Apr 21, 2022	Apr	NEWA
-----	--	----------------------	-------	---------	-----	--------------	-----	------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB		PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017	Mar	CAHN
----	--	--------------------	-------	---------	-----	--------------	-----	------

	LOTION;TOPICAL							
	CLOBETASOL PROPIONATE							
AB	PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016	Mar	CAHN	
	OINTMENT;TOPICAL							
	CLOBETASOL PROPIONATE							
AB	PAI HOLDINGS PHARM	0.05%	A208589	001	Jan 23, 2019	Mar	CAHN	
	SOLUTION;TOPICAL							
	CLOBETASOL PROPIONATE							
AT	SOLARIS PHARMA CORP	0.05%	A211240	001	Feb 17, 2022	Feb	NEWA	
	@ TOLMAR	0.05%	A076977	001	Aug 05, 2005	Feb	DISC	
>D>	AT	WOCKHARDT BIO AG	A075205	001	Nov 13, 1998	Jun	DISC	
>A>	@	0.05%	A075205	001	Nov 13, 1998	Jun	DISC	

CLOMIPHENE CITRATE

	TABLET;ORAL							
	CLOMIPHENE CITRATE							
>A>	!	COSETTE	50MG	A075528	001	Aug 30, 1999	Jun	CAHN
>D>	!	PAR PHARM	50MG	A075528	001	Aug 30, 1999	Jun	CAHN

CLONIDINE

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

ATHENA

@

@

EQ 0.17MG BASE

EQ 0.17MG BASE

EQ 0.26MG BASE

N022500 001 Dec 03, 2009 Feb CMFD

N022500 001 Dec 03, 2009 Jan CAHN

N022500 002 Dec 03, 2009 Jan CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May	CMFD	
AB		0.2MG	A070886	001	Aug 31, 1988	May	CMFD	
AB		0.3MG	A070886	003	Aug 31, 1988	May	CMFD	
AB	URL LABS	0.1MG	A070923	003	Sep 04, 1987	Apr	CAHN	
AB		0.2MG	A070923	002	Sep 04, 1987	Apr	CAHN	
AB		0.3MG	A070923	001	Sep 04, 1987	Apr	CAHN	

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

@ MAYNE PHARMA INC

0.1MG

A210680 001 Apr 30, 2018 Feb DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	DR REDDYS	EQ 75MG BASE	A076273	001	Jan 14, 2008	Apr	CAHN	
----	-----------	--------------	---------	-----	--------------	-----	------	--

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

>A>	AB	COREPHARMA	3.75MG	A215566	001	Jun 14, 2022	Jun	NEWA
>A>	AB		7.5MG	A215566	002	Jun 14, 2022	Jun	NEWA
>A>	AB		15MG	A215566	003	Jun 14, 2022	Jun	NEWA
>A>	AB	NOVITIUM PHARMA	3.75MG	A213730	001	Jun 16, 2022	Jun	NEWA
>A>	AB		7.5MG	A213730	002	Jun 16, 2022	Jun	NEWA

COLCHICINE

SOLUTION;ORAL

GLOPERBA

>D>	+	ROMEGL	0.6MG/5ML	N210942	001	Jan 30, 2019	Jun	CAHN
>A>	+	SCILEX PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jun	CAHN

TABLET;ORAL

COLCHICINE

@ PAR PHARM INC

0.6MG

AB	STRIDES PHARMA	0.6MG	A203976	001	Aug 12, 2021	Feb	DISC	
----	----------------	-------	---------	-----	--------------	-----	------	--

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

	@ LUPIN LTD	625MG	A201354	001	Dec 17, 2020	May	DISC	
AB	SPH	625MG	A213456	001	Jan 21, 2022	Jan	NEWA	

COLESTIPOL HYDROCHLORIDE

TABLET; ORAL

COLESTID

AB	+	PFIZER	1GM	N020222	001	Jul 19, 1994	Apr	CHRS
		COLESTIPOL HYDROCHLORIDE						
AB	!	IMPAX LABS	1GM	A077510	001	Oct 24, 2006	Apr	CHRS
AB		ZYDUS PHARMS	1GM	A215223	001	Mar 10, 2022	Feb	NEWA

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

>A>		@ BAUSCH	10MG/ML	A075585	001	Dec 21, 2000	Jun	CAHN
>D>		@ BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Jun	CAHN
AN		FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Mar	CMFD
AN		MICRO LABS	10MG/ML	A213658	001	Apr 29, 2022	Apr	NEWA

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

	+	@ ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987	Apr	DISC
--	---	-----------------	--------------------	---------	-----	--------------	-----	------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP		WELDING	1MG/ML	A215417	001	Apr 15, 2022	Apr	NEWA
AP		ZYDUS PHARMS	1MG/ML	A214655	001	Apr 15, 2022	Apr	NEWA
		DODEX						
AP		ACCORD HLTHCARE	1MG/ML	A083022	001		May	CTEC
			1MG/ML	A083022	001		Apr	CMFD

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

		@ ANI PHARMS	25MG	A207014	001	Mar 19, 2018	May	DISC
		@	50MG	A207014	002	Mar 19, 2018	Apr	DISC

CYCLOSPORINE

EMULSION; OPHTHALMIC

CYCLOSPORINE

AB		MYLAN	0.05%	A205894	001	Feb 02, 2022	Jan	NFTG
		RESTASIS						
AB	+	! ALLERGAN	0.05%	N050790	001	Dec 23, 2002	Jan	CFTG
		SOLUTION; ORAL						
		CYCLOSPORINE						
		@ MAYNE PHARMA	100MG/ML	A065054	001	Dec 18, 2001	Feb	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	CHARTWELL MOLECULAR	2MG/5ML	A203191	001	Jul 13, 2017	Jun	CAHN
>D>	AA	LANNETT CO INC	2MG/5ML	A203191	001	Jul 13, 2017	Jun	CAHN
		@ TRIS PHARMA INC	2MG/5ML	A205431	001	Dec 21, 2021	Apr	DISC

CYSTEAMINE BITARTRATE

GRANULE, DELAYED RELEASE; ORAL

PROCYSBI

	+	HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	May	CAHN
	+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	May	CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

CYSTEINE HYDROCHLORIDE

>A>	AP	DR REDDYS LABS SA	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Jun	CAHN
>D>	AP	ETON	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Jun	CAHN
	AP		500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Apr	NFTG
		ELCYS						
AP	+	! EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr	CFTG

CYTARABINE

	INJECTABLE; INJECTION						
	CYTARABINE						
>D>	@ HONG KONG	20MG/ML	A206189	001	Jun 26, 2020	Jun	CAHN
AP		20MG/ML	A208485	001	Feb 28, 2022	Feb	NEWA
>A>	@ MEITHEAL	20MG/ML	A206189	001	Jun 26, 2020	Jun	CAHN

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

DALFAMPRIDINE

@ HIKMA	10MG	A206646	001	Oct 24, 2018	May	DISC
---------	------	---------	-----	--------------	-----	------

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

+ PFIZER	10,000IU/4ML (2,500IU/ML)	N020287	012	Mar 15, 2022	Mar	NEWA
----------	---------------------------	---------	-----	--------------	-----	------

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTROLENE SODIUM

@ EUGIA PHARMA SPECLTS	20MG/VIAL	A205239	001	Feb 18, 2016	Mar	CAHN
------------------------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN

TABLET; ORAL

DAPAGLIFLOZIN

AB ZYDUS PHARMS	5MG	A211582	001	Feb 22, 2022	Feb	NFTG
-----------------	-----	---------	-----	--------------	-----	------

AB		A211582	002	Feb 22, 2022	Feb	NFTG
----	--	---------	-----	--------------	-----	------

FARXIGA

AB + ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb	CFTG
---------------------	-----	---------	-----	--------------	-----	------

AB +!	10MG	N202293	002	Jan 08, 2014	Feb	CFTG
-------	------	---------	-----	--------------	-----	------

DAPSONE

GEL; TOPICAL

DAPSONE

AB MYLAN	7.5%	A213847	001	Feb 04, 2022	Jan	NEWA
----------	------	---------	-----	--------------	-----	------

AB SEEGPHARM SA	5%	A210178	001	Mar 31, 2022	Mar	NEWA
-----------------	----	---------	-----	--------------	-----	------

AB TORRENT	7.5%	A214722	001	Feb 10, 2022	Feb	NEWA
------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

DAPSONE

@ VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Jan	DISC
-----------------	------	---------	-----	--------------	-----	------

@	100MG	A204074	002	May 10, 2016	Jan	DISC
---	-------	---------	-----	--------------	-----	------

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPZURA RT

+! BAXTER HLTHCARE CORP	500MG/VIAL	N213645	001	Jan 25, 2022	Jan	NEWA
-------------------------	------------	---------	-----	--------------	-----	------

DARIDOREXANT HYDROCHLORIDE

TABLET; ORAL

QUVIVIQ

+ IDORSIA	EQ 25MG BASE	N214985	001	Apr 07, 2022	Apr	NEWA
-----------	--------------	---------	-----	--------------	-----	------

+!	EQ 50MG BASE	N214985	002	Apr 07, 2022	Apr	NEWA
----	--------------	---------	-----	--------------	-----	------

DASATINIB

TABLET; ORAL

DASATINIB

@ APOTEX	80MG	A203180	001	Nov 23, 2021	May	DISC
----------	------	---------	-----	--------------	-----	------

@	140MG	A203180	002	Nov 23, 2021	May	DISC
---	-------	---------	-----	--------------	-----	------

SPRYCEL

+ BRISTOL MYERS SQUIBB	80MG	N021986	005	Oct 28, 2010	May	CTEC
------------------------	------	---------	-----	--------------	-----	------

+	140MG	N021986	006	Oct 28, 2010	May	CTEC
---	-------	---------	-----	--------------	-----	------

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

AP JIANGSU HANSOH PHARM	50MG/VIAL	A213472	001	Apr 15, 2022	Apr	NEWA
-------------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROX

GRANULE; ORAL		DEFERASIROX							
	@	AMNEAL	90MG	A214194	003	Aug 02, 2021	Mar	DISC	
AB		CIPLA	90MG	A215026	001	Feb 23, 2022	Feb	NEWA	
AB			180MG	A215026	002	Feb 23, 2022	Feb	NEWA	
AB			360MG	A215026	003	Feb 23, 2022	Feb	NEWA	
AB		MSN	90MG	A214650	003	Apr 20, 2022	Apr	NEWA	
>D>	AB	TEVA PHARMS USA	90MG	A214180	001	Nov 19, 2021	Jun	DISC	
>A>		@	90MG	A214180	001	Nov 19, 2021	Jun	DISC	
>D>	AB		180MG	A214180	002	Nov 19, 2021	Jun	DISC	
>A>		@	180MG	A214180	002	Nov 19, 2021	Jun	DISC	
>D>	AB		360MG	A214180	003	Nov 19, 2021	Jun	DISC	
>A>		@	360MG	A214180	003	Nov 19, 2021	Jun	DISC	
TABLET; ORAL		DEFERASIROX							
	@	AMNEAL	180MG	A210727	003	Jun 15, 2020	Apr	DISC	

DEFERIPRONE

TABLET; ORAL		DEFERIPRONE							
AB		HIKMA	1GM	A213239	002	Feb 08, 2022	Jan	NFTG	
AB	+	CHIESI	1GM	N021825	002	Jul 25, 2019	Jan	CFTG	

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL		DESMOPRESSIN ACETATE							
>A>	AB	!	BAUSCH	0.01MG/SPRAY	A074830	001	Jan 25, 1999	Jun	CAHN
>D>	AB	!	BAUSCH AND LOMB	0.01MG/SPRAY	A074830	001	Jan 25, 1999	Jun	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28		DESOGESTREL AND ETHINYL ESTRADIOL							
	@	MAYNE PHARMA	0.15MG, N/A; 0.02MG, 0.01MG	A076916	001	Dec 29, 2008	Jan	DISC	
	@		0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	A077182	001	Jan 24, 2006	Jan	DISC	

DESOXIMETASONE

OINTMENT; TOPICAL		DESOXIMETASONE							
AB		PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Mar	CAHN	

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL		DESVENLAFAXINE							
	+	@	SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb	CAHN
	+	@		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb	CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL		DESVENLAFAXINE SUCCINATE							
AB		LUPIN LTD	EQ 25MG BASE	A204172	003	Apr 13, 2022	Apr	NEWA	

DEXAMETHASONE

SOLUTION; ORAL		DEXAMETHASONE							
	+	!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983	Mar	CRLD
TABLET; ORAL		DEXAMETHASONE							
BP	+	HIKMA	0.5MG	A084611	001		Jan	CRLD	
AB		PRASCO	4MG	A080399	002	Apr 20, 2022	Apr	NEWA	

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION		DEXAMETHASONE SODIUM PHOSPHATE							
AP	+	!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb	CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OPHTHALMIC
MAXITROL

>A>	AT	+	IMPRIMIS PHARMS USA	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Jun	CAHN
>D>	AT	+	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Jun	CAHN

DEXAMETHASONE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRAMYCIN AND DEXAMETHASONE

AB			PADAGIS US	0.1%;0.3%	A212715	001	Feb 11, 2022	Feb	NEWA
----	--	--	------------	-----------	---------	-----	--------------	-----	------

DEXCHLORPHENIRAMINE MALEATESYRUP;ORAL
DEXCHLORPHENIRAMINE MALEATE

AA		+	PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Apr	CAHN
----	--	---	--------------------	---------	---------	-----	--------------	-----	------

DEXLANSOPRAZOLECAPSULE, DELAYED RELEASE;ORAL
DEXILANT

>D>		+	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun	CFTG
>A>	AB	+		30MG	N022287	001	Jan 30, 2009	Jun	CFTG
>A>	AB		PAR PHARM INC	30MG	A202294	002	Jun 16, 2022	Jun	NFTG

DEXMEDETOMIDINE HYDROCHLORIDEFILM;BUCCAL, SUBLINGUAL
IGALMI

+	BIOXCEL	EQ 0.12MG BASE	N215390	001	Apr 05, 2022	Apr	NEWA
+		EQ 0.18MG BASE	N215390	002	Apr 05, 2022	Apr	NEWA

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP			MEITHEAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Apr	CAHN
		@	PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021	Feb	DISC

DEXTROAMPHETAMINESYSTEM;TRANSDERMAL
XELSTRYM

+	NOVEN PHARMS INC	4.5MG/9HR	N215401	001	Mar 22, 2022	Mar	NEWA
+		9MG/9HR	N215401	002	Mar 22, 2022	Mar	NEWA
+		13.5MG/9HR	N215401	003	Mar 22, 2022	Mar	NEWA
+		18MG/9HR	N215401	004	Mar 22, 2022	Mar	NEWA

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

@	MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Feb	DISC
@		10MG	A076137	002	Jan 18, 2002	Feb	DISC
@		15MG	A076137	003	Jan 18, 2002	Feb	DISC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Jan	CTEC
		7.5MG	A090533	003	Oct 25, 2011	Jan	CTEC
		15MG	A090533	005	Oct 25, 2011	Jan	CTEC
		20MG	A090533	006	Oct 25, 2011	Jan	CTEC
		30MG	A090533	007	Oct 25, 2011	Jan	CTEC
@	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	Jan	DISC
@		5MG	A212160	002	Jun 07, 2021	Jan	DISC
@		7.5MG	A212160	003	Jun 07, 2021	Jan	DISC
@		10MG	A212160	004	Jun 07, 2021	Jan	DISC
@		15MG	A212160	005	Jun 07, 2021	Jan	DISC
@		20MG	A212160	006	Jun 07, 2021	Jan	DISC
@		30MG	A212160	007	Jun 07, 2021	Jan	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

>A> AA GUARDIAN DRUG 66%;10% A214201 001 Jun 27, 2022 Jun NEWA

DIAZEPAM

CONCENTRATE;ORAL
DIAZEPAM

>A> @ CHARTWELL MOLECULAR 5MG/ML A204433 001 Apr 14, 2014 Jun CAHN

>D> @ LANNETT CO INC 5MG/ML A204433 001 Apr 14, 2014 Jun CAHN

GEL;RECTAL

DIASTAT

+! BAUSCH 2.5MG/0.5ML (5MG/ML) N020648 001 Jul 29, 1997 May CHRS

DIASTAT ACUDIAL

+! BAUSCH 10MG/2ML (5MG/ML) N020648 007 Sep 15, 2005 May CHRS

SOLUTION;ORAL

DIAZEPAM

>A> AA CHARTWELL MOLECULAR 5MG/5ML A206477 001 Jun 24, 2016 Jun CAHN

>D> AA LANNETT CO INC 5MG/5ML A206477 001 Jun 24, 2016 Jun CAHN

TABLET;ORAL

VALIUM

AB + WAYLIS THERAP 2MG N013263 002 Mar CAHN

AB + 5MG N013263 004 Mar CAHN

AB +! 10MG N013263 006 Mar CAHN

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB STRIDES PHARMA 25MG A210078 001 Dec 03, 2019 Apr CMFD

FOR SOLUTION;ORAL

DICLOFENAC POTASSIUM

AB ANNORA PHARMA 50MG A215375 001 Mar 04, 2022 Feb NEWA

TABLET;ORAL

DICLOFENAC POTASSIUM

AB UMEDICA LABS PVT LTD 50MG A215750 001 May 11, 2022 Apr NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

CIPLA

1%

A209903 001 Aug 03, 2018 Mar CTEC

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB APOTEX 2% A207714 001 May 06, 2022 Apr NFTG

PENNSAID

AB +! HORIZON 2% N204623 001 Jan 16, 2014 Apr CFTG

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

@ GENE YORK PHARMS

10MG/ML

A212058 001 Apr 26, 2019 Feb DISC

DIGOXIN

ELIXIR;ORAL

DIGOXIN

AA AMICI 0.05MG/ML A215209 001 Mar 11, 2022 Mar NEWA

TABLET;ORAL

DIGOXIN

AB AUROBINDO PHARMA LTD 0.0625MG A214982 001 Feb 08, 2022 Jan NFTG

AB 0.125MG A214982 002 Feb 08, 2022 Jan NEWA

AB 0.25MG A214982 003 Feb 08, 2022 Jan NEWA

LANOXIN

AB + CONCORDIA 0.0625MG N020405 001 Sep 30, 1997 Jan CFTG

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL

TRUDHESA

+! IMPEL PHARMS 0.725MG/SPRAY N213436 001 Sep 02, 2021 May CAHN

DILTIAZEM HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE;ORAL							
		DILTIAZEM HYDROCHLORIDE							
AB1	MAYNE PHARMA INTL	60MG		A215775	001	May 05, 2022	Apr	NEWA	
AB1		90MG		A215775	002	May 05, 2022	Apr	NEWA	
AB1		120MG		A215775	003	May 05, 2022	Apr	NEWA	
		SOLUTION;INTRAVENOUS							
		DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%							
	+ @ EXELA PHARMA	125MG/125ML (1MG/ML)		N215252	001	Oct 28, 2021	Feb	DISC	
	+ @	250MG/250ML (1MG/ML)		N215252	002	Oct 28, 2021	Feb	DISC	

DIMETHYL FUMARATE

		CAPSULE, DELAYED RELEASE;ORAL							
		DIMETHYL FUMARATE							
	@ PHARMATHEN	120MG		A210436	001	Mar 26, 2021	Apr	DISC	
	@	240MG		A210436	002	Mar 26, 2021	Apr	DISC	
>D>	AB SAWAI USA	120MG		A210285	001	Dec 21, 2021	Jun	DISC	
>A>	@	120MG		A210285	001	Dec 21, 2021	Jun	DISC	
>D>	AB	240MG		A210285	002	Dec 21, 2021	Jun	DISC	
>A>	@	240MG		A210285	002	Dec 21, 2021	Jun	DISC	

DIPYRIDAMOLE

		INJECTABLE;INJECTION							
		DIPYRIDAMOLE							
AP	! CHARTWELL INJECTABLE	5MG/ML		A074939	001	Apr 13, 1998	Mar	CAHN	
	@ EUGIA PHARMA SPECCLTS	5MG/ML		A075769	001	Nov 27, 2002	Mar	CAHN	

DISOPYRAMIDE PHOSPHATE

		CAPSULE;ORAL							
		DISOPYRAMIDE PHOSPHATE							
AB	MAYNE PHARMA	EQ 100MG BASE		A070173	001	May 31, 1985	Feb	CMFD	
AB		EQ 150MG BASE		A070173	002	May 31, 1985	Feb	CMFD	

DIVALPROEX SODIUM

		TABLET, EXTENDED RELEASE;ORAL							
		DIVALPROEX SODIUM							
AB	UNICHEM	EQ 250MG VALPROIC ACID		A214643	001	Feb 25, 2022	Feb	NEWA	
AB		EQ 500MG VALPROIC ACID		A214643	002	Feb 25, 2022	Feb	NEWA	

DOCETAXEL

		INJECTABLE;INJECTION							
		DOCETAXEL							
AP	MEITHEAL	20MG/2ML (10MG/ML)		A209634	001	Aug 24, 2018	Apr	CAHN	
AP		80MG/8ML (10MG/ML)		A209634	002	Aug 24, 2018	Apr	CAHN	
AP		160MG/16ML (10MG/ML)		A209634	003	Aug 24, 2018	Apr	CAHN	

DOFETILIDE

		CAPSULE;ORAL							
		DOFETILIDE							
AB	TEVA PHARMS USA	0.125MG		A210018	001	Apr 15, 2022	Apr	NEWA	
AB		0.25MG		A210018	002	Apr 15, 2022	Apr	NEWA	
AB		0.5MG		A210018	003	Apr 15, 2022	Apr	NEWA	
		TABLET;ORAL							
		DOFETILIDE							
AB	VGYAAN	0.125MG		A215323	001	Apr 14, 2022	Apr	NEWA	
AB		0.25MG		A215323	002	Apr 14, 2022	Apr	NEWA	
AB		0.5MG		A215323	003	Apr 14, 2022	Apr	NEWA	

DONEPEZIL HYDROCHLORIDE

		SYSTEM;TRANSDERMAL							
		ADLARITY							
	+ CORIUM	5MG/DAY		N212304	001	Mar 11, 2022	Mar	NEWA	
	+!	10MG/DAY		N212304	002	Mar 11, 2022	Mar	NEWA	
		TABLET;ORAL							
		DONEPEZIL HYDROCHLORIDE							
AB	CHARTWELL RX	5MG		A090425	001	May 31, 2011	Mar	CAHN	
AB		10MG		A090425	002	May 31, 2011	Mar	CAHN	

DORZOLAMIDE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT	GLAND PHARMA LTD	EQ 2% BASE	A215660	001	Jan 27, 2022	Jan	NEWA
AT	! MICRO LABS	EQ 2% BASE	A204778	001	Nov 08, 2019	May	CHRS
TRUSOPT							
>D>	+ @ MERCK	EQ 2% BASE	N020408	001	Dec 09, 1994	Jun	CAHN
	+ @	EQ 2% BASE	N020408	001	Dec 09, 1994	May	DISC
>A>	+ @ MSD SUB MERCK	EQ 2% BASE	N020408	001	Dec 09, 1994	Jun	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
COSOPT

AT	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	Apr	CAHN
COSOPT PF							
AT	+! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Apr	CAHN
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE							
AT	MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	Jan	NEWA

DOXAPRAM HYDROCHLORIDEINJECTABLE;INJECTION
DOXAPRAM HYDROCHLORIDE

AP	CHARTWELL INJECTABLE	20MG/ML	A076266	001	Jan 10, 2003	Mar	CAHN
----	----------------------	---------	---------	-----	--------------	-----	------

DOXAZOSIN MESYLATETABLET;ORAL
CARDURA

AB	+! VIATRIS	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jan	CAHN
AB	+	EQ 2MG BASE	N019668	002	Nov 02, 1990	Jan	CAHN
AB	+	EQ 4MG BASE	N019668	003	Nov 02, 1990	Jan	CAHN
AB	+	EQ 8MG BASE	N019668	004	Nov 02, 1990	Jan	CAHN

DOXAZOSIN MESYLATE

	@ CHARTWELL RX	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan	CAHN
	@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan	CAHN
	@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan	CAHN
	@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan	CAHN
AB	METHOD	EQ 1MG BASE	A212727	001	Mar 15, 2022	Mar	NEWA
AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Mar	NEWA
AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Mar	NEWA
AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+	VIATRIS	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jan	CAHN
+!		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jan	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	EDENBRIDGE PHARMS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Apr	NEWA
AB	EPIC PHARMA LLC	EQ 50MG BASE	A210675	004	Mar 03, 2022	Feb	NEWA
AB		EQ 75MG BASE	A210675	005	Mar 03, 2022	Feb	NEWA
AB	JUBILANT CADISTA	EQ 10MG BASE	A215483	001	Mar 14, 2022	Mar	NEWA
AB		EQ 25MG BASE	A215483	002	Mar 14, 2022	Mar	NEWA
AB		EQ 50MG BASE	A215483	003	Mar 14, 2022	Mar	NEWA
AB		EQ 75MG BASE	A215483	004	Mar 14, 2022	Mar	NEWA
AB		EQ 100MG BASE	A215483	005	Mar 14, 2022	Mar	NEWA
AB	MANKIND PHARMA	EQ 10MG BASE	A215710	001	Feb 09, 2022	Jan	NEWA
AB		EQ 25MG BASE	A215710	002	Feb 09, 2022	Jan	NEWA
AB		EQ 50MG BASE	A215710	003	Feb 09, 2022	Jan	NEWA
AB		EQ 75MG BASE	A215710	004	Feb 09, 2022	Jan	NEWA
AB		EQ 100MG BASE	A215710	005	Feb 09, 2022	Jan	NEWA
>A>	AB	EQ 10MG BASE	A215113	001	Jun 24, 2022	Jun	NEWA
>A>	AB	EQ 25MG BASE	A215113	002	Jun 24, 2022	Jun	NEWA
>A>	AB	EQ 50MG BASE	A215113	003	Jun 24, 2022	Jun	NEWA
>A>	AB	EQ 75MG BASE	A215113	004	Jun 24, 2022	Jun	NEWA
>A>	AB	EQ 100MG BASE	A215113	005	Jun 24, 2022	Jun	NEWA
AB	! PAR PHARM	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

>D>	@ STRIDES PHARMA	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jun	CMFD
>A>	AB	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jun	CMFD

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

	@	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan CAHN
>D>	@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jun CMFD
>A>	AB	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jun CMFD
	@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Jan NEWA
AP		4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

	@ IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Mar DISC
	MONODOX					
AB	+ CHARTWELL RX	EQ 150MG BASE	N050641	004	Feb 17, 2022	Feb NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB	CADILA	EQ 50MG BASE	A207774	001	May 31, 2018	May CAHN
AB		EQ 100MG BASE	A207774	002	May 31, 2018	May CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

>A>	AB	! CHARTWELL MOLECULAR	EQ 20MG BASE	A065277	001	Nov 10, 2005	Jun CAHN
		@ EMCURE PHARMS LTD	EQ 100MG BASE	A209969	001	Nov 09, 2018	Jan DISC
>D>	AB	! LANNETT CO INC	EQ 20MG BASE	A065277	001	Nov 10, 2005	Jun CAHN
	AB	PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022	Mar NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

AB	+! DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016	Feb CFTG
		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE				
AB	ACTAVIS LABS FL INC	20MG;20MG	A212472	001	Mar 01, 2022	Feb NFTG

DROSPIRENONE

>A>		TABLET, CHEWABLE;ORAL					
>A>		DROSPIRENONE					
>A>	+!	EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022	Jun NEWA

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB	CELLTRION	100MG	A214217	001	May 05, 2022	Apr NEWA
AB		200MG	A214217	002	May 05, 2022	Apr NEWA
AB		300MG	A214217	003	May 05, 2022	Apr NEWA
	@ SLATE	100MG	A215265	001	Nov 01, 2021	May DISC
	@	200MG	A215265	002	Nov 01, 2021	May DISC
	@	300MG	A215265	003	Nov 01, 2021	May DISC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

	+ SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Feb CAHN
		EQ 30MG BASE	N212516	002	Jul 19, 2019	Feb CAHN
		EQ 40MG BASE	N212516	003	Jul 19, 2019	Feb CAHN
	+!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Feb CAHN

DUVELISIS

CAPSULE;ORAL

COPIKTRA

	+ SECURA	15MG	N211155	001	Sep 24, 2018	May CMFD
	+ @	15MG	N211155	001	Sep 24, 2018	Apr DISC
	+ @	25MG	N211155	002	Sep 24, 2018	May CMFD
	+ @	25MG	N211155	002	Sep 24, 2018	Apr DISC

EDARAVONESUSPENSION;ORAL
RADICAVA ORS

+! MITSUBISHI TANABE 105MG/5ML N215446 001 May 12, 2022 May NEWA

EFAVIRENZTABLET;ORAL
EFAVIRENZ

@ AUROBINDO PHARMA LTD 600MG A205322 001 Aug 30, 2018 Apr DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB HETERO LABS LTD V 600MG;200MG;300MG A203053 001 Jan 24, 2022 Jan NEWA

EFINACONAZOLESOLUTION;TOPICAL
EFINACONAZOLE@ LUPIN LTD 10% A212169 001 Mar 02, 2022 May DISC
AB 10% A212169 001 Mar 02, 2022 Feb NEWAEFLORNITHINE HYDROCHLORIDECREAM;TOPICAL
VANIQA

+ @ SKINMEDICA 13.9% N021145 001 Jul 27, 2000 Feb DISC

ELBASVIR; GRAZOPREVIRTABLET;ORAL
ZEPATIER>D> +! MERCK SHARP DOHME 50MG;100MG N208261 001 Jan 28, 2016 Jun CAHN
>A> +! MSD SUB MERCK 50MG;100MG N208261 001 Jan 28, 2016 Jun CAHNELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

AB AIZANT EQ 84MG BASE A212463 001 Sep 08, 2021 Feb CAHN
>D> AB TEVA PHARMS USA INC EQ 84MG BASE A212474 001 Dec 27, 2021 Jun DISC
>A> @ EQ 84MG BASE A212474 001 Dec 27, 2021 Jun DISCEMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

DESCOVY

+ GILEAD SCIENCES INC 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022 Jan NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB ALKEM LABS LTD 1MG/ML A213714 001 Mar 30, 2022 Mar NEWA
>A> AB AMNEAL 1MG/ML A212894 001 Jun 29, 2022 Jun NEWA
AB ANNORA PHARMA 1MG/ML A214467 001 Feb 24, 2022 Feb NEWA

TABLET;ORAL

ENALAPRIL MALEATE

>A> @ AIPING PHARM INC 2.5MG A075178 002 Mar 23, 2001 Jun CAHN
>A> @ 5MG A075178 001 Mar 23, 2001 Jun CAHN
>A> @ 10MG A075178 003 Mar 23, 2001 Jun CAHN
>A> @ 20MG A075178 004 Mar 23, 2001 Jun CAHN
>D> @ NOSTRUM LABS INC 2.5MG A075178 002 Mar 23, 2001 Jun CAHN
>D> @ 5MG A075178 001 Mar 23, 2001 Jun CAHN
>D> @ 10MG A075178 003 Mar 23, 2001 Jun CAHN
>D> @ 20MG A075178 004 Mar 23, 2001 Jun CAHNENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP ATHENEX INC 1.25MG/ML A075634 001 Aug 22, 2000 Jan CHRS
AP CHARTWELL INJECTABLE 1.25MG/ML A075634 001 Aug 22, 2000 Mar CAHN
AP ! HIKMA FARMACEUTICA 1.25MG/ML A078687 001 Dec 23, 2008 Jan CHRS
AP HOSPIRA 1.25MG/ML A075458 001 Aug 22, 2000 Jan CHRS

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
ENOXAPARIN SODIUM

>A> AB NANJING KING-FRIEND 300MG/3ML (100MG/ML) A214856 001 Jun 14, 2022 Jun NEWA

ENTECAVIR

TABLET;ORAL
ENTECAVIR

@ ACCORD HLTHCARE 0.5MG A205824 001 Aug 25, 2017 Apr DISC
@ 1MG A205824 002 Aug 25, 2017 Apr DISC
@ YUNG SHIN PHARM 0.5MG A208195 001 Nov 10, 2021 May DISC
@ 1MG A208195 002 Nov 10, 2021 May DISC

ENZALUTAMIDE

CAPSULE;ORAL
ENZALUTAMIDE

AB @ ACTAVIS LABS FL INC 40MG A209614 001 May 14, 2021 Feb DISC
AB APOTEX 40MG A209645 001 Apr 22, 2022 Apr NEWA
AB +! XTANDI
+! ASTELLAS 40MG N203415 001 Aug 31, 2012 Apr CTEC
+! 40MG N203415 001 Aug 31, 2012 Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS
REZIPRES

>A> +! DR REDDYS LABS SA 23.5MG/5ML (4.7MG/ML) N213536 001 Jun 14, 2021 Jun CAHN
>A> + @ 47MG/ML (47MG/ML) N213536 002 Jun 14, 2021 Jun CAHN
>A> + @ 47MG/5ML (9.4MG/ML) N213536 003 Jun 14, 2021 Jun CAHN
>D> +! ETON 23.5MG/5ML (4.7MG/ML) N213536 001 Jun 14, 2021 Jun CAHN
>D> + @ 47MG/ML (47MG/ML) N213536 002 Jun 14, 2021 Jun CAHN
>D> + @ 47MG/5ML (9.4MG/ML) N213536 003 Jun 14, 2021 Jun CAHN

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS
EPHEDRINE SULFATE

AP AGGREGA 50MG/ML (50MG/ML) A215825 001 Apr 21, 2022 Apr NEWA
+! ENDO VENTURES 25MG/5ML (5MG/ML) N213994 002 Apr 22, 2022 May NEWA
+! 50MG/10ML (5MG/ML) N213994 001 Oct 16, 2020 Feb CMFD
AP GLAND PHARMA LTD 50MG/ML (50MG/ML) A216146 001 Feb 25, 2022 Feb NEWA
AP MANKIND PHARMA 50MG/ML (50MG/ML) A216129 001 Apr 14, 2022 Apr NEWA

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

+! BELCHER 10MG/10ML (1MG/ML) N205029 002 Feb 04, 2022 Mar NEWA

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

+! BELCHER 1MG/ML (1MG/ML) N205029 001 Jul 29, 2014 Mar CDFR

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIGNOSPAN FORTE

+! DEPROCO EQ 0.02MG BASE/ML;2% A088389 001 Jan 22, 1985 Feb CRLD

LIGNOSPAN STANDARD
+! DEPROCO EQ 0.01MG BASE/ML;2% A088390 001 Jan 22, 1985 Jan CRLD

EPLERENONE

TABLET;ORAL
EPLERENONE

AB KARTHA 25MG A214663 001 Mar 23, 2022 Mar NEWA
AB 50MG A214663 002 Mar 23, 2022 Mar NEWA

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP SHUANGCHENG 75MG/100ML A213081 002 Apr 20, 2022 Apr NEWA

INTEGRILIN

>A> + @ MSD SUB MERCK 2MG/ML N020718 001 May 18, 1998 Jun CAHN
>A> + @ 75MG/100ML N020718 002 May 18, 1998 Jun CAHN
>D> + @ SCHERING 2MG/ML N020718 001 May 18, 1998 Jun CAHN
>D> + @ 75MG/100ML N020718 002 May 18, 1998 Jun CAHN

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

>A>	AB	EUGIA PHARMA	EQ 25MG BASE	A216342	001	Jun 22, 2022	Jun NEWA
>A>	AB		EQ 100MG BASE	A216342	002	Jun 22, 2022	Jun NEWA
>A>	AB		EQ 150MG BASE	A216342	003	Jun 22, 2022	Jun NEWA

ERTAPENEM SODIUMINJECTABLE; INTRAMUSCULAR, INTRAVENOUS
INVANZ

>D>	AP	+! MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun CAHN
>A>	AP	+! MSD SUB MERCK	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun CAHN

ERTUGLIFLOZIN

TABLET; ORAL

STEGLATRO

>D>		+ MERCK SHARP DOHME	5MG	N209803	001	Dec 19, 2017	Jun CAHN
>D>		+!	15MG	N209803	002	Dec 19, 2017	Jun CAHN
>A>		+ MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jun CAHN
>A>		+!	15MG	N209803	002	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SEGLUROMET

>D>		+ MERCK SHARP DOHME	2.5MG; 500MG	N209806	001	Dec 19, 2017	Jun CAHN
>D>		+	2.5MG; 1GM	N209806	002	Dec 19, 2017	Jun CAHN
>D>		+	7.5MG; 500MG	N209806	003	Dec 19, 2017	Jun CAHN
>D>		+!	7.5MG; 1GM	N209806	004	Dec 19, 2017	Jun CAHN
>A>		+ MSD SUB MERCK	2.5MG; 500MG	N209806	001	Dec 19, 2017	Jun CAHN
>A>		+	2.5MG; 1GM	N209806	002	Dec 19, 2017	Jun CAHN
>A>		+	7.5MG; 500MG	N209806	003	Dec 19, 2017	Jun CAHN
>A>		+!	7.5MG; 1GM	N209806	004	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

STEGLUJAN

>D>		+ MERCK SHARP DOHME	5MG; EQ 100MG BASE	N209805	001	Dec 19, 2017	Jun CAHN
>D>		+!	15MG; EQ 100MG BASE	N209805	002	Dec 19, 2017	Jun CAHN
>A>		+ MSD SUB MERCK	5MG; EQ 100MG BASE	N209805	001	Dec 19, 2017	Jun CAHN
>A>		+!	15MG; EQ 100MG BASE	N209805	002	Dec 19, 2017	Jun CAHN

ERYTHROMYCIN

TABLET, COATED PARTICLES; ORAL

PCE

		+ @ AZURITY	333MG	N050611	001	Sep 09, 1986	May CAHN
		+ @	500MG	N050611	002	Aug 22, 1990	May CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB		+ AZURITY	EQ 200MG BASE/5ML	N050207	001		May CAHN
		ERYPED					
AB		+ AZURITY	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	May CAHN
AB		+!	EQ 400MG BASE/5ML	N050207	002		May CAHN

TABLET, CHEWABLE; ORAL

E.E.S.

		@ AZURITY	EQ 200MG BASE	N050297	002		May CAHN
		ERYPED					
		@ AZURITY	EQ 200MG BASE	N050297	003	Jul 05, 1988	May CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN LACTOBIONATE

AP		NEXUS PHARMS	EQ 500MG BASE/VIAL	A215290	001	Feb 14, 2022	Feb NEWA
----	--	--------------	--------------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HYDROCHLORIDE

AP		EUGIA PHARMA	10MG/ML	A216244	001	Mar 21, 2022	Mar NEWA
AP			20MG/ML	A216244	002	Mar 21, 2022	Mar NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS		ESOMEPRAZOLE SODIUM					
AP	HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Feb	NEWA
	@ MYLAN	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Apr	CAHN
	@	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr	CAHN
	@ MYLAN LABS LTD	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr	DISC
	@ SUN PHARM	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Feb	CAHN
AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Feb	CAHN

ESTRADIOL

TABLET; ORAL		ESTRADIOL					
	@ LANNETT CO INC	0.5MG	A040138	001	Jan 30, 1998	May	CAHN
	@	1MG	A040138	002	Jan 30, 1998	May	CAHN
	@	2MG	A040138	003	Jan 30, 1998	May	CAHN
	@ MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Feb	DISC
	@	1MG	A040114	001	Mar 14, 1996	Feb	DISC
	@	2MG	A040114	002	Mar 14, 1996	Feb	DISC

ESTRADIOL; PROGESTERONE

CAPSULE; ORAL		BIJUVA					
	+ @ THERAPEUTICSMD INC	0.5MG;100MG	N210132	002	Dec 28, 2021	Apr	DISC
	+!	1MG;100MG	N210132	001	Oct 28, 2018	May	CTEC
AB	+!	1MG;100MG	N210132	001	Oct 28, 2018	May	CFTG
ESTRADIOL AND PROGESTERONE							
	@ AMNEAL PHARMS	1MG;100MG	A214293	001	May 16, 2022	May	DISC
AB		1MG;100MG	A214293	001	May 16, 2022	May	NFTG

ESZOPICLONE

TABLET; ORAL		ESZOPICLONE					
	@ CHARTWELL RX	1MG	A091165	001	Jul 14, 2011	Jan	CAHN
	@	2MG	A091165	002	Jul 14, 2011	Jan	CAHN
	@	3MG	A091165	003	Jul 14, 2011	Jan	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28		ZOVIA 1/35E-28					
	@ MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Jan	DISC

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL		VERARING						
>D>	AB	DR REDDYS LABS SA	0.015MG/24HR;0.12MG/24HR	A207577	001	Dec 09, 2021	Jun	DISC
>A>		@	0.015MG/24HR;0.12MG/24HR	A207577	001	Dec 09, 2021	Jun	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28		LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB1		NAARI PTE LTD	0.02MG;0.1MG	A207065	001	Aug 17, 2020	Apr	CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL		FEMCON FE						
	+ @ APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	May	CDFR	
	NEXESTA FE							
AB		AUROBINDO PHARMA LTD	0.035MG;0.4MG	A207535	001	Feb 02, 2017	May	CDFR
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
AB		AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	May	CDFR
AB		BARR	0.035MG;0.4MG	A078965	001	Aug 05, 2010	May	CDFR
AB		LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	May	CDFR
AB	!	MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	May	CDFR
AB		NAARI PTE LTD	0.035MG;0.4MG	A207066	001	Mar 29, 2017	May	CDFR
TABLET; ORAL-28		NORETHINDRONE AND ETHINYL ESTRADIOL						
	@ MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Jan	DISC	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		MAYNE PHARMA	0.02MG;1MG	A213901	001	Apr 28, 2022	Apr	NEWA	
		TABLET; ORAL							
		FINZALA							
AB		TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	May	CDFR	
		MIBELAS 24 FE							
AB		LUPIN	0.02MG;1MG	A206287	001	May 24, 2016	May	CDFR	
		MINASTRIN 24 FE							
AB	+	APIL	0.02MG;1MG	N203667	001	May 08, 2013	May	CDFR	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
>D>	AB	!	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jun	DISC
>A>			@	0.02MG;1MG	A078267	001	Sep 01, 2009	Jun	DISC
			@	0.02MG;1MG	A207514	001	Sep 11, 2017	May	CDFR
>D>	AB		GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Jun	CHRS
>A>	AB	!		0.02MG;1MG	A204847	001	Nov 17, 2017	Jun	CHRS
	AB			0.02MG;1MG	A210369	001	Dec 26, 2017	May	CDFR
			@ MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	May	CDFR
	AB		XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	May	CDFR
		TABLET; ORAL-21							
>D>		LOESTRIN 21 1.5/30							
>D>	AB	+	TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jun	DISC
>A>		+	@	0.03MG;1.5MG	N017875	001		Jun	DISC
		LOESTRIN FE 1.5/30							
>D>	AB	+	!	TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001	Jun	DISC
>A>		+	@		0.03MG;1.5MG	N017355	001	Jun	DISC
		MICROGESTIN 1.5/30							
			@ MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Jan	DISC
		MICROGESTIN 1/20							
			@ MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Jan	DISC
		TABLET; ORAL-28							
		JUNEL FE 1.5/30							
>D>	AB		BARR	0.03MG;1.5MG	A076064	001	Sep 18, 2003	Jun	CHRS
>A>	AB	!		0.03MG;1.5MG	A076064	001	Sep 18, 2003	Jun	CHRS
>D>		LOESTRIN FE 1/20							
>D>	AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jun	DISC
>A>		+	@	0.02MG;1MG	N017354	001		Jun	DISC
		MICROGESTIN FE 1.5/30							
			@ MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Jan	DISC
		MICROGESTIN FE 1/20							
			@ MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Jan	DISC
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
			@ MAYNE PHARMA	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A076629	001	Mar 18, 2010	Jan	DISC
AB			MYLAN	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A205069	001	Jun 22, 2018	Feb	CMFD
AB				0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A205069	001	Jun 22, 2018	Feb	CAHN
		TABLET, CHEWABLE; ORAL							
		FINZALA							
AB		TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Jan	CMFD	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
			@ AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	Jan	DISC

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

+ @ CADENCE HEALTH 0.03MG;0.3MG

N017612 001

Apr CRLD

TABLET; ORAL-28

CRYSELLE

AB ! DURAMED PHARMS BARR 0.03MG;0.3MG

A075840 002 Nov 30, 2001

Apr CHRS

LO/OVRAL-28

+ @ WYETH PHARMS 0.03MG;0.3MG

N017802 001

Apr CRLD

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

@ ORGANON 68MG/IMPLANT

N021529 001 Jul 17, 2006

Jan CAHN

NEXPLANON

+! ORGANON 68MG/IMPLANT

N021529 002 May 31, 2011

Jan CAHN

ETRAVIRINE

	TABLET; ORAL						
	ETRAVIRINE						
AB	CARNEGIE	100MG	A215402	001	Apr 13, 2022	Apr	NEWA
AB		200MG	A215402	002	Apr 13, 2022	Apr	NEWA

EXEMESTANE

	TABLET; ORAL						
	EXEMESTANE						
AB	EUGIA PHARMA	25MG	A216454	001	May 20, 2022	May	NEWA

EZETIMIBE

	TABLET; ORAL						
	EZETIMIBE						
	@ APOTEX	10MG	A208332	001	Jun 12, 2017	Apr	DISC

FAMCICLOVIR

	TABLET; ORAL						
	FAMCICLOVIR						
	@ CIPLA	125MG	A078278	001	Mar 21, 2011	Mar	DISC
	@	250MG	A078278	002	Mar 21, 2011	Mar	DISC
	@	500MG	A078278	003	Mar 21, 2011	Mar	DISC

FAMOTIDINE

	INJECTABLE; INJECTION						
	FAMOTIDINE PRESERVATIVE FREE						
	@ AKORN	10MG/ML	A076324	001	Nov 27, 2002	Feb	CAHN
	FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)						
	@ AKORN	10MG/ML	A076322	001	Nov 27, 2002	Feb	CAHN
	TABLET; ORAL						
	FAMOTIDINE						
AB	ZYDUS PHARMS	20MG	A216441	001	Jun 03, 2022	May	NEWA
AB		40MG	A216441	002	Jun 03, 2022	May	NEWA

FEBUXOSTAT

	TABLET; ORAL						
	FEBUXOSTAT						
AB	PRINSTON INC	40MG	A206266	001	Mar 28, 2022	Mar	NEWA
AB		80MG	A206266	002	Mar 28, 2022	Mar	NEWA

FELODIPINE

	TABLET, EXTENDED RELEASE; ORAL						
	FELODIPINE						
	@ ATLANTIDE	2.5MG	A091484	001	Aug 15, 2012	Apr	CAHN
	@	5MG	A091484	002	Aug 15, 2012	Apr	CAHN
	@	10MG	A091484	003	Aug 15, 2012	Apr	CAHN

FERRIC CARBOXYMALTOSE

	SOLUTION; INTRAVENOUS						
	INJECTAFER						
	+! AM REGENT	100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022	Feb	NEWA

FESOTERODINE FUMARATE

	TABLET, EXTENDED RELEASE; ORAL						
	FESOTERODINE FUMARATE						
AB	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	May	CMFD
AB		8MG	A204827	002	Dec 10, 2015	May	CMFD
>D>	@ DR REDDYS	4MG	A204975	001	Aug 13, 2019	Jun	CMFD
>A> AB		4MG	A204975	001	Aug 13, 2019	Jun	CMFD
>D>	@	8MG	A204975	002	Aug 13, 2019	Jun	CMFD
>A> AB		8MG	A204975	002	Aug 13, 2019	Jun	CMFD

FEXOFENADINE HYDROCHLORIDE

	CAPSULE; ORAL						
	ALLEGRA						
	@ CHATTEM SANOFI	60MG	N020625	001	Jul 25, 1996	Jan	CAHN
	@	60MG	N020625	001	Jul 25, 1996	Jan	CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

		@ MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb	DISC
AB			EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb	CAHN
>D>	AB	TEVA PHARMS USA	EQ 0.25MG BASE	A212152	001	Nov 12, 2021	Jun	DISC
>A>		@	EQ 0.25MG BASE	A212152	001	Nov 12, 2021	Jun	DISC
		GILENYA						
>D>	AB	+ NOVARTIS	EQ 0.25MG BASE	N022527	002	May 11, 2018	Jun	CTEC
>A>		+	EQ 0.25MG BASE	N022527	002	May 11, 2018	Jun	CTEC

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

		@ CHARTWELL	50MG	A079164	001	Jul 09, 2009	Feb	CAHN
		@	100MG	A079164	002	Jul 09, 2009	Feb	CAHN
		@	150MG	A079164	003	Jul 09, 2009	Feb	CAHN

FLUCONAZOLE

TABLET;ORAL

FLUCONAZOLE

>A>	AB	THINQ PHARM-CRO PVT	50MG	A076957	001	Sep 28, 2005	Jun	CAHN
>A>	AB		100MG	A076957	002	Sep 28, 2005	Jun	CAHN
>A>	AB		150MG	A076957	004	Feb 27, 2017	Jun	CAHN
>A>	AB		200MG	A076957	003	Sep 28, 2005	Jun	CAHN
>D>	AB	UNIQUE PHARM LABS	50MG	A076957	001	Sep 28, 2005	Jun	CAHN
>D>	AB		100MG	A076957	002	Sep 28, 2005	Jun	CAHN
>D>	AB		150MG	A076957	004	Feb 27, 2017	Jun	CAHN
>D>	AB		200MG	A076957	003	Sep 28, 2005	Jun	CAHN

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

AB		STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Feb	CMFD
AB			500MG	A212632	002	Apr 17, 2020	Feb	CMFD

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB		NOVITIUM PHARMA	0.1MG	A215279	001	May 31, 2022	May	NEWA
----	--	-----------------	-------	---------	-----	--------------	-----	------

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

		@ APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	May	DISC
>A>	AB	! BAUSCH	0.025MG/SPRAY	A074805	001	Feb 20, 2002	Jun	CAHN
>D>	AB	! BAUSCH AND LOMB	0.025MG/SPRAY	A074805	001	Feb 20, 2002	Jun	CAHN
>A>	AB	RICONPHARMA LLC	0.025MG/SPRAY	A207802	001	Jun 16, 2022	Jun	NEWA

FLUOCINOLONE ACETONIDE

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

		@ PAI HOLDINGS PHARM	0.01%	A088312	001	Jan 27, 1984	Apr	CAHN
--	--	----------------------	-------	---------	-----	--------------	-----	------

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

		@ EUGIA PHARMA SPECLTS	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Mar	CAHN
		@	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Mar	CAHN
		@	2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Mar	CAHN
		@	5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1		MICRO LABS	EQ 10MG BASE	A216232	001	Mar 29, 2022	Mar	NEWA
AB1			EQ 20MG BASE	A216232	002	Mar 29, 2022	Mar	NEWA
AB			EQ 40MG BASE	A216232	003	Mar 29, 2022	Mar	NEWA

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

>D>	@ PRASCO	1MG	A 089804	002	Aug 12, 1988	Jun	CMFD
>A>	AB	1MG	A 089804	002	Aug 12, 1988	Jun	CMFD
	@	1MG	A 089804	002	Aug 12, 1988	Mar	CAHN
>D>	@	2.5MG	A 089804	003	Aug 12, 1988	Jun	CMFD
>A>	AB	2.5MG	A 089804	003	Aug 12, 1988	Jun	CMFD
	@	2.5MG	A 089804	003	Aug 12, 1988	Mar	CAHN
>D>	@	5MG	A 089804	004	Aug 12, 1988	Jun	CMFD
>A>	AB	5MG	A 089804	004	Aug 12, 1988	Jun	CMFD
	@	5MG	A 089804	004	Aug 12, 1988	Mar	CAHN
>D>	@	10MG	A 089804	001	Aug 12, 1988	Jun	CMFD
>A>	AB	10MG	A 089804	001	Aug 12, 1988	Jun	CMFD
	@	10MG	A 089804	001	Aug 12, 1988	Mar	CAHN
AB	TARO PHARM INDS LTD	1MG	A 215674	001	Apr 14, 2022	Apr	NEWA
AB		2.5MG	A 215674	002	Apr 14, 2022	Apr	NEWA
AB		5MG	A 215674	003	Apr 14, 2022	Apr	NEWA
AB		10MG	A 215674	004	Apr 14, 2022	Apr	NEWA
AB	TWI PHARMS	2.5MG	A 215848	001	Apr 01, 2022	Mar	NEWA
AB		5MG	A 215848	002	Apr 01, 2022	Mar	NEWA
AB		10MG	A 215848	003	Apr 01, 2022	Mar	NEWA

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	!	ALMIRALL	0.05%	N 012806	002		Feb	CTEC
		FLURANDRENOLIDE						
		@ CINTEX SVCS	0.05%	A 205342	001	Apr 13, 2016	Feb	DISC
		LOTION; TOPICAL						
		FLURANDRENOLIDE						
		@ CINTEX SVCS	0.05%	A 205343	001	Dec 22, 2016	Feb	DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

		RISING	15MG	A 070345	002	Nov 27, 1985	Apr	CAHN
	!		30MG	A 070345	001	Nov 27, 1985	Apr	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

		@ CHARTWELL RX	125MG	A 075818	001	Sep 18, 2001	Jan	CAHN
--	--	----------------	-------	----------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

	+	@ FOUGERA PHARMS	0.05%	N 021152	001	Mar 31, 2005	Mar	DISC
AB	+		0.05%	N 021152	001	Mar 31, 2005	Mar	CHRS
		FLUTICASONE PROPIONATE						
AB	!	GLENMARK GENERICS	0.05%	A 090759	001	May 02, 2011	Mar	CHRS
		POWDER; INHALATION						
		ARMONAIR DIGIHALER						
	+	@ TEVA PHARM	0.03MG/INH	N 208798	008	Apr 08, 2022	Apr	NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB		BIONPHARMA INC	100MG	A 212182	002	Sep 16, 2020	Feb	CMFD
----	--	----------------	-------	----------	-----	--------------	-----	------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

	@	ARTHUR GRP	EQ 150MG BASE/VIAL	A 211624	001	Sep 05, 2019	Mar	CAHN
	@		EQ 150MG BASE/VIAL	A 213199	001	Oct 04, 2021	Mar	CAHN
	@	PRAXGEN	EQ 150MG BASE/VIAL	A 211624	001	Sep 05, 2019	Feb	DISC
	@		EQ 150MG BASE/VIAL	A 213199	001	Oct 04, 2021	Feb	DISC

FOSDENOPTERIN HYDROBROMIDEPOWDER; INTRAVENOUS
NULIBRY

+! SENTYNL THERAPS INC EQ 9.5MG BASE/VIAL N214018 001 Feb 26, 2021 Mar CAHN

FOSFOMYCIN TROMETHAMINEFOR SOLUTION; ORAL
FOSFOMYCIN TROMETHAMINE

AA CIPLA EQ 3GM BASE/PACKET A211881 001 Jan 26, 2022 Jan NEWA

FOSPHENYTOIN SODIUMINJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

AP ATLANTIDE EQ 50MG PHENYTOIN NA/ML A078137 001 Aug 06, 2007 Apr CAHN

FROVATRIPTAN SUCCINATETABLET; ORAL
FROVATRIPTAN SUCCINATE

AB RENATA EQ 2.5MG BASE A213891 001 Apr 06, 2022 May CAHN

AB ZENARA EQ 2.5MG BASE A213891 001 Apr 06, 2022 Mar NEWA

FULVESTRANTINJECTABLE; INTRAMUSCULAR
FULVESTRANT

AO @ APOTEX 50MG/ML A211730 001 Jun 11, 2021 Jan DISC

AO JIANGSU HANSOH PHARM 50MG/ML A214682 001 Feb 10, 2022 Feb NEWA

AO ZYDUS PHARMS 50MG/ML A215234 001 Jul 29, 2021 Feb CMFD

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

AP HONG KONG 10MG/ML A212803 001 Jan 27, 2022 Jan NEWA

AP MEITHEAL 10MG/ML A212803 001 Jan 27, 2022 Mar CAHN

SOLUTION; ORAL
FUROSEMIDE

! HIKMA 10MG/ML A070434 001 Apr 22, 1987 May CTEC

@ WOCKHARDT BIO AG 10MG/ML A070655 001 Oct 02, 1987 May DISC

TABLET; ORAL
FUROSEMIDE

@ EPIC PHARMA LLC 40MG N018750 002 Jul 30, 1984 Mar CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

>A> @ CHARTWELL RX 100MG A091008 001 Oct 26, 2017 Jun CAHN

>A> @ 300MG A091008 002 Oct 26, 2017 Jun CAHN

>A> @ 400MG A091008 003 Oct 26, 2017 Jun CAHN

>D> @ HENGRUI PHARMA 100MG A091008 001 Oct 26, 2017 Jun CAHN

>D> @ 300MG A091008 002 Oct 26, 2017 Jun CAHN

>D> @ 400MG A091008 003 Oct 26, 2017 Jun CAHN

NEURONTIN

AB + VIATRIS 100MG N020235 001 Dec 30, 1993 Feb CAHN

AB + 300MG N020235 002 Dec 30, 1993 Feb CAHN

AB +! 400MG N020235 003 Dec 30, 1993 Feb CAHN

SOLUTION; ORAL
GABAPENTIN

>A> AA BELCHER 250MG/5ML A091286 001 Mar 14, 2016 Jun CAHN

>A> @ PAI HOLDINGS PHARM 250MG/5ML A211330 001 Dec 03, 2019 Feb CAHN

>D> AA TRIS PHARMA INC 250MG/5ML A091286 001 Mar 14, 2016 Jun CAHN

>D> @ VISTAPHARM 250MG/5ML A211330 001 Dec 03, 2019 Feb CAHN

NEURONTIN

AA +! VIATRIS 250MG/5ML N021129 001 Mar 02, 2000 Feb CAHN

TABLET; ORAL
NEURONTIN

AB + VIATRIS 600MG N020882 001 Oct 09, 1998 Feb CAHN

AB +! 800MG N020882 002 Oct 09, 1998 Feb CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL
HORIZANT

+	AZURITY	300MG	N022399	002	Dec 13, 2011	Mar	CAHN
+	!	600MG	N022399	001	Apr 06, 2011	Mar	CAHN

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS
GADOTERATE MEGLUMINE

>A>	AP	HENGRUI PHARMA	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Jun	CAHN
>A>	AP		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Jun	CAHN
>A>	AP		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Jun	CAHN
>A>	AP		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Jun	CAHN
>A>	AP		37.69GM/100ML (376.9MG/ML)	A215982	001	Apr 15, 2022	Jun	CAHN
>D>	AP	JIANGSU HENGRUI MED	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Jun	CAHN
	AP		1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Apr	NEWA
>D>	AP		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Jun	CAHN
	AP		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Apr	NEWA
>D>	AP		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Jun	CAHN
	AP		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Apr	NEWA
>D>	AP		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Jun	CAHN
	AP		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Apr	NEWA
>D>	AP		37.69GM/100ML (376.9MG/ML)	A215982	001	Apr 15, 2022	Jun	CAHN
	AP		37.69GM/100ML (376.9MG/ML)	A215982	001	Apr 15, 2022	Apr	NEWA

GALLIUM GA-68 GOZETOTIDE

POWDER;INTRAVENOUS
ILLUCCIX

+	!	TELEX	N/A	N214032	001	Dec 17, 2021	Mar	CPOT
		LOCAMETZ						
+	!	AAA USA NOVARTIS	N/A	N215841	001	Mar 23, 2022	Mar	NEWA

SOLUTION;INTRAVENOUS

>A>		GALLIUM GA 68 GOZETOTIDE							
>A>	+	!	UNIV CA LOS ANGELES	30ML (0.5-5mCi/mL)	N212642	001	Dec 01, 2020	Jun	CTNA
>A>	+	!	UNIV OF CA SAN FRAN	20ML (0.5-5mCi/mL)	N212643	001	Dec 01, 2020	Jun	CTNA

GALLIUM GA-68 PSMA-11

SOLUTION;INTRAVENOUS

>D>		GALLIUM GA 68 PSMA-11							
>D>	+	!	UNIV CA LOS ANGELES	30ML (0.5-5mCi/mL)	N212642	001	Dec 01, 2020	Jun	CTNA
>D>	+	!	UNIV OF CA SAN FRAN	20ML (0.5-5mCi/mL)	N212643	001	Dec 01, 2020	Jun	CTNA

GANAXOLONE

>A>		SUSPENSION;ORAL							
>A>		ZTALMY							
>A>	+	!	MARINUS	50MG/ML	N215904	001	Jun 01, 2022	Jun	NEWA

GANCICLOVIR SODIUM

INJECTABLE;INJECTION
GANCICLOVIR SODIUM
@ STERISCIENCE

EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Feb	CAHN
--------------------	---------	-----	--------------	-----	------

GANIRELIX ACETATE

INJECTABLE;INJECTION
FYREMADEL

AP		SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	May	CTNA
		GANIRELIX ACETATE						
AP		AMPHASTAR PHARMS INC	250MCG/0.5ML	A212613	001	Apr 07, 2022	Apr	NEWA
AP		HONG KONG	250MCG/0.5ML	A214996	001	Jun 06, 2022	May	NEWA

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

>D>		@ MYLAN	0.5%	A206446	001	Jun 08, 2018	Jun	CAHN
>A>		@ RISING	0.5%	A206446	001	Jun 08, 2018	Jun	CAHN

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	TEYRO LABS	EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Apr	CAHN
AP		EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Apr	CAHN

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

@	CHARTWELL RX	600MG	A074615	001	Sep 29, 1995	Feb	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

GEMIFLOXACIN MESYLATETABLET; ORAL
FACTIVE

+	@ LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jan	DISC
	GEMIFLOXACIN MESYLATE						
@	ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jan	DISC

GLIPIZIDETABLET; ORAL
GLIPIZIDE

AB	!	APOTEX	10MG	A075795	002	Jun 13, 2001	May	CHRS
AB		AUROBINDO PHARMA USA	5MG	A074226	001	May 10, 1994	Feb	CAHN
AB			10MG	A074226	002	May 10, 1994	Feb	CAHN
		GLUCOTROL						
+	@	PFIZER	5MG	N017783	001	May 08, 1984	May	DISC
+	@		10MG	N017783	002	May 08, 1984	May	DISC

GLYBURIDETABLET; ORAL
GLYBURIDE (MICRONIZED)

@	CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998	Feb	CAHN
@		3MG	A075174	002	Jun 22, 1998	Feb	CAHN

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

@	ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021	May	DISC
---	--------------	----------	---------	-----	--------------	-----	------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYCOPYRROLATE

+	!	FRESENIUS KABI USA	0.6MG/3ML (0.2MG/ML)	N214919	001	Apr 21, 2022	Apr	NEWA
---	---	--------------------	----------------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

GLYCOPYRROLATE

>A>	AA	ANNORA PHARMA	1MG/5ML	A213698	001	Jul 05, 2022	Jun	NEWA
>A>	AA	SUVEN PHARMS	1MG/5ML	A212467	001	Jul 05, 2022	Jun	NEWA

GRANISETRON HYDROCHLORIDEINJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

AP	AMNEAL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May	CAHN

GUANFACINE HYDROCHLORIDETABLET; ORAL
GUANFACINE HYDROCHLORIDE

AB	TWI PHARMS	EQ 1MG BASE	A216399	001	Jun 08, 2022	May	NEWA
AB		EQ 2MG BASE	A216399	002	Jun 08, 2022	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May	CMFD
AB		EQ 2MG BASE	A213428	002	Nov 25, 2020	May	CMFD
AB		EQ 3MG BASE	A213428	003	Nov 25, 2020	May	CMFD
AB		EQ 4MG BASE	A213428	004	Nov 25, 2020	May	CMFD

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

>A>	AB	ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jun	NEWA
>A>	AB		1MG	A200854	002	Jul 01, 2022	Jun	NEWA
>A>	AB		2MG	A200854	003	Jul 01, 2022	Jun	NEWA
>A>	AB		5MG	A200854	004	Jul 01, 2022	Jun	NEWA
>A>	AB		10MG	A200854	005	Jul 01, 2022	Jun	NEWA
>A>	AB		20MG	A200854	006	Jul 01, 2022	Jun	NEWA
	AB	SANDOZ	0.5MG	A071209	002	Nov 17, 1986	Mar	CMS1
	AB		1MG	A071209	003	Nov 17, 1986	Mar	CMS1
		@	2MG	A071209	004	Nov 17, 1986	Mar	CMS1

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992	Mar	CTEC
		@ HOSPIRA	4,000 UNITS/100ML	N019805	001	Jan 25, 1989	Mar	DISC
		HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
		@ HOSPIRA	5,000 UNITS/100ML	N019805	002	Jan 25, 1989	Mar	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

AB	+	!	AZURITY	37.5MG;20MG	N020727	001	Jun 23, 2005	Mar	CFTG
		+		37.5MG;20MG	N020727	001	Jun 23, 2005	Mar	CAHN
		ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE							
AB			RICONPHARMA LLC	37.5MG;20MG	A215586	001	Apr 06, 2022	Mar	NFTG

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

		@	CHARTWELL RX	25MG	A087565	001	Mar 09, 1982	Feb	CAHN
		@		50MG	A084912	001		Feb	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@	CHARTWELL RX	25MG;40MG	A071060	001	Aug 26, 1987	Feb	CAHN
		@		25MG;80MG	A071061	001	Aug 26, 1987	Jan	CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

>D>		@	LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Jun	CTNA
>D>		@		12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May	DISC
	AB			12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May	CTNA
>D>		@		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Jun	CTNA
		@		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May	DISC
	AB			12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May	CTNA
>D>		@		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Jun	CTNA
		@		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May	DISC
	AB			25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May	CTNA
>A>		QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
>A>		@	LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Jun	CTNA
>A>		@		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Jun	CTNA
>A>		@		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Jun	CTNA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>D>	AB		MYLAN	25MG;37.5MG	A074701	001	Jun 07, 1996	Jun	DISC
>A>		@		25MG;37.5MG	A074701	001	Jun 07, 1996	Jun	DISC

TABLET; ORAL

MAXZIDE

AB	+	!	AUROBINDO PHARMA USA	50MG;75MG	N019129	001	Oct 22, 1984	Feb	CAHN
			MAXZIDE-25						
AB	+		AUROBINDO PHARMA USA	25MG;37.5MG	N019129	003	May 13, 1988	Feb	CAHN
			TRIAMTERENE AND HYDROCHLOROTHIAZIDE						
AB			RUBICON	25MG;37.5MG	A216211	001	Feb 23, 2022	Feb	NEWA
AB				50MG;75MG	A216211	002	Feb 23, 2022	Feb	NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL
HYDROCODONE BITARTRATE

AB	ALVOGEN	20MG	A208269	001	Mar 01, 2021	May	CAHN
AB		30MG	A208269	002	Mar 01, 2021	May	CAHN
AB		40MG	A208269	003	Mar 01, 2021	May	CAHN
AB		60MG	A208269	004	Mar 01, 2021	May	CAHN
AB		80MG	A208269	005	Mar 01, 2021	May	CAHN
AB		100MG	A208269	006	Mar 01, 2021	May	CAHN
AB		120MG	A208269	007	Mar 01, 2021	May	CAHN

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

>D>	AT	LANNETT CO INC	2.5%	A040503	001	Mar 12, 2004	Jun	DISC
>A>		@	2.5%	A040503	001	Mar 12, 2004	Jun	DISC

LOTION; TOPICAL
ALA-SCALP

>A>		DERM RX	2%	A083231	001		Jun	CAHN
>D>		MARNEL PHARMS	2%	A083231	001		Jun	CAHN

HYDROCORTISONE

>D>	AT	LANNETT CO INC	2.5%	A040417	001	Jul 30, 2003	Jun	DISC
>A>		@	2.5%	A040417	001	Jul 30, 2003	Jun	DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROMORPHONE HYDROCHLORIDE

>A>		HOSPIRA INC	0.5MG/0.5ML	N200403	004	Jun 13, 2022	Jun	NEWA
-----	--	-------------	-------------	---------	-----	--------------	-----	------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
CYANOKIT

@ BTG INTL 2.5GM/VIAL (5GM/KIT)
+! 5GM/VIAL (5GM/KIT)

N022041	002	Dec 15, 2006	Mar	CAHN
N022041	001	Apr 08, 2011	Mar	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

!	ACCORD HLTHCARE	400MG	A213342	004	Aug 18, 2021	Jan	CHRS
!		400MG	A213342	004	Aug 18, 2021	Jan	CHRS
AB	AUROBINDO PHARMA USA	200MG	A040274	001	May 29, 1998	May	CAHN
+	NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022	Jan	NEWA
+!		300MG	N214581	002	Jan 14, 2022	Jan	NEWA

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL
HYDROXYZINE HYDROCHLORIDE

@ PAI HOLDINGS PHARM 10MG/5ML

A040391	001	Apr 10, 2002	Jan	CAHN
---------	-----	--------------	-----	------

TABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May	CMFD
AB		25MG	A087871	003	Dec 20, 1982	May	CMFD
AB		50MG	A087871	001	Dec 20, 1982	May	CMFD

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

AB	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	May	CTEC
AB	STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	May	NEWA

TABLET; ORAL

IBUPROFEN
@ SUNSHINE 400MG
@ 600MG
@ 800MG

A204062	001	Sep 10, 2018	Mar	CAHN
A204062	002	Sep 10, 2018	Mar	CAHN
A204062	003	Sep 10, 2018	Mar	CAHN
A215318	001	Mar 30, 2022	Mar	NEWA
A215318	002	Mar 30, 2022	Mar	NEWA
A215318	003	Mar 30, 2022	Mar	NEWA

AB	YICHANG HUMANWELL	400MG	A215318	001	Mar 30, 2022	Mar	NEWA
AB		600MG	A215318	002	Mar 30, 2022	Mar	NEWA
AB		800MG	A215318	003	Mar 30, 2022	Mar	NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

AB	+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Apr	CTEC
AB	+		2MG	N022192	002	May 06, 2009	Apr	CTEC
AB	+		4MG	N022192	003	May 06, 2009	Apr	CTEC
AB	+		6MG	N022192	004	May 06, 2009	Apr	CTEC
AB	+		8MG	N022192	005	May 06, 2009	Apr	CTEC
AB	+		10MG	N022192	006	May 06, 2009	Apr	CTEC
AB	+		12MG	N022192	007	May 06, 2009	Apr	CTEC

ILOPERIDONE

AB		LUPIN LTD	1MG	A206890	001	May 05, 2022	Apr	NEWA
AB			2MG	A206890	002	May 05, 2022	Apr	NEWA
AB			4MG	A206890	003	May 05, 2022	Apr	NEWA
AB			6MG	A206890	004	May 05, 2022	Apr	NEWA
AB			8MG	A206890	005	May 05, 2022	Apr	NEWA
AB			10MG	A206890	006	May 05, 2022	Apr	NEWA
AB			12MG	A206890	007	May 05, 2022	Apr	NEWA

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

>A>	AB	QILU PHARM HAINAN	EQ 100MG BASE	A212135	001	Jun 21, 2022	Jun	NEWA
>A>	AB		EQ 400MG BASE	A212135	002	Jun 21, 2022	Jun	NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

	@	CHARTWELL RX	1.25MG	A074594	001	May 23, 1996	Feb	CAHN
	@		2.5MG	A074594	002	May 23, 1996	Feb	CAHN

IODIXANOL

INJECTABLE; INJECTION

IODIXANOL

AP		HENGRUI PHARMA	55%	A214271	001	May 19, 2022	May	NFTG
AP			65.2%	A214271	002	May 19, 2022	May	NFTG
		VISIPAQUE 270						
AP	+	GE HEALTHCARE	55%	N020351	001	Mar 22, 1996	May	CFTG
		VISIPAQUE 320						
AP	+	GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996	May	CFTG

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

AP	+	GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011	Mar	CFTG
AP		IOFLUPANE I-123						
AP		CURIUM	5mCi/2.5ML (2mCi/ML)	A213792	001	Mar 30, 2022	Mar	NFTG

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>A>		@ BAUSCH	0.02%	A075835	001	Oct 15, 2001	Jun	CAHN
>D>		@ BAUSCH AND LOMB INC	0.02%	A075835	001	Oct 15, 2001	Jun	CAHN

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

>A>	AB	BAUSCH	0.021MG/SPRAY	A076025	001	Mar 31, 2003	Jun	CAHN
>A>	AB		0.042MG/SPRAY	A076103	001	Mar 31, 2003	Jun	CAHN
>D>	AB	BAUSCH AND LOMB	0.021MG/SPRAY	A076025	001	Mar 31, 2003	Jun	CAHN
>D>	AB		0.042MG/SPRAY	A076103	001	Mar 31, 2003	Jun	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP		EUGIA PHARMA	500MG/25ML (20MG/ML)	A213278	004	Apr 11, 2022	Apr	NEWA
----	--	--------------	----------------------	---------	-----	--------------	-----	------

ISONIAZID

SYRUP; ORAL

ISONIAZID

	@	CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Mar	CAHN
--	---	--------------	----------	---------	-----	--------------	-----	------

	TABLET;ORAL							
	ISONIAZID							
AA	MIKART	100MG	A040090	001	Jun 26, 1997	Mar	CAHN	
AA		300MG	A040090	002	Jun 26, 1997	Mar	CAHN	
	<u>ISOSORBIDE MONONITRATE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	ISOSORBIDE MONONITRATE							
AB	SHANDONG	120MG	A214115	001	Apr 29, 2022	Apr	NEWA	
AB	ZYDUS PHARMS	30MG	A075395	001	Mar 16, 2000	Mar	CAHN	
AB		60MG	A075395	002	Mar 16, 2000	Mar	CAHN	
AB		120MG	A075395	003	Mar 16, 2000	Mar	CAHN	
	<u>ITRACONAZOLE</u>							
	CAPSULE;ORAL							
	ITRACONAZOLE							
	@ JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	May	DISC	
	<u>IVABRADINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	CORLANOR							
+	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan	CTEC	
+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan	CTEC	
	IVABRADINE HYDROCHLORIDE							
	@ CENTAUR PHARMS PVT	EQ 5MG BASE	A214051	001	Dec 30, 2021	Jan	DISC	
	@	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan	DISC	
	<u>KETOROLAC TROMETHAMINE</u>							
	INJECTABLE;INJECTION							
	KETOROLAC TROMETHAMINE							
	@ STERISCIENCE	15MG/ML	A078299	001	Jul 16, 2007	Feb	CAHN	
	@	15MG/ML	A201155	001	Aug 04, 2014	Feb	CAHN	
	@	30MG/ML	A078299	002	Jul 16, 2007	Feb	CAHN	
	@	30MG/ML	A201155	002	Aug 04, 2014	Feb	CAHN	
	SOLUTION/DROPS;OPHTHALMIC							
	KETOROLAC TROMETHAMINE							
>D>	AT	AKORN	0.4%	A078399	001	Nov 05, 2009	Jun	DISC
>A>		@	0.4%	A078399	001	Nov 05, 2009	Jun	DISC
	TABLET;ORAL							
	KETOROLAC TROMETHAMINE							
AB	HAVIX	10MG	A215788	001	Mar 23, 2022	Mar	NEWA	
AB	SENORES PHARMS	10MG	A215788	001	Mar 23, 2022	Mar	CAHN	
	<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE</u>							
	SOLUTION;IRRIGATION							
	OMIDRIA							
AT	+	RAYNER SURGICAL	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Feb	CAHN
	<u>KETOTIFEN FUMARATE</u>							
	DRUG-ELUTING CONTACT LENS;OPHTHALMIC							
	ACUVUE THERAVISION WITH KETOTIFEN							
	+	JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	Feb	NEWA
	<u>LABETALOL HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	LABETALOL HYDROCHLORIDE							
	@ STERISCIENCE	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN	
	<u>LACOSAMIDE</u>							
	SOLUTION;INTRAVENOUS							
	LACOSAMIDE							
AP	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A214677	001	May 03, 2022	Apr	NEWA	
AP	INDOCO	200MG/20ML (10MG/ML)	A214301	001	Apr 07, 2022	Apr	NFTG	
>A>	AP	ZYDUS PHARMS	200MG/20ML (10MG/ML)	A209465	001	Jun 29, 2022	Jun	NEWA
	VIMPAT							
AP	+	UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008	Apr	CFTG
	SOLUTION;ORAL							
	LACOSAMIDE							
AA	ALKEM LABS LTD	10MG/ML	A214672	001	May 19, 2022	May	NFTG	
AA	HETERO LABS LTD III	10MG/ML	A209301	001	May 31, 2022	May	NEWA	

SOLUTION;ORAL							
VIMPAT							
AA	+!	UCB INC	10MG/ML	N022255	001	Apr 20, 2010	May CFTG
TABLET;ORAL							
LACOSAMIDE							
AB		ALEMBIC PHARMS LTD	50MG	A204974	001	Mar 17, 2022	Mar NFTG
AB			100MG	A204974	002	Mar 17, 2022	Mar NFTG
AB			150MG	A204974	003	Mar 17, 2022	Mar NFTG
AB			200MG	A204974	004	Mar 17, 2022	Mar NFTG
AB		ALKEM LABS LTD	50MG	A214695	001	Mar 31, 2022	Mar NEWA
AB			100MG	A214695	002	Mar 31, 2022	Mar NEWA
AB			150MG	A214695	003	Mar 31, 2022	Mar NEWA
AB			200MG	A214695	004	Mar 31, 2022	Mar NEWA
AB		AMNEAL PHARMS	50MG	A204857	001	Mar 17, 2022	Mar NFTG
AB			100MG	A204857	002	Mar 17, 2022	Mar NFTG
AB			150MG	A204857	003	Mar 17, 2022	Mar NFTG
AB			200MG	A204857	004	Mar 17, 2022	Mar NFTG
AB		GLENMARK PHARMS LTD	50MG	A205006	001	Mar 17, 2022	Mar NFTG
AB			100MG	A205006	002	Mar 17, 2022	Mar NFTG
AB			150MG	A205006	003	Mar 17, 2022	Mar NFTG
AB			200MG	A205006	004	Mar 17, 2022	Mar NFTG
AB		HETERO LABS LTD V	50MG	A204787	001	Mar 17, 2022	Mar NFTG
AB			100MG	A204787	002	Mar 17, 2022	Mar NFTG
AB			150MG	A204787	003	Mar 17, 2022	Mar NFTG
AB			200MG	A204787	004	Mar 17, 2022	Mar NFTG
AB		INDOCO	50MG	A208308	001	Mar 17, 2022	Mar NFTG
AB			100MG	A208308	002	Mar 17, 2022	Mar NFTG
AB			150MG	A208308	003	Mar 17, 2022	Mar NFTG
AB			200MG	A208308	004	Mar 17, 2022	Mar NFTG
AB		MSN LABS PVT LTD	50MG	A204921	001	Mar 17, 2022	Mar NFTG
AB			100MG	A204921	002	Mar 17, 2022	Mar NFTG
AB			150MG	A204921	003	Mar 17, 2022	Mar NFTG
AB			200MG	A204921	004	Mar 17, 2022	Mar NFTG
AB		SCIEGEN PHARMS INC	50MG	A205237	001	Mar 17, 2022	Mar NFTG
AB			100MG	A205237	002	Mar 17, 2022	Mar NFTG
AB			150MG	A205237	003	Mar 17, 2022	Mar NFTG
AB			200MG	A205237	004	Mar 17, 2022	Mar NFTG
AB		SUN PHARM	50MG	A205031	001	Mar 17, 2022	Mar NFTG
AB			100MG	A205031	002	Mar 17, 2022	Mar NFTG
AB			150MG	A205031	003	Mar 17, 2022	Mar NFTG
AB			200MG	A205031	004	Mar 17, 2022	Mar NFTG
VIMPAT							
AB	+	UCB INC	50MG	N022253	001	Oct 28, 2008	Mar CFTG
AB	+		100MG	N022253	002	Oct 28, 2008	Mar CFTG
AB	+		150MG	N022253	003	Oct 28, 2008	Mar CFTG
AB	+!		200MG	N022253	004	Oct 28, 2008	Mar CFTG
<u>LACTULOSE</u>							
SOLUTION;ORAL							
LACTULOSE							
>D>	AA	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jun DISC
>A>		@	10GM/15ML	A207786	001	Jun 11, 2018	Jun DISC
SOLUTION;ORAL, RECTAL							
LACTULOSE							
>D>	AA	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jun DISC
>A>		@	10GM/15ML	A203762	001	Mar 27, 2015	Jun DISC
<u>LAMIVUDINE; ZIDOVUDINE</u>							
TABLET;ORAL							
LAMIVUDINE AND ZIDOVUDINE							
		@ CHARTWELL RX	150MG;300MG	A079081	001	May 25, 2011	Mar CAHN
<u>LAMOTRIGINE</u>							
TABLET, FOR SUSPENSION;ORAL							
LAMICTAL CD							
AB	+	GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Jan CDFR
AB	+		5MG	N020764	001	Aug 24, 1998	Jan CDFR
AB	+!		25MG	N020764	002	Aug 24, 1998	Jan CDFR
		@	100MG	N020764	003	Aug 24, 1998	Jan CDFR
LAMOTRIGINE							
AB		ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	Jan CDFR
AB			25MG	A201168	002	Jun 12, 2014	Jan CDFR
AB		AUROBINDO PHARMA	5MG	A090401	002	Nov 04, 2009	Jan CDFR

TABLET, FOR SUSPENSION;ORAL
LAMOTRIGINE

AB		25MG	A090401	003	Nov 04, 2009	Jan CDFR
AB	DR REDDYS LABS LTD	5MG	A076701	001	Jan 22, 2009	Jan CDFR
AB		25MG	A076701	002	Jan 22, 2009	Jan CDFR
AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	Jan CDFR
AB		25MG	A079099	002	Feb 19, 2009	Jan CDFR
	@ JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jan CDFR
		25MG	A200220	002	Feb 28, 2011	Jan CDFR
	@ MYLAN	5MG	A076630	001	Jan 22, 2009	Jan CDFR
		25MG	A076630	002	Jan 22, 2009	Jan CDFR
	@ SANDOZ	5MG	A078409	002	Jan 22, 2009	Jan CDFR
		25MG	A078409	003	Jan 22, 2009	Jan CDFR
AB	TARO	5MG	A079204	001	Feb 04, 2009	Jan CDFR
AB		25MG	A079204	002	Feb 04, 2009	Jan CDFR
	@ TEVA	5MG	A076420	001	Jun 21, 2006	Jan CDFR
		25MG	A076420	002	Jun 21, 2006	Jan CDFR
AB	WATSON LABS	2MG	A076928	001	Jan 22, 2009	Jan CDFR
AB		5MG	A076928	002	Jan 22, 2009	Jan CDFR
AB		25MG	A076928	003	Jan 22, 2009	Jan CDFR
AB	ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009	Jan CDFR
AB		25MG	A078009	003	Jan 22, 2009	Jan CDFR

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB	AMRING PHARMS	25MG	A214124	001	Feb 03, 2022	Jan NEWA
AB		50MG	A214124	002	Feb 03, 2022	Jan NEWA
AB		100MG	A214124	003	Feb 03, 2022	Jan NEWA
AB		200MG	A214124	004	Feb 03, 2022	Jan NEWA
>D> AB	IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jun DISC
>A>	@	25MG	A200828	001	Jul 15, 2013	Jun DISC
>D> AB		50MG	A200828	002	Jul 15, 2013	Jun DISC
>A>	@	50MG	A200828	002	Jul 15, 2013	Jun DISC
>D> AB		100MG	A200828	003	Jul 15, 2013	Jun DISC
>A>	@	100MG	A200828	003	Jul 15, 2013	Jun DISC
>D> AB		200MG	A200828	004	Jul 15, 2013	Jun DISC
>A>	@	200MG	A200828	004	Jul 15, 2013	Jun DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	ATLANTIDE	15MG	A202176	001	Sep 14, 2012	Apr CAHN
AB		30MG	A202176	002	Sep 14, 2012	Apr CAHN

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL
LANTHANUM CARBONATE

AB	BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan NEWA
AB		EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan NEWA
AB		EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan NEWA
AB	INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan NEWA
AB		EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan NEWA
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan NEWA

LEFLUNOMIDE

TABLET;ORAL
LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan CMFD
AB		20MG	A213497	002	May 10, 2021	Jan CMFD
>D> AB	FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jun CAHN
>D> AB		20MG	A077087	002	Sep 13, 2005	Jun CAHN
>A> AB	WANBANG BIOPHARMS	10MG	A077087	001	Sep 13, 2005	Jun CAHN
>A> AB		20MG	A077087	002	Sep 13, 2005	Jun CAHN

LEUPROLIDE ACETATE

FOR SUSPENSION;INTRAMUSCULAR
LUTRATE DEPOT KIT

>D>	+!	GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun CAHN
	+!		22.5MG/VIAL	N205054	001	Aug 28, 2018	May CMFD
>A>	+!	INVAGEN PHARMS	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun CAHN
		INJECTABLE;INJECTION					
		LEUPROLIDE ACETATE					
AP	EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	May NEWA	

>D>	INJECTABLE; INJECTION								
>D>	LUPRON DEPOT								
>D>	+ @ ABBVIE ENDOCRINE INC	3.75MG/VIAL		N020011	001	Oct 22, 1990	Jun	CDFR	
>D>	+!	3.75MG		N020011	002	Oct 26, 1995	Jun	CDFR	
>A>	POWDER; INTRAMUSCULAR								
>A>	LUPRON DEPOT								
>A>	+ @ ABBVIE ENDOCRINE INC	3.75MG/VIAL		N020011	001	Oct 22, 1990	Jun	CDFR	
>A>	+!	3.75MG		N020011	002	Oct 26, 1995	Jun	CDFR	
<u>LEUPROLIDE MESYLATE</u>									
	EMULSION; SUBCUTANEOUS								
	CAMCEVI KIT								
	+! ACCORD	EQ 42MG BASE		N211488	001	May 25, 2021	Jan	CAHN	
<u>LEVETIRACETAM</u>									
	INJECTABLE; INTRAVENOUS								
	LEVETIRACETAM								
AP	PRINSTON INC	500MG/5ML (100MG/ML)		A209474	001	Mar 28, 2022	Mar	NEWA	
	SOLUTION; ORAL								
	LEVETIRACETAM								
>A> AA	AIPING PHARM INC	100MG/ML		A090079	001	Apr 11, 2012	Jun	CAHN	
>A> AA	BELCHER	100MG/ML		A090461	001	Sep 30, 2010	Jun	CAHN	
>D> AA	GENUS	100MG/ML		A090079	001	Apr 11, 2012	Jun	CAHN	
>D> AA	TRIS PHARMA INC	100MG/ML		A090461	001	Sep 30, 2010	Jun	CAHN	
	@ WOCKHARDT BIO AG	100MG/ML		A090028	001	Mar 03, 2010	Apr	DISC	
	TABLET; ORAL								
	LEVETIRACETAM								
AB	ALKEM LABS LTD	250MG		A216375	001	May 27, 2022	May	NEWA	
AB		500MG		A216375	002	May 27, 2022	May	NEWA	
AB		750MG		A216375	003	May 27, 2022	May	NEWA	
AB		1GM		A216375	004	May 27, 2022	May	NEWA	
	@ LOTUS PHARM CO LTD	500MG		A090906	001	Nov 05, 2010	Apr	DISC	
AB	SCIEGEN PHARMS INC	250MG		A215069	003	May 27, 2022	May	NEWA	
AB		500MG		A215069	004	May 27, 2022	May	NEWA	
>D>	@	750MG		A215069	001	Jun 11, 2021	Jun	CMFD	
>A> AB		750MG		A215069	001	Jun 11, 2021	Jun	CMFD	
	@	750MG		A215069	001	Jun 11, 2021	Apr	DISC	
>D>	@	1GM		A215069	002	Jun 11, 2021	Jun	CMFD	
>A> AB		1GM		A215069	002	Jun 11, 2021	Jun	CMFD	
	@	1GM		A215069	002	Jun 11, 2021	Apr	DISC	
	@ SECAN PHARMS	500MG		A205102	004	Dec 16, 2015	Jan	DISC	
	@	1GM		A205102	003	Dec 16, 2015	Jan	DISC	
AB	STALLION LABS	250MG		A079042	001	Jan 15, 2009	Mar	CAHN	
AB		500MG		A079042	002	Jan 15, 2009	Mar	CAHN	
AB		750MG		A079042	003	Jan 15, 2009	Mar	CAHN	
AB		1GM		A079042	004	Jan 15, 2009	Mar	CAHN	
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>									
	SOLUTION; ORAL								
	LEVOCETIRIZINE DIHYDROCHLORIDE								
>A> AA	CHARTWELL MOLECULAR	2.5MG/5ML		A204599	001	May 15, 2017	Jun	CAHN	
>D> AA	LANNETT CO INC	2.5MG/5ML		A204599	001	May 15, 2017	Jun	CAHN	
	XYZAL								
	+ @ CHATTEM SANOFI	2.5MG/5ML		N022157	001	Jan 28, 2008	Jan	CAHN	
	TABLET; ORAL								
	XYZAL								
	+ @ CHATTEM SANOFI	5MG		N022064	001	May 25, 2007	Jan	CAHN	
<u>LEVOFLOXACIN</u>									
	TABLET; ORAL								
	LEVOFLOXACIN								
AB	CHARTWELL MOLECULAR	250MG		A076890	001	Mar 30, 2012	Mar	CAHN	
AB		500MG		A076890	002	Mar 30, 2012	Mar	CAHN	
AB		750MG		A076890	003	Mar 30, 2012	Mar	CAHN	
<u>LEVOLEUCOVORIN CALCIUM</u>									
	SOLUTION; INTRAVENOUS								
	LEVOLEUCOVORIN CALCIUM								
	@ PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A213797	001	Nov 02, 2021	Feb	DISC	

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

@ L PERRIGO CO

0.75MG

A090740 001 Dec 30, 2010 May DISC

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

@ TEVA PHARMS USA INC

0.112MG

A211369 003 Apr 16, 2021 Jan DISC

TIROSINT

>A>	+	INSTITUT BIOCHIMIQUE	0.0375MG	N021924	014	Jun 22, 2022	Jun NEWA
>A>	+		0.044MG	N021924	015	Jun 22, 2022	Jun NEWA
>A>	+		0.0625MG	N021924	016	Jun 22, 2022	Jun NEWA
	+		0.112MG	N021924	008	Oct 02, 2009	Jan CTEC

SOLUTION;ORAL

ERMEZA

+! MYLAN

150MCG/5ML

N215809 001 Apr 29, 2022 Apr NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

AB1, GENUS LIFESCIENCES

0.025MG

N021137 001 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.05MG

N021137 002 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.075MG

N021137 003 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.088MG

N021137 004 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.1MG

N021137 005 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.112MG

N021137 006 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.125MG

N021137 007 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.137MG

N021137 008 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.15MG

N021137 009 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.175MG

N021137 010 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.2MG

N021137 011 Jun 06, 2003 Jan CMFD

AB3,

AB4

AB1,

0.3MG

N021137 012 Jun 06, 2003 Jan CMFD

AB3,

AB4

LEVOTHYROXINE SODIUM

AB1, WATSON LABS TEVA

0.025MG

A207588 001 May 10, 2022 Apr NEWA

AB2

AB1,

0.05MG

A207588 002 May 10, 2022 Apr NEWA

AB2

AB1,

0.075MG

A207588 003 May 10, 2022 Apr NEWA

AB2

AB1,

0.088MG

A207588 004 May 10, 2022 Apr NEWA

AB2

AB1,

0.1MG

A207588 005 May 10, 2022 Apr NEWA

AB2

AB1,

0.112MG

A207588 006 May 10, 2022 Apr NEWA

AB2

AB1,

0.125MG

A207588 007 May 10, 2022 Apr NEWA

AB2

AB1,

0.137MG

A207588 008 May 10, 2022 Apr NEWA

AB2

AB1,

0.15MG

A207588 009 May 10, 2022 Apr NEWA

AB2

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB1,		0.175MG	A207588	010	May 10, 2022	Apr	NEWA
AB2							
AB1,		0.2MG	A207588	011	May 10, 2022	Apr	NEWA
AB2							
AB1,		0.3MG	A207588	012	May 10, 2022	Apr	NEWA
AB2							

THYRO-TABS

AB1, +	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.05MG	N021116	002	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.075MG	N021116	003	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.088MG	N021116	010	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.1MG	N021116	004	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.112MG	N021116	011	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.125MG	N021116	005	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.137MG	N021116	012	Dec 07, 2004	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.15MG	N021116	006	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.175MG	N021116	007	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.2MG	N021116	008	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							
AB1, +		0.3MG	N021116	009	Oct 24, 2002	Apr	CTEC
AB2,							
AB3,							
AB4							

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

AKTEN

+!	THEA PHARMA	3.5%	N022221	001	Oct 07, 2008	Apr	CAHN
----	-------------	------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>A>	AP	AFAXYS	1%	A215132	001	Jun 09, 2022	Jun	NEWA
	AP	SINETICA SA	4%	A214269	001	May 05, 2022	Apr	NEWA
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
	AP	! HOSPIRA	4%	A088295	001	May 17, 1984	Apr	CTEC

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT		NOVITIUM PHARMA	4%	A216250	001	Mar 23, 2022	Mar	NEWA
----	--	-----------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

>D>	@	ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jun	CAHN
	@		2.5%;2.5%	A212482	001	Jul 27, 2021	Jan	DISC
AB		ALEOR DERMACEUTICALS	2.5%;2.5%	A213923	001	Apr 08, 2022	Apr	NEWA

	CREAM; TOPICAL								
	LIDOCAINE AND PRILOCAINE								
>A>	@ PADAGIS US	2.5%; 2.5%		A212482	001	Jul 27, 2021	Jun	CAHN	
	<u>LINEZOLID</u>								
	SOLUTION; INTRAVENOUS								
	LINEZOLID								
	@ HOSPIRA INC	600MG/300ML (2MG/ML)		A205442	001	Jul 07, 2015	May	DISC	
	<u>LISINOPRIL</u>								
	TABLET; ORAL								
	LISINOPRIL								
	@ GRAVITI PHARMS	2.5MG		A075999	001	Jul 01, 2002	Apr	CAHN	
	@	5MG		A075999	002	Jul 01, 2002	Apr	CAHN	
	@	10MG		A075999	003	Jul 01, 2002	Apr	CAHN	
	@	20MG		A075999	004	Jul 01, 2002	Apr	CAHN	
	@	30MG		A075999	005	Jul 01, 2002	Apr	CAHN	
	@	40MG		A075999	006	Jul 01, 2002	Apr	CAHN	
	@ STRIDES PHARMA	2.5MG		A076071	001	Jul 01, 2002	Jan	CAHN	
	@	5MG		A076071	002	Jul 01, 2002	Jan	CAHN	
	@	10MG		A076071	003	Jul 01, 2002	Jan	CAHN	
	@	20MG		A076071	004	Jul 01, 2002	Jan	CAHN	
	@	30MG		A076071	005	Jul 01, 2002	Jan	CAHN	
	@	40MG		A076071	006	Jul 01, 2002	Jan	CAHN	
	PRINIVIL								
	@ MERCK	5MG		N019558	001	Dec 29, 1987	Mar	DISC	
	@	40MG		N019558	004	Oct 25, 1988	Mar	DISC	
	<u>LITHIUM CITRATE</u>								
	SYRUP; ORAL								
	LITHIUM CITRATE								
	+ @ HIKMA	EQ 300MG CARBONATE/5ML		N018421	001		Apr	DISC	
	! PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML		A070755	001	May 21, 1986	Apr	CAHN	
	! WOCKHARDT BIO AG	EQ 300MG CARBONATE/5ML		A070755	001	May 21, 1986	Apr	CTEC	
AA	!	EQ 300MG CARBONATE/5ML		A070755	001	May 21, 1986	Apr	CHRS	
	<u>LOPERAMIDE HYDROCHLORIDE</u>								
	CAPSULE; ORAL								
	LOPERAMIDE HYDROCHLORIDE								
	@ CHARTWELL RX	2MG		A072993	001	Aug 28, 1992	Mar	CAHN	
	<u>LOPINAVIR; RITONAVIR</u>								
	TABLET; ORAL								
	LOPINAVIR AND RITONAVIR								
AB	LAURUS	100MG; 25MG		A213857	001	Mar 21, 2022	Mar	NEWA	
AB		200MG; 50MG		A213857	002	Mar 21, 2022	Mar	NEWA	
	<u>LORAZEPAM</u>								
	CAPSULE, EXTENDED RELEASE; ORAL								
	LOREEV XR								
	+ ALMATICA	1.5MG		N214826	004	Feb 16, 2022	Feb	NEWA	
	CONCENTRATE; ORAL								
	LORAZEPAM								
>D> AA	LANNETT CO INC	2MG/ML		A079244	001	Apr 28, 2009	Jun	DISC	
>A>	@	2MG/ML		A079244	001	Apr 28, 2009	Jun	DISC	
	<u>LUBIPROSTONE</u>								
	CAPSULE; ORAL								
	LUBIPROSTONE								
	@ AMNEAL	8MCG		A209450	001	Nov 30, 2021	May	DISC	
	@	24MCG		A209450	002	Nov 30, 2021	May	DISC	
>A> AB	ANCHEN PHARMS	8MCG		A201442	001	Jun 27, 2022	Jun	NEWA	
>A> AB		24MCG		A201442	002	Jun 27, 2022	Jun	NEWA	
AB	DR REDDYS	8MCG		A206994	001	Feb 08, 2022	Jan	NEWA	
AB		24MCG		A206994	002	Feb 08, 2022	Jan	NEWA	
AB	TEVA PHARMS USA INC	8MCG		A209920	001	Jan 18, 2022	Jan	NEWA	
AB		24MCG		A209920	002	Jan 18, 2022	Jan	NEWA	

LUMATEPERONE TOSYLATECAPSULE;ORAL
CAPLYTA

+	INTRA-CELLULAR	EQ 10.5MG BASE	N209500	002	Apr 22, 2022	May	NEWA
+		EQ 21MG BASE	N209500	003	Apr 22, 2022	May	NEWA

>D> LUTETIUM DOTATATE LU-177>D> SOLUTION;INTRAVENOUS
>D> LUTATHERA

>D>	+	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jun	CAIN
-----	---	-------------	----------	---------	-----	--------------	-----	------

>A> LUTETIUM LU 177 DOTATATE>A> SOLUTION;INTRAVENOUS
>A> LUTATHERA

>A>	+	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jun	CAIN
-----	---	-------------	----------	---------	-----	--------------	-----	------

LUTETIUM LU-177 VIPIVOTIDE TETRAJETANSOLUTION;INTRAVENOUS
PLUVICTO

+	AAA USA NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022	Mar	NEWA
---	------------------	----------	---------	-----	--------------	-----	------

MAFENIDE ACETATEFOR SOLUTION;TOPICAL
MAFENIDE ACETATE

AT	!	PAR FORM	5%	A201511	001	Feb 12, 2013	Feb	CHRS
		SULFAMYLON						

+	@	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Feb	DISC
---	---	---------------------	----	---------	-----	--------------	-----	------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATEINJECTABLE;INJECTION
KABILYTE

>D>	AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;	A215371	001	Jun 08, 2022	Jun	CTNA
			526MG/100ML;502MG/100ML					

AP			30MG/100ML;37MG/100ML;368MG/100ML;	A215371	001	Jun 08, 2022	May	NFTG
			526MG/100ML;502MG/100ML					

>A> MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

>A>	AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;	A215370	001	Jun 29, 2022	Jun	NFTG
			526MG/100ML;502MG/100ML					

>A> MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

>A>	AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;	A215371	001	Jun 08, 2022	Jun	CTNA
			526MG/100ML;502MG/100ML					

>D> PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;	N017378	001		Jun	CFTG
			526MG/100ML;502MG/100ML					

>A>	AP	+	30MG/100ML;37MG/100ML;368MG/100ML;	N017378	001		Jun	CFTG
			526MG/100ML;502MG/100ML					

>A> PLASMA-LYTE A IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;	N017378	002	Nov 22, 1982	May	CFTG
			526MG/100ML;502MG/100ML					

MAGNESIUM SULFATEINJECTABLE;INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

>A>	AP	MILLA PHARMS	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jun	CAHN
-----	----	--------------	--------------------	---------	-----	--------------	-----	------

>A>	AP		4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jun	CAHN
-----	----	--	---------------------	---------	-----	--------------	-----	------

>A>	AP		4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jun	CAHN
-----	----	--	--------------------	---------	-----	--------------	-----	------

>D>	AP	PTS CONSULTING	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jun	CAHN
-----	----	----------------	--------------------	---------	-----	--------------	-----	------

>D>	AP		4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jun	CAHN
-----	----	--	---------------------	---------	-----	--------------	-----	------

>D>	AP		4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jun	CAHN
-----	----	--	--------------------	---------	-----	--------------	-----	------

MARAVIROCTABLET;ORAL
MARAVIROC

AB		HETERO LABS LTD III	150MG	A203347	001	Feb 07, 2022	Jan	NFTG
----	--	---------------------	-------	---------	-----	--------------	-----	------

AB			300MG	A203347	002	Feb 07, 2022	Jan	NFTG
----	--	--	-------	---------	-----	--------------	-----	------

SELZENTRY

AB	+	VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007	Jan	CFTG
----	---	---------------	-------	---------	-----	--------------	-----	------

AB	+		300MG	N022128	002	Aug 06, 2007	Jan	CFTG
----	---	--	-------	---------	-----	--------------	-----	------

MAVACAMTENCAPSULE;ORAL
CAMZYOS

+	MYOKARDIA	2.5MG	N214998	001	Apr 28, 2022	Apr	NEWA
+		5MG	N214998	002	Apr 28, 2022	Apr	NEWA
+		10MG	N214998	003	Apr 28, 2022	Apr	NEWA
+	!	15MG	N214998	004	Apr 28, 2022	Apr	NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA	APNAR PHARMA LP	12.5MG	A087128	002		Apr	CAHN
AA		25MG	A087128	001		Apr	CAHN
AA	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Feb	NEWA
AA		25MG	A200432	002	Feb 17, 2022	Feb	NEWA
AA		50MG	A200432	003	Feb 17, 2022	Feb	NEWA

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

AA	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Feb	NEWA
----	----------------	------	---------	-----	--------------	-----	------

MELOXICAM

CAPSULE;ORAL

VIVLODEX

+	@ ICEUTICA OPERATIONS	5MG	N207233	001	Oct 22, 2015	Mar	CAHN
+	@	10MG	N207233	002	Oct 22, 2015	Mar	CAHN

SUSPENSION;ORAL

MELOXICAM

+	!	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	May	CTNA
+	!		7.5MG/5ML	N021530	001	Jun 01, 2004	May	CMFD

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

@	NANJING	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Apr	CAHN
---	---------	-------------------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

@	ANI PHARMS	14MG	A205365	002	Feb 28, 2020	Apr	DISC
---	------------	------	---------	-----	--------------	-----	------

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	ALLIED	5MG	A209527	001	May 07, 2018	Feb	CAHN
AB		10MG	A209527	002	May 07, 2018	Feb	CAHN
	@ RISING	5MG	A079225	001	Jan 30, 2015	Jan	CAHN
	@	10MG	A079225	002	Jan 30, 2015	Jan	CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

@	GENUS	50MG	A040893	001	Jun 24, 2009	Apr	CAHN
@		75MG	A040893	002	Jun 24, 2009	Apr	CAHN
@		100MG	A040893	003	Jun 24, 2009	Apr	CAHN
@		150MG	A040893	004	Jun 24, 2009	Apr	CAHN
@	MIKART	50MG	A040893	001	Jun 24, 2009	Mar	CAHN
@		75MG	A040893	002	Jun 24, 2009	Mar	CAHN
@		100MG	A040893	003	Jun 24, 2009	Mar	CAHN
@		150MG	A040893	004	Jun 24, 2009	Mar	CAHN

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

MESALAMINE

AB	SUN PHARM	500MG	A214585	001	May 11, 2022	Apr	NFTG
AB	TEVA PHARMS USA	375MG	A209970	001	May 06, 2022	Apr	NEWA

AB	+	!	TAKEDA PHARMS USA	500MG	N020049	002	Jul 08, 2004	Apr	CFTG
----	---	---	-------------------	-------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

ASACOL HD

+	@	APIL	800MG	N021830	001	May 29, 2008	May	DISC
---	---	------	-------	---------	-----	--------------	-----	------

MESALAMINE

!	ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017	May	CTEC	
AB	!		800MG	A203286	001	Jul 21, 2017	May	CHRS

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB1	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Feb	CTEC	
AB		750MG	A078596	002	Jan 03, 2008	Feb	CTEC	
	@ AMTA	500MG	A213394	001	Aug 03, 2021	Jan	DISC	
	@	1GM	A213394	002	Aug 03, 2021	Jan	DISC	
>A>	AB3	PRINSTON INC	500MG	A212681	001	Jun 09, 2022	Jun	NEWA
>A>	AB3		1GM	A212681	002	Jun 09, 2022	Jun	NEWA
	AB2	SCIEGEN PHARMS INC	500MG	A214629	001	Feb 22, 2022	Feb	NEWA
	AB2		1GM	A214629	002	Feb 22, 2022	Feb	NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

	+ @ TAKEDA PHARMS USA	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	May	DISC
--	-----------------------	--------------------	---------	-----	--------------	-----	------

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

@ NOSTRUM LABS INC

5MG

A210484 001 Aug 02, 2018 Feb DISC

@

10MG

A210484 002 Aug 02, 2018 Feb DISC

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB BAUSCH AND LOMB INC

25MG

A207438 001 Oct 05, 2018 Apr CAHN

AB

50MG

A207438 002 Oct 05, 2018 Apr CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB + VALIDUS PHARMS

1GM

N017681 001 Apr CMFD

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE LPF

	+ @ HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan	CRLD
--	-------------	-----------------	---------	-----	--------------	-----	------

METHOTREXATE PRESERVATIVE FREE

	+ @ HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan	CRLD
--	-------------	------------------------------------	---------	-----	--------------	-----	------

	+ @	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan	CRLD
--	-----	---------------------------------------	---------	-----	--------------	-----	------

METHOTREXATE SODIUM

	+ @ HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan	CRLD
--	-------------	------------------	---------	-----	--	-----	------

	+ @	EQ 20MG BASE/VIAL	N011719	001		Jan	CRLD
--	-----	-------------------	---------	-----	--	-----	------

	+ @	EQ 25MG BASE/ML	N011719	005		Jan	CRLD
--	-----	-----------------	---------	-----	--	-----	------

	+ @	EQ 50MG BASE/VIAL	N011719	003		Jan	CRLD
--	-----	-------------------	---------	-----	--	-----	------

	+ @	EQ 100MG BASE/VIAL	N011719	006		Jan	CRLD
--	-----	--------------------	---------	-----	--	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

	@ EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	CAHN
--	------------------------	------------------------------------	---------	-----	--------------	-----	------

@

EQ 100MG BASE/4ML (EQ 25MG BASE/ML)

A201529 002 Mar 29, 2012 Mar CAHN

@

EQ 200MG BASE/8ML (EQ 25MG BASE/ML)

A201529 003 Mar 29, 2012 Mar CAHN

@

EQ 250MG BASE/10ML (EQ 25MG BASE/ML)

A201529 004 Mar 29, 2012 Mar CAHN

AP HIKMA

EQ 250MG BASE/10ML (EQ 25MG BASE/ML)

A089343 001 Sep 16, 1986 Jan CHRS

+ @ HOSPIRA

EQ 1GM BASE/VIAL

N011719 009 Apr 07, 1988 Jan CRLD

MEXATE-AQ

	+ @ BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan	CRLD
--	-------------------	-----------------	---------	-----	--------------	-----	------

METHYLPHENIDATE

FILM, EXTENDED RELEASE;TRANSDERMAL

DAYTRANA

AB	+ NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar	CFTG
----	--------------------	---------------------	---------	-----	--------------	-----	------

AB	+	15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar	CFTG
----	---	---------------------	---------	-----	--------------	-----	------

AB	+	20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar	CFTG
----	---	---------------------	---------	-----	--------------	-----	------

AB	+!	30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar	CFTG
----	----	---------------------	---------	-----	--------------	-----	------

METHYLPHENIDATE

AB	MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	A206497	001	Mar 14, 2022	Mar	NFTG
----	--------------------	---------------------	---------	-----	--------------	-----	------

AB		15MG/9HR (1.6MG/HR)	A206497	002	Mar 14, 2022	Mar	NFTG
----	--	---------------------	---------	-----	--------------	-----	------

FILM, EXTENDED RELEASE;TRANSDERMAL
METHYLPHENIDATE

AB		20MG/9HR (2.2MG/HR)	A206497	003	Mar 14, 2022	Mar	NFTG
AB		30MG/9HR (3.3MG/HR)	A206497	004	Mar 14, 2022	Mar	NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
METADATE CD

AB2	+	AYTU BIOPHARMA	10MG	N021259	003	May 27, 2003	May	CAHN
AB2	+		20MG	N021259	001	Apr 03, 2001	May	CAHN
AB2	+		30MG	N021259	002	Jun 19, 2003	May	CAHN
AB2	+		40MG	N021259	004	Feb 19, 2006	May	CAHN
AB2	+		50MG	N021259	005	Feb 19, 2006	May	CAHN
AB2	+		60MG	N021259	006	Feb 19, 2006	May	CAHN

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS LABS FL	72MG	A076655	002	Feb 28, 2022	Feb	NEWA
AB	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Feb	CTEC
>D>	AB	RHODES PHARMS	18MG	A214111	001	May 31, 2022	Jun	DISC
>A>		@	18MG	A214111	001	May 31, 2022	Jun	DISC
	AB		18MG	A214111	001	May 31, 2022	May	NEWA
>D>	AB		27MG	A214111	002	May 31, 2022	Jun	DISC
>A>		@	27MG	A214111	002	May 31, 2022	Jun	DISC
	AB		27MG	A214111	002	May 31, 2022	May	NEWA
>D>	AB		36MG	A214111	003	May 31, 2022	Jun	DISC
>A>		@	36MG	A214111	003	May 31, 2022	Jun	DISC
	AB		36MG	A214111	003	May 31, 2022	May	NEWA
>D>	AB		54MG	A214111	004	May 31, 2022	Jun	DISC
>A>		@	54MG	A214111	004	May 31, 2022	Jun	DISC
	AB		54MG	A214111	004	May 31, 2022	May	NEWA
>A>		RELEXXII						
>A>	+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022	Jun	NEWA
>A>	+		27MG	N216117	002	Jun 23, 2022	Jun	NEWA
>A>	+		36MG	N216117	003	Jun 23, 2022	Jun	NEWA
>A>	+		45MG	N216117	004	Jun 23, 2022	Jun	NEWA
>A>	+		54MG	N216117	005	Jun 23, 2022	Jun	NEWA
>A>	+		63MG	N216117	006	Jun 23, 2022	Jun	NEWA
>A>	+		72MG	N216117	007	Jun 23, 2022	Jun	NEWA

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

	@	AMNEAL	4MG	A207481	001	Sep 21, 2021	Mar	DISC
	@		8MG	A207481	002	Sep 21, 2021	Mar	DISC
	@		16MG	A207481	003	Sep 21, 2021	Mar	DISC
	@		32MG	A207481	004	Sep 21, 2021	Mar	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB		PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Jan	NEWA
AB			80MG/ML	A214297	002	Jan 21, 2022	Jan	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Jan	CMFD
AP			EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Jan	CMFD
AP			EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Jan	CMFD
AP			EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Jan	CMFD
AP			EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Jan	CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB	!	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Feb	CTEC
AB		NOVITIUM PHARMA	10MG	A215270	001	Feb 18, 2022	Feb	NEWA

METOCLOPRAMIDE HYDROCHLORIDEINJECTABLE; INJECTION
REGLAN

+ @ HIKMA EQ 5MG BASE/ML N017862 001 Jan CRLD

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ CHARTWELL RX EQ 5MG BASE A074478 001 Oct 05, 1995 Mar CAHN

@ EQ 10MG BASE A072215 001 Jan 30, 1990 Mar CAHN

@ EQ 10MG BASE A074478 002 Oct 05, 1995 Mar CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

@ STERISCIENCE 1MG/ML A090317 001 Apr 19, 2010 Feb CAHN

TABLET; ORAL

METOPROLOL TARTRATE

@ CHARTWELL RX 50MG A073288 001 Mar 25, 1994 Mar CAHN

@ 100MG A073289 001 Mar 25, 1994 Mar CAHN

METRONIDAZOLE

GEL; VAGINAL

METRONIDAZOLE

AB GLENMARK PHARMS LTD 0.75% A215794 001 Jan 27, 2022 Jan NEWA

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

@ RISING 500MG/100ML A205531 001 May 09, 2017 Jan CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@ STERISCIENCE EQ 1MG BASE/ML A090315 001 Nov 29, 2010 Jan CAHN

@ EQ 5MG BASE/ML A090315 002 Nov 29, 2010 Jan CAHN

MIDAZOLAM HYDROCHLORIDE

@ STERISCIENCE EQ 1MG BASE/ML A090316 001 May 04, 2011 Feb CAHN

@ EQ 5MG BASE/ML A090316 002 May 04, 2011 Feb CAHN

SOLUTION; INTRAMUSCULAR

SEIZALAM

+! MMT EQ 50MG BASE/10ML (EQ 5MG BASE/ML) N209566 001 Sep 14, 2018 May CAHN

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

AB BRECKENRIDGE 100MG A209325 001 Feb 03, 2022 Jan NEWA

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

+! JOURNEY EQ 4% BASE N212379 001 Oct 18, 2019 Jan CAHN

ZILXI

+! JOURNEY EQ 1.5% BASE N213690 001 May 28, 2020 Jan CAHN

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

>D> AB TORRENT EQ 50MG BASE A065062 001 Nov 30, 2000 Jun CAHN

>A> AB EQ 50MG BASE A065062 001 Nov 30, 2000 Jun CAHN

>D> AB EQ 75MG BASE A065062 002 Nov 30, 2000 Jun CAHN

>A> AB EQ 75MG BASE A065062 002 Nov 30, 2000 Jun CAHN

>D> AB EQ 100MG BASE A065062 003 Nov 30, 2000 Jun CAHN

>A> AB EQ 100MG BASE A065062 003 Nov 30, 2000 Jun CAHN

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB BEXIMCO PHARMS USA EQ 50MG BASE A215466 001 May 27, 2022 May NEWA

AB EQ 75MG BASE A215466 002 May 27, 2022 May NEWA

AB EQ 100MG BASE A215466 003 May 27, 2022 May NEWA

>D> AB TORRENT EQ 50MG BASE A065156 001 Jan 06, 2004 Jun CAHN

>A> AB EQ 50MG BASE A065156 001 Jan 06, 2004 Jun CAHN

>D> AB EQ 75MG BASE A065156 002 Jan 06, 2004 Jun CAHN

>A> AB EQ 75MG BASE A065156 002 Jan 06, 2004 Jun CAHN

>D> AB EQ 100MG BASE A065156 003 Jan 06, 2004 Jun CAHN

>A> AB EQ 100MG BASE A065156 003 Jan 06, 2004 Jun CAHN

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB	SQUARE PHARMS	15MG	A205798	001	Jun 01, 2017	Jan CAHN
AB		30MG	A205798	002	Jun 01, 2017	Jan CAHN
AB		45MG	A205798	003	Jun 01, 2017	Jan CAHN

MISOPROSTOL

TABLET;ORAL
CYTOTEC

AB	+ PFIZER	0.1MG	N019268	003	Sep 21, 1990	Mar CTEC
AB	+!	0.2MG	N019268	001	Dec 27, 1988	Mar CTEC
MISOPROSTOL						
AB	ANI PHARMS	0.1MG	A076095	001	Jul 10, 2002	Mar CMFD
AB		0.2MG	A076095	002	Jul 10, 2002	Mar CMFD

MITAPIVAT SULFATE

TABLET;ORAL
PYRUKYND

	+ AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022	Feb NEWA
		EQ 20MG BASE	N216196	002	Feb 17, 2022	Feb NEWA
		EQ 50MG BASE	N216196	003	Feb 17, 2022	Feb NEWA

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
RYALTRIS

	+! GLENMARK SPECIALTY	0.025MG/SPRAY;0.665MG/SPRAY	N211746	001	Jan 13, 2022	Jan NEWA
--	-----------------------	-----------------------------	---------	-----	--------------	----------

MONTELUKAST SODIUM

GRANULE;ORAL
SINGULAIR

AB	+! ORGANON	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	Mar CAHN
----	------------	--------------------	---------	-----	--------------	----------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

	@ NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jan DISC
	@	30MG	A203158	002	Aug 04, 2021	Jan DISC
	@	50MG	A203158	003	Aug 04, 2021	Jan DISC
	@	60MG	A203158	004	Aug 04, 2021	Jan DISC
	@	80MG	A203158	005	Aug 04, 2021	Jan DISC
	@	100MG	A203158	006	Aug 04, 2021	Jan DISC

INJECTABLE;INJECTION
MORPHINE SULFATE

	+! HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	May CMFD
	+ @	50MG/ML	N202515	006	Apr 29, 2021	Jan DISC
	INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Jan CMFD

TABLET;ORAL

MORPHINE SULFATE

	@ RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Feb DISC
AB		15MG	A215584	001	Feb 07, 2022	Jan NEWA
	@	30MG	A215584	002	Feb 07, 2022	Feb DISC
AB		30MG	A215584	002	Feb 07, 2022	Jan NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
MOXEZA

>A>	AT2	+! IMPRIMIS PHARMS USA	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun CAHN
>D>	AT2	+! NOVARTIS	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun CAHN
MOXIFLOXACIN HYDROCHLORIDE							
	AT1	INDOCO	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Apr CAHN

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

AB	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan NEWA
----	-----------------	----------	---------	-----	--------------	----------

TABLET;ORAL

MYCOPHENOLATE MOFETIL

>D>		@ AMNEAL	500MG	A090606	001	Jul 16, 2010	Jun CMFD
>A>	AB		500MG	A090606	001	Jul 16, 2010	Jun CMFD

NADOLOL

TABLET; ORAL

NADOLOL

>A>	AB	AUROBINDO PHARMA LTD	20MG	A201893	003	Jun 07, 2022	Jun	NEWA
-----	----	----------------------	------	---------	-----	--------------	-----	------

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

@ STERISCIENCE

EQ 1GM BASE/VIAL

A200002 001 Apr 07, 2014 Feb CAHN

@

EQ 2GM BASE/VIAL

A200002 002 Apr 07, 2014 Feb CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

+ @ EUROHLTH INTL SARL

EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)

N020459 001 Apr 17, 1995 Jan CPOT

+ @

EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

N020459 002 Apr 17, 1995 Jan CPOT

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

! PURDUE PHARMA LP

EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

A212955 001 Feb 08, 2022 Jan NEWA

REVEX

+ @ EUROHLTH INTL SARL

EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)

N020459 001 Apr 17, 1995 Jan CDFR

+ @

EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

N020459 002 Apr 17, 1995 Jan CDFR

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

>A>

AP

HIKMA

1MG/ML

A212300 001 Jun 10, 2022 Jun NEWA

>A>

AP

MYLAN LABS LTD

1MG/ML

A213843 001 Jun 09, 2022 Jun NEWA

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

+ @ KALEO INC

10MG/0.4ML (10MG/0.4ML)

N215457 001 Feb 28, 2022 May DISC

+!

10MG/0.4ML (10MG/0.4ML)

N215457 001 Feb 28, 2022 Feb NEWA

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

>A>

AB

PADAGIS ISRAEL

4MG/SPRAY

A211951 001 Jun 21, 2022 Jun NEWA

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

@ WOODWARD SPECL

50MG/ML

N013132 001 Jun 12, 1986 Apr CAHN

@

100MG/ML

N013132 002 Jun 12, 1986 Apr CAHN

+ @

200MG/ML

N013132 003 Jun 12, 1986 Apr CAHN

NAPROXEN

SUSPENSION; ORAL

NAPROXEN

AB

HETERO LABS LTD III

25MG/ML

A215776 001 Jun 07, 2022 May NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

AB

AJANTA PHARMA LTD

EQ 2.5MG BASE

A213349 001 Mar 31, 2022 Mar NEWA

AB

EQ 5MG BASE

A213349 002 Mar 31, 2022 Mar NEWA

AB

EQ 10MG BASE

A213349 003 Mar 31, 2022 Mar NEWA

AB

EQ 20MG BASE

A213349 004 Mar 31, 2022 Mar NEWA

AB

PRINSTON INC

EQ 2.5MG BASE

A212682 001 Apr 07, 2022 Apr NEWA

AB

EQ 5MG BASE

A212682 002 Apr 07, 2022 Apr NEWA

AB

EQ 10MG BASE

A212682 003 Apr 07, 2022 Apr NEWA

AB

EQ 20MG BASE

A212682 004 Apr 07, 2022 Apr NEWA

AB

REYOUNG

EQ 2.5MG BASE

A212917 001 Dec 17, 2021 May CAHN

AB

EQ 5MG BASE

A212917 002 Dec 17, 2021 May CAHN

AB

EQ 10MG BASE

A212917 003 Dec 17, 2021 May CAHN

AB

EQ 20MG BASE

A212917 004 Dec 17, 2021 May CAHN

AB

UNICHEM

EQ 2.5MG BASE

A213830 001 Mar 15, 2022 Mar NEWA

AB

EQ 5MG BASE

A213830 002 Mar 15, 2022 Mar NEWA

AB

EQ 10MG BASE

A213830 003 Mar 15, 2022 Mar NEWA

AB

EQ 20MG BASE

A213830 004 Mar 15, 2022 Mar NEWA

NITROGLYCERIN

TABLET; SUBLINGUAL

NITROGLYCERIN

AB	ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022	Feb NEWA
AB		0.4MG	A210153	002	Mar 08, 2022	Feb NEWA
AB		0.6MG	A210153	003	Mar 08, 2022	Feb NEWA
	NITROSTAT					
AB	+ VIATRIS	0.3MG	N021134	001	May 01, 2000	Jan CAHN
AB	+	0.4MG	N021134	002	May 01, 2000	Jan CAHN
AB	+	0.6MG	N021134	003	May 01, 2000	Jan CAHN

NIZATIDINE

>D> SOLUTION; ORAL

>D> NIZATIDINE

>D>	! AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Jun DISC
>A>	@	15MG/ML	A090576	001	Nov 18, 2009	Jun DISC

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 10MG BASE

A074835 001 Jun 30, 1997 Feb CAHN

@ EQ 25MG BASE

A074835 002 Jun 30, 1997 Feb CAHN

@ EQ 50MG BASE

A074835 003 Jun 30, 1997 Feb CAHN

@ EQ 75MG BASE

A074835 004 Jun 30, 1997 Feb CAHN

NYSTATIN

SUSPENSION; ORAL

NILSTAT

+ @ GLENMARK PHARMS LTD 100,000 UNITS/ML

N050299 001 Apr CAHN

NYSTATIN

AA MEDLEY PHARMS 100,000 UNITS/ML A214346 001 Mar 10, 2022 Feb NEWA

AA VISTAPHARM 100,000 UNITS/ML A064142 002 Mar 07, 2011 May CMS1

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT ALEOR DERMACEUTICALS 100,000 UNITS/GM; 0.1% A214186 001 Mar 04, 2022 Feb NEWA

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE; ORAL

MYCAPSSA

+! AMRYT EQ 20MG BASE

N208232 001 Jun 26, 2020 Jan CAHN

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP HERITAGE PHARMS EQ 0.05MG BASE/ML A204669 001 Dec 27, 2018 Apr CMFD

AP EQ 0.1MG BASE/ML A204669 002 Dec 27, 2018 Apr CMFD

AP EQ 0.2MG BASE/ML A203765 001 Sep 07, 2018 Apr CMFD

AP EQ 0.5MG BASE/ML A204669 003 Dec 27, 2018 Apr CMFD

AP EQ 1MG BASE/ML A203765 002 Sep 07, 2018 Apr CMFD

OFLOXACIN

SOLUTION/DROPS; OTIC

OFLOXACIN

>D> AT FDC LTD 0.3% A215038 001 Jan 19, 2022 Jun DISC

>A> @ 0.3% A215038 001 Jan 19, 2022 Jun DISC

AT 0.3% A215038 001 Jan 19, 2022 Jan NEWA

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AB CHARTWELL MOLECULAR 2.5MG A203333 001 Mar 15, 2016 Mar CAHN

AB 5MG A203333 002 Mar 15, 2016 Mar CAHN

AB 7.5MG A203333 003 Mar 15, 2016 Mar CAHN

AB 10MG A203333 004 Mar 15, 2016 Mar CAHN

AB 15MG A203333 005 Mar 15, 2016 Mar CAHN

AB 20MG A203333 006 Mar 15, 2016 Mar CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB CHARTWELL MOLECULAR 5MG A203456 001 Mar 16, 2016 Mar CAHN

AB 10MG A203456 002 Mar 16, 2016 Mar CAHN

AB 15MG A203456 003 Mar 16, 2016 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB 20MG A203456 004 Mar 16, 2016 Mar CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

>A> AB GLW 1GM CONTAINS AT LEAST 900MG OF THE A091028 001 Apr 07, 2014 Jun CAHN
ETHYL ESTERS OF OMEGA-3 FATTY

>D> AB TEVA PHARMS USA 1GM CONTAINS AT LEAST 900MG OF THE A091028 001 Apr 07, 2014 Jun CAHN
ACIDS
ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

@ STRIDES PHARMA 10MG A075876 001 May 29, 2003 Jan CAHN

@ 20MG A075876 002 May 29, 2003 Jan CAHN

@ 40MG A075876 003 Jan 21, 2009 Jan CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB CHARTWELL MOLECULES 4MG A077406 003 Dec 26, 2006 Apr CMFD

AB 8MG A077406 004 Dec 26, 2006 Apr CMFD

16MG A077406 001 Dec 26, 2006 Apr CMFD

24MG A077406 002 Dec 26, 2006 Apr CMFD

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP ATLANTIDE EQ 2MG BASE/ML A077577 001 Dec 26, 2006 Mar CAHN

>D> AP EUGIA PHARMA EQ 2MG BASE/ML A202599 001 Dec 21, 2012 Jun DISC

>A> @ EQ 2MG BASE/ML A202599 001 Dec 21, 2012 Jun DISC

@ STERISCIENCE EQ 2MG BASE/ML A078257 001 Apr 23, 2008 Feb CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP ATLANTIDE EQ 2MG BASE/ML A077716 001 Dec 26, 2006 Mar CAHN

@ STERISCIENCE EQ 2MG BASE/ML A078244 001 Apr 23, 2008 Feb CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@ AUROBINDO PHARMA EQ 24MG BASE A078539 003 Jul 31, 2007 Feb DISC

@ CASI PHARMS INC EQ 24MG BASE A077517 003 Jun 25, 2007 Feb DISC

AB CHARTWELL MOLECULES EQ 4MG BASE A077303 001 Jun 25, 2007 May CMFD

AB EQ 8MG BASE A077303 002 Jun 25, 2007 May CMFD

AB ! EQ 24MG BASE A077303 004 Jun 25, 2007 May CMFD

@ DR REDDYS LABS LTD EQ 16MG BASE A076183 004 Dec 26, 2006 Mar DISC

@ EQ 24MG BASE A076183 001 Dec 26, 2006 Feb DISC

AB GLENMARK GENERICS EQ 8MG BASE A077535 002 Jun 25, 2007 May CHRS

AB ! EQ 8MG BASE A077535 002 Jun 25, 2007 Feb CHRS

@ EQ 24MG BASE A077535 003 Jun 25, 2007 Feb DISC

@ TEVA EQ 4MG BASE A076252 001 Jun 25, 2007 Feb DISC

@ EQ 8MG BASE A076252 002 Jun 25, 2007 Feb DISC

@ EQ 24MG BASE A076252 003 Jun 25, 2007 Feb DISC

ZOFRAN

+ @ NOVARTIS EQ 4MG BASE N020103 001 Dec 31, 1992 Feb DISC

+ @ EQ 8MG BASE N020103 002 Dec 31, 1992 Feb DISC

+ @ EQ 24MG BASE N020103 003 Aug 27, 1999 Feb DISC

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB ALVOGEN EQ 6MG BASE/ML A208823 001 Oct 31, 2017 May CAHN

@ APTAPHARMA INC EQ 6MG BASE/ML A212858 001 Aug 30, 2021 Mar DISC

AB HETERO LABS LTD V EQ 6MG BASE/ML A209590 001 Mar 28, 2022 Mar NEWA

AB LEADING PHARMA LLC EQ 6MG BASE/ML A214949 001 Feb 28, 2022 Feb NEWA

AB MSN EQ 6MG BASE/ML A215313 001 May 02, 2022 Apr NEWA

AB STRIDES PHARMA EQ 6MG BASE/ML A211894 001 Jan 13, 2022 Jan NEWA

OTESECONAZOLECAPSULE;ORAL
VIVJOA

+! MYCOVIA PHARMS 150MG N215888 001 Apr 26, 2022 Apr NEWA

OXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUM@ STERISCIENCE EQ 1GM BASE/VIAL A091486 001 Aug 25, 2014 Feb CAHN
@ EQ 2GM BASE/VIAL A091486 002 Aug 25, 2014 Feb CAHNOXALIPLATININJECTABLE; INTRAVENOUS
OXALIPLATIN@ CHARTWELL MOLECULAR 50MG/10ML (5MG/ML) A208523 001 Feb 10, 2017 Mar CAHN
@ 100MG/20ML (5MG/ML) A208523 002 Feb 10, 2017 Mar CAHNOXAZEPAMCAPSULE;ORAL
OXAZEPAMAB UNITED RES LABS 10MG A071026 002 Aug 10, 1987 Apr CAHN
AB 15MG A071026 003 Aug 10, 1987 Apr CAHN
AB 30MG A071026 001 Aug 10, 1987 Apr CAHN
SERAX
+ @ ALPHARMA US PHARMS 10MG N015539 002 Jan CRLD
+ @ 15MG N015539 004 Jan CRLD
+ @ 30MG N015539 006 Jan CRLDOXYBUTYNIN CHLORIDESYRUP;ORAL
OXYBUTYNIN CHLORIDEAA ! CHARTWELL RX 5MG/5ML A075039 001 Jan 29, 1999 Mar CAHN
! LANNETT CO INC 5MG/5ML A074520 001 Mar 29, 1996 Mar CHRS
@ WOCKHARDT BIO AG 5MG/5ML A074868 001 Feb 12, 1997 Mar DISCOXYCODONE HYDROCHLORIDESOLUTION;ORAL
OXYCODONE HYDROCHLORIDE@ NOVEL LABS INC 100MG/5ML A204603 001 Apr 29, 2015 Feb DISC
@ WOCKHARDT BIO AG 5MG/5ML A206456 001 Jun 16, 2015 Apr DISC

TABLET;ORAL

ROXYBOND

PROTEGA PHARMS 5MG N209777 001 Apr 20, 2017 Mar CMFD
@ 5MG N209777 001 Apr 20, 2017 Feb CAHN
15MG N209777 002 Apr 20, 2017 Mar CMFD
@ 15MG N209777 002 Apr 20, 2017 Feb CAHN
30MG N209777 003 Apr 20, 2017 Mar CMFD
@ 30MG N209777 003 Apr 20, 2017 Feb CAHNPACLITAXELINJECTABLE; INJECTION
PACLITAXEL

AP GLAND PHARMA LTD 6MG/ML A207326 001 Aug 23, 2016 Feb CTNA

PACRITINIB CITRATECAPSULE;ORAL
VONJO

+! CTI BIOPHARMA CORP EQ 100MG BASE N208712 001 Feb 28, 2022 Feb NEWA

PALIPERIDONETABLET, EXTENDED RELEASE;ORAL
PALIPERIDONE>A> AB LUPIN LTD 1.5MG A208643 001 Jun 29, 2022 Jun NEWA
>A> AB 3MG A208643 002 Jun 29, 2022 Jun NEWA
>A> AB 6MG A208643 003 Jun 29, 2022 Jun NEWA
>A> AB 9MG A208643 004 Jun 29, 2022 Jun NEWA

PALONOSETRON HYDROCHLORIDEINJECTABLE; INTRAVENOUS
PALONOSETRON HYDROCHLORIDE

	@ EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jan	DISC
	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jan	DISC

PANTOPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
PANTOPRAZOLE SODIUM

AP	ASPIRO	EQ 40MG BASE/VIAL	A213778	001	May 18, 2022	May	NEWA
AP	BE PHARMS	EQ 40MG BASE/VIAL	A216171	001	May 18, 2022	May	NEWA
AP	GLAND PHARMA LTD	EQ 40MG BASE/VIAL	A204400	001	May 18, 2022	May	NEWA
AP	KNACK	EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	May	NEWA

PARICALCITOLSOLUTION; INTRAVENOUS
PARICALCITOL

	@ RISING	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Mar	DISC
--	----------	-------------------------	---------	-----	--------------	-----	------

PAROXETINE HYDROCHLORIDECAPSULE; ORAL
PAXIL

	+ @ APOTEX	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb	CAHN
	+ @	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb	CAHN
	+ @	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb	CAHN
	+ @	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb	CAHN

SUSPENSION; ORAL
PAXIL

AB	+! APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb	CAHN
----	-----------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 10MG BASE	A076618	001	Aug 15, 2005	Mar	CAHN
AB		EQ 20MG BASE	A076618	002	Aug 15, 2005	Mar	CAHN
AB		EQ 30MG BASE	A076618	003	Aug 15, 2005	Mar	CAHN
AB		EQ 40MG BASE	A076618	004	Aug 15, 2005	Mar	CAHN

PAXIL

AB	+ APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb	CAHN
AB	+	EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb	CAHN
AB	+	EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb	CAHN
AB	+!	EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb	CAHN
	@	EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

	@ SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan	DISC
	@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan	DISC
AB		EQ 37.5MG BASE	A213612	003	May 26, 2022	May	NEWA

PAXIL CR

AB	+ APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb	CAHN
AB	+	EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb	CAHN
AB	+!	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb	CAHN

PAROXETINE MESYLATETABLET; ORAL
PEXEVA

>D>	+! SEBELA IRELAND LTD	EQ 40MG BASE	N021299	004	Jul 03, 2003	Jun	DISC
>A>	+ @	EQ 40MG BASE	N021299	004	Jul 03, 2003	Jun	DISC

PEGAPTANIB SODIUMINJECTABLE; INTRAVITREAL
MACUGEN

>A>	+ @ BAUSCH AND LOMB INC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	Jun	CAHN
>D>	+ @ VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	Jun	CAHN

PEMETREXEDSOLUTION; INTRAVENOUS
PEMETREXED

	+! ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	May	CMFD
	+!	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	May	CMFD
	+!	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	May	CMFD

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

ALIMTA

AP	+	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	May CFTG
AP	+		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	May CFTG

PEMETREXED DISODIUM

AP		ACCORD HLTHCARE	EQ 100MG BASE/VIAL	A203485	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A203485	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A203485	003	May 25, 2022	May NEWA
AP		APOTEX	EQ 100MG BASE/VIAL	A203774	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A203774	002	May 25, 2022	May NFTG
AP			EQ 750MG BASE/VIAL	A209851	001	May 25, 2022	May NEWA
AP			EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	May NEWA
AP		BIOCON PHARMA	EQ 1GM BASE/VIAL	A211090	001	May 25, 2022	May NEWA
AP		DR REDDYS	EQ 100MG BASE/VIAL	A202596	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A202596	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A202596	003	May 25, 2022	May NEWA
AP		EUGIA PHARMA	EQ 100MG BASE/VIAL	A214632	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A214632	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A214632	003	May 25, 2022	May NEWA
AP		FRESENIUS KABI USA	EQ 100MG BASE/VIAL	A090384	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A090384	002	May 25, 2022	May NFTG
AP	!		EQ 750MG BASE/VIAL	A090384	003	May 25, 2022	May NEWA
AP	!		EQ 1GM BASE/VIAL	A090384	004	May 25, 2022	May NEWA
AP		HOSPIRA	EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	May NEWA
AP		JIANGSU HANSOH PHARM	EQ 100MG BASE/VIAL	A208696	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A208696	002	May 25, 2022	May NFTG
AP		NANG KUANG PHARM CO	EQ 100MG BASE/VIAL	A207352	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A207352	002	May 25, 2022	May NFTG
AP		QILU PHARM HAINAN	EQ 100MG BASE/VIAL	A204890	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A204890	002	May 25, 2022	May NFTG
AP		WAVERLEY PHARMA INC	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	May NFTG
AP		ZYDUS PHARMS	EQ 100MG BASE/VIAL	A214073	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A214073	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A214073	003	May 25, 2022	May NEWA

SOLUTION; INTRAVENOUS

PEMETREXED

>A>	+	HOSPIRA INC	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Jun NEWA
>A>	+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Jun NEWA
>A>	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Jun NEWA
	+	SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	May NEWA
	+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	May NEWA
	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	May NEWA

PEMETREXED DITROMETHAMINE

>A>		POWDER; INTRAVENOUS					
>A>		PEMETREXED					
>A>	+	HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Jun NEWA
>A>	+		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Jun NEWA
>A>	+		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Jun NEWA

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

AP		XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022	Mar NEWA
----	--	-------------	------------	---------	-----	--------------	----------

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB		APPCO	2MG	A210163	001	May 18, 2022	May NEWA
AB			4MG	A210163	002	May 18, 2022	May NEWA
AB			8MG	A210163	003	May 18, 2022	May NEWA
AB			16MG	A210163	004	May 18, 2022	May NEWA
	@	MYLAN	2MG	A206691	001	Apr 14, 2017	Mar DISC
	@		4MG	A206691	002	Apr 14, 2017	Mar DISC
	@		8MG	A206691	003	Apr 14, 2017	Mar DISC

	TABLET;ORAL								
	PERPHENAZINE								
	@	16MG		A206691	004	Apr 14, 2017		Mar	DISC
	<u>PHENDIMETRAZINE TARTRATE</u>								
	TABLET;ORAL								
	PHENDIMETRAZINE TARTRATE								
AA	CHARTWELL	35MG		A089452	001	Oct 30, 1991		Apr	CAHN
	<u>PHENTERMINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	PHENTERMINE HYDROCHLORIDE								
AA	+! SANDOZ	30MG		A087190	001			Feb	CRLD
	<u>PHENYLEPHRINE HYDROCHLORIDE</u>								
	SOLUTION;INTRAVENOUS								
	BIORPHEN								
>A>	+! DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)		N212909	001	Oct 21, 2019		Jun	CAHN
>A>	+ @	10MG/ML (10MG/ML)		N212909	002	Mar 11, 2021		Jun	CAHN
>D>	+! ETON PHARMS	0.5MG/5ML (0.1MG/ML)		N212909	001	Oct 21, 2019		Jun	CAHN
>D>	+ @	10MG/ML (10MG/ML)		N212909	002	Mar 11, 2021		Jun	CAHN
	PHENYLEPHRINE HYDROCHLORIDE								
AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)		A213237	001	Jul 01, 2020		Feb	CMFD
AP1		50MG/5ML (10MG/ML)		A213237	002	Jul 01, 2020		Feb	CMFD
AP1		100MG/10ML (10MG/ML)		A213237	003	Jul 01, 2020		Feb	CMFD
	@ PAR STERILE PRODUCTS	10MG/ML (10MG/ML)		A210025	001	Dec 21, 2018		Jan	DISC
	<u>PHENYTOIN</u>								
	SUSPENSION;ORAL								
	DILANTIN-125								
AB	+! VIATRIS	125MG/5ML		N008762	001			Feb	CAHN
	DILANTIN-30								
	@ VIATRIS	30MG/5ML		N008762	002			Feb	CAHN
	PHENYTOIN								
AB	PAI HOLDINGS PHARM	125MG/5ML		A040420	001	Apr 19, 2002		Apr	CAHN
AB	VISTAPHARM	125MG/5ML		A040342	002	Aug 18, 2005		May	CMS1
	<u>PHENYTOIN SODIUM</u>								
	CAPSULE;ORAL								
	DILANTIN								
	+! VIATRIS	30MG EXTENDED		A084349	001			Feb	CAHN
AB	+!	100MG EXTENDED		A084349	002			Feb	CAHN
	<u>PHYTONADIONE</u>								
	INJECTABLE;INJECTION								
	PHYTONADIONE								
AB2	! CIPLA	1MG/0.5ML		A212424	001	Apr 22, 2022		Apr	NFTG
AB2		1MG/0.5ML		A214596	001	Apr 22, 2022		Apr	NFTG
AB2	!	10MG/ML		A212424	002	Apr 22, 2022		Apr	NFTG
AB2		10MG/ML		A214596	002	Apr 22, 2022		Apr	NFTG
AB1	DR REDDYS	10MG/ML		A207719	001	May 22, 2019		Apr	CTEC
	VITAMIN K1								
AB1	+! HOSPIRA	10MG/ML		A087955	001	Jul 25, 1983		Apr	CTEC
	<u>PILOCARPINE HYDROCHLORIDE</u>								
	SOLUTION;OPHTHALMIC								
	ISOPTO CARPINE								
AT	+! NOVARTIS	1%		N200890	001	Jun 22, 2010		May	CHRS
AT	+!	2%		N200890	002	Jun 22, 2010		May	CHRS
	<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>								
	INJECTABLE;INJECTION								
	PIPERACILLIN AND TAZOBACTAM								
AP	STERISCIENCE	EQ 2GM BASE/VIAL;EQ 250MG		A065458	001	Aug 15, 2014		May	CMFD
	@	BASE/VIAL							
		EQ 2GM BASE/VIAL;EQ 250MG		A065458	001	Aug 15, 2014		Feb	CAHN
		BASE/VIAL							
AP		EQ 3GM BASE/VIAL;EQ 375MG		A065458	002	Aug 15, 2014		May	CMFD
	@	BASE/VIAL							
		EQ 3GM BASE/VIAL;EQ 375MG		A065458	002	Aug 15, 2014		Feb	CAHN
		BASE/VIAL							
AP		EQ 4GM BASE/VIAL;EQ 500MG		A065458	003	Aug 15, 2014		May	CMFD
		BASE/VIAL							

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

@ EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL A065458 003 Aug 15, 2014 Feb CAHN

PIRFENIDONE

CAPSULE; ORAL

PIRFENIDONE

AB ACCORD HLTHCARE 267MG A212731 001 Jan 20, 2022 Jan NEWA
 AB AMNEAL 267MG A212569 001 Jan 03, 2022 May CMFD
 @ 267MG A212569 001 Jan 03, 2022 Jan DISC
 >A> AB SANDOZ INC 267MG A212600 001 Jun 13, 2022 Jun NEWA

TABLET; ORAL

ESBRIET

AB + GENENTECH INC 267MG N208780 001 Jan 11, 2017 Jan CFTG
 AB +! 801MG N208780 003 Jan 11, 2017 Jan CFTG

PIRFENIDONE

AB ACCORD HLTHCARE 267MG A212730 001 Jan 25, 2022 Jan NFTG
 AB 801MG A212730 002 Jan 25, 2022 Jan NFTG
 AB ALEMBIC PHARMS LTD 267MG A212708 001 May 20, 2022 May NEWA
 AB 801MG A212708 002 May 20, 2022 May NEWA
 AB AMNEAL 267MG A212570 001 Mar 25, 2022 Mar NEWA
 AB 801MG A212570 002 Mar 25, 2022 Mar NEWA
 AB MICRO LABS 267MG A212680 001 May 18, 2022 May NEWA
 AB 801MG A212680 002 May 18, 2022 May NEWA
 AB MSN 267MG A212772 001 May 24, 2022 May NEWA
 AB 801MG A212772 002 May 24, 2022 May NEWA
 AB SANDOZ INC 267MG A212560 001 Apr 28, 2022 Apr NEWA
 AB 801MG A212560 002 Apr 28, 2022 Apr NEWA
 AB TEVA PHARMS USA 267MG A212759 001 Jan 25, 2022 Jan NFTG
 AB 801MG A212759 002 Jan 25, 2022 Jan NFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

@ NOVEL LABS INC 420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11 A090019 001 May 27, 2009 Feb DISC
 .2GM/BOT

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

@ MYLAN 1MG A210275 001 Jan 26, 2022 Feb CAHN
 @ 1MG A210275 001 Jan 26, 2022 Feb DISC
 AB 1MG A210275 001 Jan 26, 2022 Jan NEWA
 @ 2MG A210275 002 Jan 26, 2022 Feb CAHN
 @ 2MG A210275 002 Jan 26, 2022 Feb DISC
 AB 2MG A210275 002 Jan 26, 2022 Jan NEWA
 @ 3MG A210275 003 Jan 26, 2022 Feb CAHN
 @ 3MG A210275 003 Jan 26, 2022 Feb DISC
 AB 3MG A210275 003 Jan 26, 2022 Jan NEWA
 @ 4MG A210275 004 Jan 26, 2022 Feb CAHN
 @ 4MG A210275 004 Jan 26, 2022 Feb DISC
 AB 4MG A210275 004 Jan 26, 2022 Jan NEWA
 AB TEVA PHARMS USA 1MG A209956 001 May 04, 2022 Apr NEWA
 AB 2MG A209956 002 May 04, 2022 Apr NEWA
 AB 3MG A209956 003 May 04, 2022 Apr NEWA
 AB 4MG A209956 004 May 04, 2022 Apr NEWA

POMALYST

AB + CELGENE 1MG N204026 001 Feb 08, 2013 Apr CTEC
 + 1MG N204026 001 Feb 08, 2013 Feb CTEC
 AB + 1MG N204026 001 Feb 08, 2013 Jan CTEC
 AB + 2MG N204026 002 Feb 08, 2013 Apr CTEC
 + 2MG N204026 002 Feb 08, 2013 Feb CTEC
 AB + 2MG N204026 002 Feb 08, 2013 Jan CTEC
 AB + 3MG N204026 003 Feb 08, 2013 Apr CTEC
 + 3MG N204026 003 Feb 08, 2013 Feb CTEC
 AB + 3MG N204026 003 Feb 08, 2013 Jan CTEC
 AB +! 4MG N204026 004 Feb 08, 2013 Apr CTEC
 +! 4MG N204026 004 Feb 08, 2013 Feb CTEC
 AB +! 4MG N204026 004 Feb 08, 2013 Jan CTEC

POSACONAZOLE

	FOR SUSPENSION, DELAYED RELEASE;ORAL NOXAFIL POWDERMIX KIT							
	+ @ MSD MERCK CO	300MG	N214770	001	May 31, 2021	Jan	DISC	
	SOLUTION;INTRAVENOUS NOXAFIL							
AP	+! MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	May	CFTG	
	POSACONAZOLE							
AP	PAR STERILE PRODUCTS	300MG/16.7ML (18MG/ML)	A208768	001	May 25, 2022	May	NFTG	
	TABLET, DELAYED RELEASE;ORAL POSACONAZOLE							
AB	BIOCON PHARMA	100MG	A214476	001	Feb 04, 2022	Jan	NEWA	
AB	DR REDDYS	100MG	A212500	001	Apr 07, 2022	Apr	NEWA	
AB	SPEGX LLC	100MG	A212226	001	May 10, 2022	Apr	NEWA	

POTASSIUM ACETATE

	INJECTABLE;INJECTION POTASSIUM ACETATE							
	@ EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Mar	DISC	

POTASSIUM CHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL POTASSIUM CHLORIDE							
	@ LANNETT CO INC	8MEQ	A204210	001	Mar 28, 2016	Mar	DISC	
	@	10MEQ	A204210	002	Mar 28, 2016	Mar	DISC	
	@ TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	May	DISC	
	@	10MEQ	A201944	002	Mar 04, 2016	May	DISC	
	FOR SOLUTION;ORAL POTASSIUM CHLORIDE							
AA	GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jan	NEWA	
AA	RUBICON	20MEQ	A214108	001	Mar 24, 2022	Mar	NEWA	
	INJECTABLE;INJECTION POTASSIUM CHLORIDE 10MEQ							
AP	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar	CMFD	
AP		746MG/100ML	A211087	002	Sep 09, 2020	Mar	CMFD	
	POTASSIUM CHLORIDE 20MEQ							
AP	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar	CMFD	
AP		1.49GM/100ML	A211087	005	May 07, 2021	Mar	CMFD	
	POTASSIUM CHLORIDE 40MEQ							
AP	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	CMFD	
	SOLUTION;ORAL POTASSIUM CHLORIDE							
AA	RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022	Jan	NEWA	
AA		40MEQ/15ML	A214656	002	Jan 13, 2022	Jan	NEWA	
	@ TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022	Apr	DISC	
AA		20MEQ/15ML	A214076	001	Jan 26, 2022	Jan	NEWA	
	@	40MEQ/15ML	A214076	002	Jan 26, 2022	Apr	DISC	
AA		40MEQ/15ML	A214076	002	Jan 26, 2022	Jan	NEWA	
AA	WES PHARMA INC	20MEQ/15ML	A213062	001	Jun 06, 2022	May	NEWA	
AA		40MEQ/15ML	A213062	002	Jun 06, 2022	May	NEWA	

TABLET, EXTENDED RELEASE;ORAL

K-TAB

	+ @ ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Mar	DISC	
--	------------	------	---------	-----	--------------	-----	------	--

PRAMIPEXOLE DIHYDROCHLORIDE

	TABLET;ORAL MIRAPEX							
	+ @ BOEHRINGER INGELHEIM	0.125MG	N020667	001	Jul 01, 1997	Mar	DISC	
	+ @	0.25MG	N020667	002	Jul 01, 1997	Mar	DISC	
	+ @	0.5MG	N020667	006	Feb 12, 1998	Mar	DISC	
	+ @	0.75MG	N020667	007	Jul 30, 2007	Mar	DISC	
	+ @	1MG	N020667	003	Jul 01, 1997	Mar	DISC	
	+ @	1.5MG	N020667	005	Jul 01, 1997	Mar	DISC	
	PRAMIPEXOLE DIHYDROCHLORIDE							
AB	! GLENMARK GENERICS	0.25MG	A090781	002	Oct 08, 2010	Mar	CHRS	
	TABLET, EXTENDED RELEASE;ORAL PRAMIPEXOLE DIHYDROCHLORIDE							
AB	ALEMBIC PHARMS LTD	0.375MG	A204518	001	Jan 02, 2019	Apr	CMFD	
AB		0.75MG	A204518	002	Jan 02, 2019	Apr	CMFD	
AB		1.5MG	A204518	003	Jan 02, 2019	Apr	CMFD	

<u>TABLET, EXTENDED RELEASE;ORAL</u>							
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>							
AB		2.25MG	A204518	004	Jan 02, 2019	Apr	CMFD
AB		3MG	A204518	005	Jan 02, 2019	Apr	CMFD
AB		3.75MG	A204518	006	Jan 02, 2019	Apr	CMFD
AB		4.5MG	A204518	007	Jan 02, 2019	Apr	CMFD
AB	NOVAST LABS	0.375MG	A213444	001	Feb 03, 2022	Jan	NEWA
AB		0.75MG	A213444	002	Feb 03, 2022	Jan	NEWA
AB		1.5MG	A213444	003	Feb 03, 2022	Jan	NEWA
AB		2.25MG	A213444	004	Feb 03, 2022	Jan	NEWA
AB		3MG	A213444	005	Feb 03, 2022	Jan	NEWA
AB		3.75MG	A213444	006	Feb 03, 2022	Jan	NEWA
AB		4.5MG	A213444	007	Feb 03, 2022	Jan	NEWA
<u>PRASUGREL HYDROCHLORIDE</u>							
TABLET;ORAL							
PRASUGREL							
	@ USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Apr	DISC
	@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Apr	DISC
<u>PRAZOSIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
PRAZOSIN HYDROCHLORIDE							
	@ ANI PHARMS	EQ 5MG BASE	A072577	003	May 16, 1989	Feb	DISC
<u>PREDNISOLONE</u>							
TABLET;ORAL							
PREDNISOLONE							
+!	WATSON LABS	5MG	A080354	001		Mar	CRLD
<u>PREDNISONE</u>							
SOLUTION;ORAL							
PREDNISONE							
+!	HIKMA	5MG/5ML	A088703	001	Nov 08, 1984	May	CRLD
TABLET;ORAL							
PREDNISONE							
AB	AUROBINDO PHARMA LTD	2.5MG	A215672	001	Mar 28, 2022	Mar	NEWA
AB		5MG	A215672	002	Mar 28, 2022	Mar	NEWA
AB		10MG	A215672	003	Mar 28, 2022	Mar	NEWA
AB		20MG	A215672	004	Mar 28, 2022	Mar	NEWA
AB		50MG	A215672	005	Mar 28, 2022	Mar	NEWA
<u>PREGABALIN</u>							
CAPSULE;ORAL							
PREGABALIN							
AB	ALLIED	50MG	A210585	001	Dec 26, 2019	Feb	CAHN
AB		75MG	A210585	002	Dec 26, 2019	Feb	CAHN
AB		100MG	A210585	003	Dec 26, 2019	Feb	CAHN
AB		150MG	A210585	004	Dec 26, 2019	Feb	CAHN
AB		200MG	A210585	005	Dec 26, 2019	Feb	CAHN
AB		300MG	A210585	006	Dec 26, 2019	Feb	CAHN
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Feb	NEWA
AB		50MG	A212988	002	Mar 08, 2022	Feb	NEWA
AB		75MG	A212988	003	Mar 08, 2022	Feb	NEWA
AB		100MG	A212988	004	Mar 08, 2022	Feb	NEWA
AB		150MG	A212988	005	Mar 08, 2022	Feb	NEWA
AB		200MG	A212988	006	Mar 08, 2022	Feb	NEWA
AB		225MG	A212988	007	Mar 08, 2022	Feb	NEWA
AB		300MG	A212988	008	Mar 08, 2022	Feb	NEWA
AB	LUPIN LTD	25MG	A091040	001	May 03, 2022	Apr	NEWA
AB		50MG	A091040	002	May 03, 2022	Apr	NEWA
AB		75MG	A091040	003	May 03, 2022	Apr	NEWA
AB		100MG	A091040	004	May 03, 2022	Apr	NEWA
AB		150MG	A091040	005	May 03, 2022	Apr	NEWA
AB		200MG	A091040	006	May 03, 2022	Apr	NEWA
AB		225MG	A091040	007	May 03, 2022	Apr	NEWA
AB		300MG	A091040	008	May 03, 2022	Apr	NEWA
SOLUTION;ORAL							
PREGABALIN							
AA	INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL

PREGABALIN

	@ MYLAN	82.5MG	A211948	001	Apr 13, 2021	Mar	DISC
AB		82.5MG	A211948	001	Apr 13, 2021	Mar	CAHN
	@	165MG	A211967	001	Nov 04, 2021	Mar	DISC
AB	RUBICON	82.5MG	A215249	001	Mar 22, 2022	Mar	NEWA
AB		165MG	A215249	002	Mar 22, 2022	Mar	NEWA
AB		330MG	A215249	003	Mar 22, 2022	Mar	NEWA

PRIMIDONE

TABLET;ORAL

PRIMIDONE

>A>	AB	RUBICON	50MG	A214896	001	Jun 28, 2022	Jun	NEWA
>A>	AB		250MG	A214896	002	Jun 28, 2022	Jun	NEWA

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

>A>	AB	ZENARA	EQ 5MG BASE	A216202	001	Jun 13, 2022	Jun	NEWA
>A>	AB		EQ 10MG BASE	A216202	002	Jun 13, 2022	Jun	NEWA

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

	@ ATLANTIDE	25MG/ML	A040785	001	Sep 26, 2008	Mar	CAHN	
	@	50MG/ML	A040785	002	Sep 26, 2008	Mar	CAHN	
AP	+!	WEST-WARD PHARMS INT	25MG/ML	A083312	001		Apr	CRLD
AP	+!		50MG/ML	A083312	002		Apr	CRLD

PROPRANOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

	@ ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Feb	DISC	
	@ CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000	Mar	CAHN	
AP	!	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	Feb	CTEC

SOLUTION;ORAL

PROPRANOLOL HYDROCHLORIDE

	@ PAI HOLDINGS PHARM	20MG/5ML	A071984	001	Mar 03, 1989	Apr	CAHN
	@	40MG/5ML	A071985	001	Mar 03, 1989	Apr	CAHN

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	@ CHARTWELL RX	10MG	A070663	001	Jun 13, 1986	Mar	CAHN
	@	20MG	A070664	001	Jun 13, 1986	Mar	CAHN
	@	40MG	A070665	001	Jun 13, 1986	Mar	CAHN
	@	60MG	A070666	001	Oct 10, 1986	Mar	CAHN
	@	80MG	A070667	001	Jun 13, 1986	Mar	CAHN

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

PYRIDOSTIGMINE BROMIDE

AA		MILLA PHARMS	60MG/5ML	A212405	001	Apr 19, 2022	Apr	NEWA
----	--	--------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

>D>		EYWA	30MG	A211181	002	May 14, 2019	Jun	CTEC
>A>	AB		30MG	A211181	002	May 14, 2019	Jun	CTEC
>A>	AB	IMPAX LABS	30MG	A040502	002	Jun 28, 2022	Jun	NEWA

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

>A>	AB	HETERO LABS LTD V	EQ 25MG BASE	A204316	001	Jun 16, 2022	Jun	NEWA
>A>	AB		EQ 50MG BASE	A204316	002	Jun 16, 2022	Jun	NEWA
>A>	AB		EQ 100MG BASE	A204316	003	Jun 16, 2022	Jun	NEWA
>A>	AB		EQ 200MG BASE	A204316	004	Jun 16, 2022	Jun	NEWA
>A>	AB		EQ 300MG BASE	A204316	005	Jun 16, 2022	Jun	NEWA
>A>	AB		EQ 400MG BASE	A204316	006	Jun 16, 2022	Jun	NEWA

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB		PRINSTON INC	EQ 50MG BASE	A208781	001	Apr 26, 2022	Apr	NEWA
AB			EQ 150MG BASE	A208781	002	Apr 26, 2022	Apr	NEWA
AB			EQ 200MG BASE	A208781	003	Apr 26, 2022	Apr	NEWA
AB			EQ 300MG BASE	A208781	004	Apr 26, 2022	Apr	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@	CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Mar	CAHN
@		EQ 10MG BASE	A076803	002	Mar 02, 2005	Mar	CAHN
@		EQ 20MG BASE	A076803	003	Mar 02, 2005	Mar	CAHN
@		EQ 40MG BASE	A076803	004	Mar 02, 2005	Mar	CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@	EYWA	324MG	A212589	001	Sep 17, 2021	Mar	DISC
!	SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Mar	CTEC

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

>D>	+	MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013	Jun	CAHN
>A>	+	MSD SUB MERCK	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013	Jun	CAHN

TABLET;ORAL

ISENTRESS

>D>	+	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jun	CAHN
>A>	+	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jun	CAHN

ISENTRESS HD

>D>	+	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017	Jun	CAHN
>A>	+	MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Jun	CAHN

TABLET, CHEWABLE;ORAL

ISENTRESS

>D>	+	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011	Jun	CAHN
>D>	+		EQ 100MG BASE	N203045	002	Dec 21, 2011	Jun	CAHN
>A>	+	MSD SUB MERCK	EQ 25MG BASE	N203045	001	Dec 21, 2011	Jun	CAHN
>A>	+		EQ 100MG BASE	N203045	002	Dec 21, 2011	Jun	CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@	CHARTWELL RX	1.25MG	A077514	001	Jun 18, 2008	Mar	CAHN
@		2.5MG	A077514	002	Jun 18, 2008	Mar	CAHN
@		5MG	A077514	003	Jun 18, 2008	Mar	CAHN
@		10MG	A077514	004	Jun 18, 2008	Mar	CAHN

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

+	SPIL	500MG	N216018	001	Feb 28, 2022	Mar	CAHN
+	!	1GM	N216018	002	Feb 28, 2022	Mar	CAHN
+	SUN PHARMA GLOBAL	500MG	N216018	001	Feb 28, 2022	Feb	NEWA
+	!	1GM	N216018	002	Feb 28, 2022	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB		HETERO LABS LTD III	500MG	A212788	001	May 05, 2022	Apr	NEWA
AB			1GM	A212788	002	May 05, 2022	Apr	NEWA
AB		I3 PHARMS	500MG	A213517	001	Apr 27, 2022	Apr	NEWA
AB			1GM	A213517	002	Apr 27, 2022	Apr	NEWA
AB		VKT PHARMA	500MG	A214035	001	Jan 19, 2022	Jan	NEWA
AB			1GM	A214035	002	Jan 19, 2022	Jan	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@	DR REDDYS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Jan	DISC
@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Jan	DISC

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

AP	+	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008	Apr	CFTG
AP		IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	May	NEWA

SOLUTION; INTRAVENOUS
REGADENOSON

AP	ACCORD HLTHCARE	0.4MG/5ML (0.08MG/ML)	A213236	001	Apr 11, 2022	Apr	NFTG
AP	APOTEX	0.4MG/5ML (0.08MG/ML)	A207604	001	Apr 11, 2022	Apr	NFTG
AP	DR REDDYS	0.4MG/5ML (0.08MG/ML)	A213210	001	Apr 11, 2022	Apr	NFTG
AP	HONG KONG	0.4MG/5ML (0.08MG/ML)	A212806	001	Apr 11, 2022	Apr	NFTG
AP	IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	May	CMS1

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

>A>	AB	CHARTWELL MOLECULAR	150MG	A065390	001	Mar 28, 2008	Jun	CAHN
>A>	AB		300MG	A065390	002	Mar 28, 2008	Jun	CAHN
>D>	AB	LANNETT CO INC	150MG	A065390	001	Mar 28, 2008	Jun	CAHN
>D>	AB		300MG	A065390	002	Mar 28, 2008	Jun	CAHN

RILUZOLE

SUSPENSION; ORAL
TIGLUTIK KIT

>A>	+	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Jun	CAHN
>D>	+	ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018	Jun	CAHN

RISPERIDONE

SOLUTION; ORAL
RISPERIDONE

	@	ATLANTIDE	1MG/ML	A078744	001	Oct 08, 2009	Apr	CAHN
	@	CHARTWELL MOLECULAR	1MG/ML	A202386	001	Jan 12, 2015	May	CAHN
AA		LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	May	CAHN

RITONAVIR

TABLET; ORAL
RITONAVIR

AB		CIPLA	100MG	A202573	001	Jan 15, 2015	Mar	CAHN
AB			100MG	A203759	001	May 10, 2022	Apr	NEWA

RIZATRIPTAN BENZOATE

TABLET; ORAL
RIZATRIPTAN BENZOATE

AB		CREEKWOOD PHARMS	EQ 5MG BASE	A202047	001	Dec 31, 2012	May	CAHN
AB			EQ 10MG BASE	A202047	002	Dec 31, 2012	May	CAHN
	@	JUBILANT GENERICS	EQ 5MG BASE	A203252	001	Dec 31, 2014	May	DISC
	@		EQ 10MG BASE	A203252	002	Dec 31, 2014	May	DISC

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

AP		PRINSTON INC	50MG/5ML (10MG/ML)	A212668	001	May 26, 2022	May	NEWA
AP			100MG/10ML (10MG/ML)	A212668	002	May 26, 2022	May	NEWA

ROFLUMILAST

TABLET; ORAL
ROFLUMILAST

AB		PRINSTON INC	500MCG	A208299	001	May 10, 2022	Apr	NEWA
AB		ZYDUS PHARMS	500MCG	A208303	001	Feb 10, 2022	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ROPINIROLE HYDROCHLORIDE

AB		PRINSTON INC	EQ 2MG BASE	A204413	001	May 11, 2022	Apr	NEWA
AB			EQ 4MG BASE	A204413	002	May 11, 2022	Apr	NEWA
AB			EQ 6MG BASE	A204413	003	May 11, 2022	Apr	NEWA
AB			EQ 8MG BASE	A204413	004	May 11, 2022	Apr	NEWA
AB			EQ 12MG BASE	A204413	005	May 11, 2022	Apr	NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL
ROSUVASTATIN CALCIUM

	@	STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan	CAHN
	@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan	CAHN
	@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan	CAHN
	@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan	CAHN
	@	ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar	CAHN

<u>TABLET;ORAL</u>									
ROSUVASTATIN CALCIUM									
	@								
			EQ 10MG BASE		A206513	002	Mar 01, 2019	Mar	CAHN
	@		EQ 20MG BASE		A206513	003	Mar 01, 2019	Mar	CAHN
	@		EQ 40MG BASE		A206513	004	Mar 01, 2019	Mar	CAHN
<u>RUFINAMIDE</u>									
SUSPENSION;ORAL									
RUFINAMIDE									
	@	LUPIN LTD	40MG/ML		A213457	001	Dec 18, 2020	Apr	DISC
<u>SAMARIUM SM-153 LEXIDRONAM PENTASODIUM</u>									
INJECTABLE;INJECTION									
QUADRAMET									
	+	@ LANTHEUS MEDICAL	50mCi/ML		N020570	001	Mar 28, 1997	Jan	DISC
<u>SAPROPTERIN DIHYDROCHLORIDE</u>									
POWDER;ORAL									
SAPROPTERIN DIHYDROCHLORIDE									
AB		DR REDDYS	500MG/PACKET		A215798	001	May 13, 2022	May	NEWA
<u>SELEGILINE HYDROCHLORIDE</u>									
TABLET;ORAL									
SELEGILINE HYDROCHLORIDE									
	@	BOSCOGEN	5MG		A074912	001	Apr 30, 1998	Apr	DISC
<u>SELENIUM SULFIDE</u>									
LOTION/SHAMPOO;TOPICAL									
SELENIUM SULFIDE									
>D>	AT	!	PADAGIS US	2.5%	A089996	001	Jan 10, 1991	Jun	CTEC
>A>		!		2.5%	A089996	001	Jan 10, 1991	Jun	CTEC
>D>	AT		WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983	Jun	DISC
>A>		@		2.5%	A088228	001	Sep 01, 1983	Jun	DISC
<u>SELINEXOR</u>									
TABLET;ORAL									
XPOVIO									
	+	KARYOPHARM THERAPS	20MG		N212306	001	Jul 03, 2019	Mar	CHRS
	+	!		60MG	N212306	004	Apr 15, 2021	Mar	CHRS
<u>SEMAGLUTIDE</u>									
SOLUTION;SUBCUTANEOUS									
OZEMPIC									
	+	!	NOVO	8MG/3ML (2.68MG/ML)	N209637	003	Mar 28, 2022	Apr	NEWA
<u>SERTRALINE HYDROCHLORIDE</u>									
CONCENTRATE;ORAL									
ZOLOFT									
AA	+	!	VIATRIS	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jan	CAHN
TABLET;ORAL									
ZOLOFT									
AB	+		VIATRIS	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jan	CAHN
AB	+			EQ 50MG BASE	N019839	001	Dec 30, 1991	Jan	CAHN
AB	+	!		EQ 100MG BASE	N019839	002	Dec 30, 1991	Jan	CAHN
	+	@		EQ 150MG BASE	N019839	003	Dec 30, 1991	Jan	CAHN
	+	@		EQ 200MG BASE	N019839	004	Dec 30, 1991	Jan	CAHN
<u>SEVELAMER CARBONATE</u>									
TABLET;ORAL									
SEVELAMER CARBONATE									
	@	LUPIN LTD	800MG		A204600	001	Jan 14, 2021	May	DISC
AB		MICRO LABS	800MG		A215537	001	Feb 07, 2022	Jan	NEWA
	@	STRIDES PHARMA	800MG		A201069	001	Aug 05, 2020	Jan	CAHN
<u>SILDENAFIL CITRATE</u>									
FOR SUSPENSION;ORAL									
REVATIO									
AB	+	!	VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Feb	CAHN
SILDENAFIL CITRATE									
AB		LUPIN LTD	EQ 10MG BASE/ML		A211638	001	Mar 23, 2022	Mar	NEWA
AB		MSN	EQ 10MG BASE/ML		A214641	001	Feb 08, 2022	Jan	NEWA
	@	TRIS PHARMA INC	EQ 10MG BASE/ML		A212312	001	Nov 17, 2021	Apr	DISC

		SOLUTION; INTRAVENOUS							
		REVATIO							
AP	+!	VIATRIS	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Feb	CAHN	
		TABLET; ORAL							
		REVATIO							
AB	+!	VIATRIS	EQ 20MG BASE	N021845	001	Jun 03, 2005	Feb	CAHN	
		VIAGRA							
AB	+	VIATRIS	EQ 25MG BASE	N020895	001	Mar 27, 1998	Feb	CAHN	
AB	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	Feb	CAHN	
AB	+!		EQ 100MG BASE	N020895	003	Mar 27, 1998	Feb	CAHN	
<u>SILODOSIN</u>									
		CAPSULE; ORAL							
		SILODOSIN							
		@ UPSHER SMITH LABS		4MG		A213230		001 Jan 03, 2022 Feb DISC	
		@		8MG		A213230		002 Jan 03, 2022 Feb DISC	
<u>SIMVASTATIN</u>									
		TABLET; ORAL							
		SIMVASTATIN							
		@ CHARTWELL RX		5MG		A077766		001 Dec 20, 2006 Mar CAHN	
		@		10MG		A077766		002 Dec 20, 2006 Mar CAHN	
		@		20MG		A077766		003 Dec 20, 2006 Mar CAHN	
		@		40MG		A077766		004 Dec 20, 2006 Mar CAHN	
		@		80MG		A077766		005 Dec 20, 2006 Mar CAHN	
<u>SIROLIMUS</u>									
		GEL; TOPICAL							
		HYFTOR							
		+! NOBELPHARMA		0.2%		N213478		001 Mar 22, 2022 Mar NEWA	
		SOLUTION; ORAL							
		SIROLIMUS							
>D>	AA	TORRENT	1MG/ML	A215016	001	Dec 27, 2021	Jun	DISC	
>A>		@	1MG/ML	A215016	001	Dec 27, 2021	Jun	DISC	
<u>SODIUM BICARBONATE</u>									
		INJECTABLE; INJECTION							
		SODIUM BICARBONATE							
AP	!	HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Apr	CHRS	
<u>SODIUM CHLORIDE</u>									
		SOLUTION; INTRAVENOUS							
		SODIUM CHLORIDE 23.4%							
AP		FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A212070	003	Feb 14, 2022	Feb	NFTG	
AP	+!	HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb	CFTG	
<u>SODIUM FLUORIDE F-18</u>									
		INJECTABLE; INTRAVENOUS							
		SODIUM FLUORIDE F 18							
		+ @ NIH NCI DCTD		10-200mCi/ML		N022494		001 Jan 26, 2011 Mar CRLD	
<u>SODIUM NITROPRUSSIDE</u>									
		INJECTABLE; INJECTION							
		SODIUM NITROPRUSSIDE							
>D>	AP	AKORN	25MG/ML	A208635	001	May 04, 2017	Jun	DISC	
>A>		@	25MG/ML	A208635	001	May 04, 2017	Jun	DISC	
	AP	BE PHARMS	25MG/ML	A214971	001	Jul 12, 2021	Apr	CMFD	
		@	25MG/ML	A214971	001	Jul 12, 2021	Jan	DISC	
	AP	CAPLIN	25MG/ML	A211016	001	Nov 29, 2019	Mar	CAHN	
<u>SODIUM PHENYL BUTYRATE</u>									
>A>		PELLETS; ORAL							
>A>		PHEBURANE							
>A>	+!	MEDUNIK	84GM/BOT	N216513	001	Jun 17, 2022	Jun	NEWA	

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE; INJECTION
SODIUM PHOSPHATES

AP	FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Mar	NFTG	
AP	+	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Mar	CFTG

SODIUM POLYSTYRENE SULFONATEPOWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

	+ @ PAI HOLDINGS PHARM	453.6GM/BOT	A088786	001	Sep 11, 1984	Apr	CAHN	
AA	ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CMFD	
AA	+	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Mar	CTEC

SOFOSBUVIRTABLET; ORAL
SOFOSBUVIR

AB	TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022	Jan	NFTG	
AB	+	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013	Jan	CFTG

SOLIFENACIN SUCCINATETABLET; ORAL
SOLIFENACIN SUCCINATE

	@ AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	Jan	DISC	
	@	10MG	A209719	002	May 20, 2019	Jan	DISC	
>A>	AB	ANNORA PHARMA	5MG	A215761	001	Jun 15, 2022	Jun	NEWA
>A>	AB		10MG	A215761	002	Jun 15, 2022	Jun	NEWA

SOLRIAMFETOL HYDROCHLORIDETABLET; ORAL
SUNOSI

	+ AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019	May	CAHN
	+	EQ 150MG BASE	N211230	002	Jun 17, 2019	May	CAHN

SONIDEGIB PHOSPHATECAPSULE; ORAL
ODOMZO

	+	SUN PHARM	EQ 200MG BASE	N205266	001	Jul 24, 2015	Feb	CAHN
--	---	-----------	---------------	---------	-----	--------------	-----	------

SORAFENIB TOSYLATETABLET; ORAL
NEXAVAR

AB	+	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	Apr	CTEC
AB		DR REDDYS	EQ 200MG BASE	A216073	001	Jun 07, 2022	May	NEWA
AB		MYLAN	EQ 200MG BASE	A207012	001	Sep 10, 2020	Apr	CMFD

SOTALOL HYDROCHLORIDESOLUTION; ORAL
SOTYLIZE

	+	AZURITY	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014	Mar	CAHN
--	---	---------	-----------------	---------	-----	--------------	-----	------

STERILE WATER FOR INJECTIONLIQUID; N/A
STERILE WATER FOR INJECTION

AP	!	MEDEFIL INC	100% (5ML)	A211188	004	Dec 02, 2019	Feb	CTEC
AP		NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Feb	CMFD

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE

AP		BE PHARMS	20MG/ML	A216003	001	Feb 07, 2022	Jan	NEWA
AP		MEITHEAL	20MG/ML	A214514	001	Oct 19, 2021	Mar	CAHN

SUCRALFATE

	SUSPENSION;ORAL							
	SUCRALFATE							
AB	VISTAPHARM	1GM/10ML	A211884	001	Mar 15, 2022	Mar	NEWA	
	TABLET;ORAL							
	SUCRALFATE							
AB	AMNEAL PHARMS	1GM	A215576	001	Apr 15, 2022	Apr	NEWA	

SULFAMETHOXAZOLE; TRIMETHOPRIM

	SUSPENSION;ORAL							
	SULFAMETHOXAZOLE AND TRIMETHOPRIM							
	@ LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021	May	DISC	
AB	NOVITIUM PHARMA	200MG/5ML;40MG/5ML	A214330	001	Feb 08, 2022	Jan	NEWA	

SUMATRIPTAN SUCCINATE

	INJECTABLE;SUBCUTANEOUS							
	SUMATRIPTAN SUCCINATE							
	@ STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb	CAHN	
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb	CAHN	

SUNITINIB MALATE

	CAPSULE;ORAL							
	SUNITINIB MALATE							
AB	DR REDDYS	EQ 12.5MG BASE	A215843	001	Apr 11, 2022	Apr	NEWA	
AB		EQ 25MG BASE	A215843	002	Apr 11, 2022	Apr	NEWA	
AB		EQ 37.5MG BASE	A215843	003	Apr 11, 2022	Apr	NEWA	
AB		EQ 50MG BASE	A215843	004	Apr 11, 2022	Apr	NEWA	

TADALAFIL

>A>	SUSPENSION;ORAL							
>A>	TADLIQ							
>A>	+! CMP DEV LLC	20MG/5ML	N214522	001	Jun 17, 2022	Jun	NEWA	
	TABLET;ORAL							
	TADALAFIL							
AB1	AUSTARPHARMA	2.5MG	A208824	001	Oct 27, 2020	Mar	CAHN	
AB1		5MG	A208824	002	Oct 27, 2020	Mar	CAHN	
AB1		10MG	A208824	003	Oct 27, 2020	Mar	CAHN	
AB1		20MG	A208824	004	Oct 27, 2020	Mar	CAHN	
	@ CHARTWELL RX	2.5MG	A210716	001	Dec 29, 2020	May	CAHN	
	@	5MG	A210716	002	Dec 29, 2020	May	CAHN	
	@	10MG	A210716	003	Dec 29, 2020	May	CAHN	
	@	20MG	A210716	004	Dec 29, 2020	May	CAHN	

TAFLUPROST

	SOLUTION/DROPS;OPHTHALMIC							
	TAFLUPROST							
AT	SANDOZ INC	0.0015%	A209040	001	Jan 28, 2022	Jan	NEWA	
	ZIOPTAN							
AT	+! THEA PHARMA	0.0015%	N202514	001	Feb 10, 2012	Apr	CAHN	

TAMSULOSIN HYDROCHLORIDE

	CAPSULE;ORAL							
	TAMSULOSIN HYDROCHLORIDE							
AB	ACME LABS	0.4MG	A214730	001	May 04, 2022	Apr	NEWA	

TAPINAROF

	CREAM;TOPICAL							
	VTAMA							
	+! DERMAVANT SCI	1%	N215272	001	May 23, 2022	May	NEWA	

TAVABOROLE

	SOLUTION;TOPICAL							
	TAVABOROLE							
AB	CHARTWELL RX	5%	A211963	001	Feb 03, 2021	Mar	CAHN	
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Mar	CMFD	

TAZAROTENE

LOTION; TOPICAL
ARAZLO

+! BAUSCH 0.045% N211882 001 Dec 18, 2019 May CAHN

TECHNETIUM TC-99M SUCCIMER

POWDER; INTRAVENOUS
NEPHROSCAN

+! THERAGNOSTICS N/A N214993 001 Feb 18, 2022 Mar CAIN

TECHNETIUM TC-99M SUCCIMER KIT

POWDER; INTRAVENOUS
NEPHROSCAN

+! THERAGNOSTICS N/A N214993 001 Feb 18, 2022 Feb NEWA

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVUE

+! GE HEALTHCARE N/A N020372 001 Feb 09, 1996 Feb CMFD

TECOVIRIMAT

SOLUTION; INTRAVENOUS
TPOXX

+! SIGA TECHNOLOGIES 200MG/20ML (10MG/ML) N214518 001 May 18, 2022 May NEWA

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS
GATTEX KIT

+! TAKEDA PHARMS USA 5MG/VIAL N203441 001 Dec 21, 2012 Apr CAHN

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM

>D> +! ALFASIGMA EQ 6MG BASE N021200 002 Jul 24, 2002 Jun DISC

>A> + @ EQ 6MG BASE N021200 002 Jul 24, 2002 Jun DISC

TEMOZOLOMIDE

CAPSULE; ORAL
TEMOZOLOMIDE

>D> AB ANI PHARMS 5MG A203490 001 Jul 13, 2016 Jun DISC

>A> @ 5MG A203490 001 Jul 13, 2016 Jun DISC

>D> AB 20MG A203490 002 Jul 13, 2016 Jun DISC

>A> @ 20MG A203490 002 Jul 13, 2016 Jun DISC

>D> AB 100MG A203490 003 Jul 13, 2016 Jun DISC

>A> @ 100MG A203490 003 Jul 13, 2016 Jun DISC

>D> AB 140MG A203490 004 Jul 13, 2016 Jun DISC

>A> @ 140MG A203490 004 Jul 13, 2016 Jun DISC

>D> AB 180MG A203490 005 Jul 13, 2016 Jun DISC

>A> @ 180MG A203490 005 Jul 13, 2016 Jun DISC

>A> @ 250MG A203490 006 Jul 13, 2016 Mar DISC

AB HERITAGE 5MG A078879 001 Mar 01, 2010 Jan CMFD

AB 20MG A078879 002 Mar 01, 2010 Jan CMFD

AB 100MG A078879 003 Mar 01, 2010 Jan CMFD

AB 140MG A078879 005 Mar 01, 2010 Jan CMFD

AB 180MG A078879 006 Mar 01, 2010 Jan CMFD

AB 250MG A078879 004 Mar 01, 2010 Jan CMFD

TENAPANOR HYDROCHLORIDE

TABLET; ORAL
IBSRELA

+! ARDELYX INC EQ 50MG BASE N211801 001 Sep 12, 2019 Feb CMFD

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

AB CHARTWELL EQ 250MG BASE A078199 001 Jul 02, 2007 Mar CMFD

TERBUTALINE SULFATE

	INJECTABLE; INJECTION						
	TERBUTALINE SULFATE						
AP	! CHARTWELL INJECTABLE	1MG/ML		A076770	001	Apr 23, 2004	Mar CAHN

TESTOSTERONE

	GEL; TRANSDERMAL						
	ANDROGEL						
	+ @ ABBVIE	1.62% (20.25MG/1.25GM PACKET)		N022309	002	Sep 07, 2012	Jan DISC
	+ @	1.62% (40.5MG/2.5GM PACKET)		N022309	003	Sep 07, 2012	Jan DISC
	+ @	25MG/2.5GM PACKET		N021015	001	Feb 28, 2000	Jan DISC
	+ @	50MG/5GM PACKET		N021015	002	Feb 28, 2000	Jan DISC
	TESTOSTERONE						
AB1	! ACTAVIS LABS UT INC	50MG/5GM PACKET		A076737	002	Jan 27, 2006	Jan CHRS
AB2	! PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)		A205781	002	Jul 12, 2017	Jan CHRS

TESTOSTERONE CYPIONATE

	SOLUTION; INTRAMUSCULAR						
	TESTOSTERONE CYPIONATE						
>A>	+! SLAYBACK PHARMA LLC	200MG/ML (200MG/ML)		N216318	001	Jun 02, 2022	Jun NEWA

TESTOSTERONE UNDECANOATE

	CAPSULE; ORAL						
	TLANDO						
	+! ANTARES PHARMA INC	112.5MG		N208088	001	Mar 28, 2022	Mar NEWA

TETRABENAZINE

	TABLET; ORAL						
	TETRABENAZINE						
	@ HIKMA	12.5MG		A209739	001	Apr 08, 2019	Feb DISC
	@	25MG		A209739	002	Apr 08, 2019	Feb DISC

THIAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	THIAMINE HYDROCHLORIDE						
AP	EUGIA PHARMA	100MG/ML		A208703	001	Apr 20, 2022	Apr NEWA

THIOGUANINE

	TABLET; ORAL						
	THIOGUANINE						
	+! WOODWARD SPECL	40MG		N012429	001		Apr CAHN

THIOTHIXENE

	CAPSULE; ORAL						
	THIOTHIXENE						
AB	AMNEAL	1MG		A215456	001	Feb 28, 2022	Feb NEWA
AB		2MG		A215456	002	Feb 28, 2022	Feb NEWA
AB		5MG		A215456	003	Feb 28, 2022	Feb NEWA
AB		10MG		A215456	004	Feb 28, 2022	Feb NEWA

TICAGRELOR

	TABLET; ORAL						
	BRILINTA						
	+ ASTRAZENECA	60MG		N022433	002	Sep 03, 2015	Feb CTEC
	TICAGRELOR						
	@ MYLAN	60MG		A208597	001	Jul 09, 2021	Feb DISC
	@	90MG		A208597	002	Jul 09, 2021	Feb DISC

TIGECYCLINE

	POWDER; INTRAVENOUS						
	TIGECYCLINE						
>D>	AP XELLIA PHARMS APS	50MG/VIAL		A205722	001	Oct 18, 2019	Jun DISC
>A>	@	50MG/VIAL		A205722	001	Oct 18, 2019	Jun DISC

TIMOLOL

	SOLUTION/DROPS; OPHTHALMIC						
	BETIMOL						
AT	+! THEA PHARMA	EQ 0.25% BASE		N020439	001	Mar 31, 1995	Apr CAHN
AT	+!	EQ 0.5% BASE		N020439	002	Mar 31, 1995	Apr CAHN

TIMOLOL MALEATE

		SOLUTION, GEL FORMING/DROPS;OPHTHALMIC							
		TIMOLOL MALEATE							
>A>	AB	GLAND PHARMA LTD	EQ 0.25% BASE	A214645	001	Jun 24, 2022	Jun	NEWA	
		TIMOPTIC-XE							
	AB	+ BAUSCH	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr	CAHN	
	AB	+ BAUSCH	EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr	CAHN	
		SOLUTION/DROPS;OPHTHALMIC							
		TIMOPTIC							
	AT1	+ BAUSCH	EQ 0.25% BASE	N018086	001		Apr	CAHN	
	AT1	+ BAUSCH	EQ 0.5% BASE	N018086	002		Apr	CAHN	
		TIMOPTIC IN OCUDOSE							
	AT3	+! BAUSCH AND LOMB INC	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Feb	CAHN	
	AT3	+! BAUSCH AND LOMB INC	EQ 0.5% BASE	N019463	002	Nov 05, 1986	Feb	CAHN	

TIOPRONIN

		TABLET;ORAL							
		TIOPRONIN							
	AB	PAR PHARM INC	100MG	A216198	001	Jun 02, 2022	May	NEWA	

TIRZEPATIDE

		SOLUTION;SUBCUTANEOUS							
		MOUNJARO							
	+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	May	NEWA	
	+!	ELI LILLY AND CO	5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	May	NEWA	
	+!	ELI LILLY AND CO	7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	May	NEWA	
	+!	ELI LILLY AND CO	10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	May	NEWA	
	+!	ELI LILLY AND CO	12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	May	NEWA	
	+!	ELI LILLY AND CO	15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	May	NEWA	

TOFACITINIB CITRATE

		TABLET, EXTENDED RELEASE;ORAL							
		TOFACITINIB							
		@ ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Jan	DISC	
		@ ZYDUS PHARMS	EQ 22MG BASE	A214264	002	Aug 19, 2021	Jan	DISC	
		XELJANZ XR							
	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Jan	CTEC	
	+!	PFIZER	EQ 22MG BASE	N208246	002	Dec 12, 2019	Jan	CTEC	

TOLVAPTAN

		TABLET;ORAL							
		SAMSCA							
	AB	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb	CFTG	
		TOLVAPTAN							
	AB	PAR PHARM INC	15MG	A206119	001	Feb 15, 2022	Feb	NFTG	
	AB	PAR PHARM INC	30MG	A206119	002	Feb 15, 2022	Feb	NEWA	

TOPIRAMATE

		TABLET;ORAL							
		TOPIRAMATE							
	@	ATLANTIDE	25MG	A090353	001	Sep 01, 2010	Apr	CAHN	
	@	ATLANTIDE	50MG	A090353	002	Sep 01, 2010	Apr	CAHN	
	@	ATLANTIDE	100MG	A090353	003	Sep 01, 2010	Apr	CAHN	
	@	ATLANTIDE	200MG	A090353	004	Sep 01, 2010	Apr	CAHN	
	@	UPSHER SMITH LABS	25MG	A078499	001	Jan 07, 2010	Mar	DISC	
	@	UPSHER SMITH LABS	50MG	A078499	002	Jan 07, 2010	Mar	DISC	
	@	UPSHER SMITH LABS	100MG	A078499	003	Jan 07, 2010	Mar	DISC	
	@	UPSHER SMITH LABS	200MG	A078499	004	Jan 07, 2010	Mar	DISC	

TOPOTECAN HYDROCHLORIDE

		INJECTABLE;INJECTION							
		TOPOTECAN HYDROCHLORIDE							
	AP	TEYRO LABS	EQ 4MG BASE/VIAL	A091199	001	Dec 01, 2010	Apr	CAHN	
		SOLUTION;INTRAVENOUS							
		TOPOTECAN HYDROCHLORIDE							
	@	MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar	DISC	

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

>D>	AB1	MYLAN	200MG	A205257	002	Dec 22, 2015	Jun	DISC
>A>		@	200MG	A205257	002	Dec 22, 2015	Jun	DISC
>D>	AB1		300MG	A205257	003	Dec 22, 2015	Jun	DISC
>A>		@	300MG	A205257	003	Dec 22, 2015	Jun	DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

>D>	AP	AKORN	100MG/ML	A206594	001	Sep 28, 2017	Jun	DISC
>A>		@	100MG/ML	A206594	001	Sep 28, 2017	Jun	DISC
>D>	AP		100MG/ML	A206634	001	Jun 09, 2016	Jun	DISC
>A>		@	100MG/ML	A206634	001	Jun 09, 2016	Jun	DISC

TRANLYCYPROMINE SULFATE

TABLET;ORAL
TRANLYCYPROMINE SULFATE

>A>	AB	CROSSMEDIKA SA	EQ 10MG BASE	A213503	001	Jun 27, 2022	Jun	NEWA
-----	----	----------------	--------------	---------	-----	--------------	-----	------

TREPROSTINIL

POWDER; INHALATION
TYVASO DPI

+	UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022	May	NEWA
+		0.032MG/INH	N214324	002	May 23, 2022	May	NEWA
+		0.048MG/INH	N214324	003	May 23, 2022	May	NEWA
+	!	0.064MG/INH	N214324	004	May 23, 2022	May	NEWA

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED;NASAL
NASACORT

@	CHATTEM SANOFI	0.055MG/INH	N019798	001	Jul 11, 1991	Jan	CAHN
@		0.055MG/INH	N019798	001	Jul 11, 1991	Jan	CAHN

FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR
ZILRETTA

+	!	PACIRA PHARMS INC	32MG/VIAL	N208845	001	Oct 06, 2017	Feb	CAHN
---	---	-------------------	-----------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION
TRIAMCINOLONE ACETONIDE

AB	CUSTOPHARM INC	40MG/ML	A213543	001	Jan 19, 2022	Jan	NEWA	
>A>	AB	EUGIA PHARMA	40MG/ML	A212400	001	Jul 05, 2022	Jun	NEWA
AB	LONG GROVE PHARMS	40MG/ML	A213543	001	Jan 19, 2022	Jan	CAHN	

SPRAY, METERED;NASAL
TRIAMCINOLONE ACETONIDE

@	PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan	CAHN
---	---------------------	---------------	---------	-----	--------------	-----	------

TRIAMTERENE

CAPSULE;ORAL
TRIAMTERENE

>A>	AB	EYWA	50MG	A214768	001	Jul 06, 2022	Jun	NEWA
>A>	AB		100MG	A214768	002	Jul 06, 2022	Jun	NEWA

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL
TRIENTINE HYDROCHLORIDE

>A>	AB	HETERO LABS LTD III	250MG	A216356	001	Jun 23, 2022	Jun	NEWA
		@ LUPIN LTD	250MG	A211637	001	May 21, 2020	Apr	DISC

TRIENTINE TETRAHYDROCHLORIDE

TABLET;ORAL
CUVRIOR

+	!	ORPHALAN	300MG	N215760	001	Apr 28, 2022	Apr	NEWA
---	---	----------	-------	---------	-----	--------------	-----	------

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
TRIPTODUR KIT

>D>	+	!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	CAHN
>A>	+	!	AZURITY	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun	CAHN

TROSPIUM CHLORIDE

TABLET; ORAL		TROSPIUM CHLORIDE					
AB	AMICI	20MG		A215781	001	Feb 16, 2022	Feb NEWA
AB	ENALTEC	20MG		A215781	001	Feb 16, 2022	May CAHN

UPADACITINIB

TABLET, EXTENDED RELEASE; ORAL		RINVOQ					
	+ ABBVIE INC	15MG		N211675	001	Aug 16, 2019	Jan CHRS
	+	30MG		N211675	002	Jan 14, 2022	Apr CHRS
	+!	30MG		N211675	002	Jan 14, 2022	Jan NEWA
	+!	45MG		N211675	003	Mar 16, 2022	Mar NEWA

URSODIOL

CAPSULE; ORAL		ACTIGALL					
	@ TEVA BRANDED PHARM	150MG		N019594	001	Dec 31, 1987	Apr CAHN
AB	+!	300MG		N019594	002	Dec 31, 1987	Apr CAHN
CAPSULE; ORAL		URSODIOL					
	@ VGYAAN	300MG		A214329	001	Jul 28, 2021	Feb DISC

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL		VALGANCICLOVIR HYDROCHLORIDE					
AB	AIRIS PHARMA PVT LTD	50MG/ML		A210169	001	Feb 17, 2022	Feb NEWA
TABLET; ORAL		VALGANCICLOVIR HYDROCHLORIDE					
	@ MYLAN	EQ 450MG BASE		A205151	001	Mar 03, 2021	Mar DISC
AB		EQ 450MG BASE		A205151	001	Mar 03, 2021	Mar CAHN

VALPROATE SODIUM

INJECTABLE; INJECTION		VALPROATE SODIUM					
	@ MYLAN	EQ 100MG BASE/ML		A208120	001	Dec 22, 2021	May DISC

VALPROIC ACID

SYRUP; ORAL		VALPROIC ACID					
	@ WOCKHARDT BIO AG	250MG/5ML		A070868	001	Jul 01, 1986	Mar DISC

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION		VANCOCIN HYDROCHLORIDE					
	@ STERISCIENCE	EQ 500MG BASE/VIAL		A060180	001		Jan CAHN
	@	EQ 500MG BASE/VIAL		A062476	001	Mar 15, 1984	Jan CAHN
	@	EQ 500MG BASE/VIAL		A062716	001	Mar 13, 1987	Jan CAHN
	@	EQ 500MG BASE/VIAL		A062812	001	Nov 17, 1987	Jan CAHN
	@	EQ 1GM BASE/VIAL		A060180	002	Mar 21, 1986	Jan CAHN
	@	EQ 1GM BASE/VIAL		A062476	002	Mar 21, 1986	Jan CAHN
	@	EQ 1GM BASE/VIAL		A062716	002	Mar 13, 1987	Jan CAHN
	@	EQ 1GM BASE/VIAL		A062812	002	Nov 17, 1987	Jan CAHN
	@	EQ 10GM BASE/VIAL		A062812	003	Nov 17, 1987	Jan CAHN
INJECTABLE; INJECTION		VANCOMYCIN HYDROCHLORIDE					
>A>	AP ASPIRO	EQ 500MG BASE/VIAL		A216591	001	Jul 06, 2022	Jun NEWA
>A>	AP	EQ 1GM BASE/VIAL		A216591	002	Jul 06, 2022	Jun NEWA
	AP KNACK	EQ 500MG BASE/VIAL		A213059	001	Feb 15, 2022	Feb NEWA
	AP	EQ 750MG BASE/VIAL		A213059	002	Feb 15, 2022	Feb NEWA
	AP	EQ 1GM BASE/VIAL		A213059	003	Feb 15, 2022	Feb NEWA
POWDER; INTRAVENOUS		VANCOMYCIN HYDROCHLORIDE					
	+ @ MYLAN LABS LTD	EQ 250MG BASE/VIAL		N209481	001	Jul 10, 2018	Feb DISC

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL		LEVITRA					
	+ @ BAYER HLTHCARE	EQ 20MG BASE		N021400	004	Aug 19, 2003	Feb DISC
TABLET; ORAL		VARDENAFIL HYDROCHLORIDE					
AB	! ZYDUS PHARMS	EQ 20MG BASE		A208960	004	Oct 31, 2018	Feb CHRS

TABLET, ORALLY DISINTEGRATING;ORAL
STAXYN

	+ @	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	May	DISC
		VARDENAFIL HYDROCHLORIDE						
AB	!	ALEMBIC PHARMS LTD	10MG	A208324	001	Nov 16, 2018	May	CHRS

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

	+ @	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Apr	DISC
	+ @		EQ 1MG BASE	N021928	002	May 10, 2006	Apr	DISC
AB	+		EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CHRS
		VARENICLINE TARTRATE						
		PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Apr	CTEC
	!		EQ 1MG BASE	A201785	002	Aug 11, 2021	Apr	CTEC
AB	!		EQ 1MG BASE	A201785	002	Aug 11, 2021	Feb	CHRS

>A> VENLAFAXINE BESYLATE

>A> TABLET, EXTENDED RELEASE;ORAL

>A> VENLAFAXINE BESYLATE

>A>	+	ALMATICA	EQ 112.5MG BASE	N215429	001	Jun 29, 2022	Jun	NEWA
-----	---	----------	-----------------	---------	-----	--------------	-----	------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

@ YICHANG HUMANWELL

EQ 37.5MG BASE

A214654 001 Aug 06, 2021 Jan DISC

@

EQ 75MG BASE

A214654 002 Aug 06, 2021 Jan DISC

@

EQ 150MG BASE

A214654 003 Aug 06, 2021 Jan DISC

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

>D>	AB	+	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Jun	CAHN
>D>	AB	+		180MG	N019614	003	Jan 09, 1992	Jun	CAHN
>D>	AB	+		240MG	N019614	002	May 29, 1990	Jun	CAHN
>D>		+		360MG	N019614	004	May 10, 1996	Jun	CAHN
>A>	AB	+	SOCIETAL CDMO	120MG	N019614	001	May 29, 1990	Jun	CAHN
>A>	AB	+		180MG	N019614	003	Jan 09, 1992	Jun	CAHN
>A>	AB	+		240MG	N019614	002	May 29, 1990	Jun	CAHN
>A>		+		360MG	N019614	004	May 10, 1996	Jun	CAHN

VERELAN PM

>D>		+	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Jun	CAHN
>D>		+		200MG	N020943	002	Nov 25, 1998	Jun	CAHN
>D>		+		300MG	N020943	003	Nov 25, 1998	Jun	CAHN
>A>		+	SOCIETAL CDMO	100MG	N020943	001	Nov 25, 1998	Jun	CAHN
>A>		+		200MG	N020943	002	Nov 25, 1998	Jun	CAHN
>A>		+		300MG	N020943	003	Nov 25, 1998	Jun	CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP		ACIC PHARMS	2.5MG/ML	A215829	001	Mar 17, 2022	Mar	NEWA
>A>	AP	MANKIND PHARMA	2.5MG/ML	A214653	001	Jun 15, 2022	Jun	NEWA

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

@ CHARTWELL RX

40MG

A073168 001 Jul 31, 1992 Mar CAHN

@

80MG

A071423 001 May 24, 1988 Mar CAHN

@

120MG

A071424 001 May 25, 1988 Mar CAHN

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

>A>	AA		ELITE LABS INC	500MG/PACKET	A214961	001	Jun 24, 2022	Jun	NEWA
	AA		LUPIN LTD	500MG/PACKET	A211790	001	Mar 10, 2022	Mar	NEWA

TABLET;ORAL

VIGABATRIN

>A>	AB		AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Jun	NEWA
	AB		AUROBINDO PHARMA LTD	500MG	A215601	001	May 10, 2022	Apr	NEWA
	AB		ZYDUS	500MG	A215707	001	Jan 19, 2022	Jan	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILAZODONE HYDROCHLORIDE

AB	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	May	CMFD
AB		20MG	A208212	002	Sep 30, 2019	May	CMFD
AB		40MG	A208212	003	Sep 30, 2019	May	CMFD

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP	!	JIANGSU HANSOH PHARM	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012	Apr	CHRS
----	---	----------------------	-----------------	---------	-----	--------------	-----	------

VORICONAZOLE

INJECTABLE; INTRAVENOUS

VORICONAZOLE

>D>	AP	HONG KONG	200MG/VIAL	A214516	001	May 09, 2022	Jun	CAHN
	AP		200MG/VIAL	A214516	001	May 09, 2022	Apr	NEWA
>A>	AP	MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Jun	CAHN

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

>D>	+	!	MERCK	100MG	N021991	001	Oct 06, 2006	Jun	CAHN
>A>	+	!	MSD SUB MERCK	100MG	N021991	001	Oct 06, 2006	Jun	CAHN

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Mar	CTEC
+		EQ 10MG BASE	N204447	002	Sep 30, 2013	Mar	CTEC
+	!	EQ 20MG BASE	N204447	004	Sep 30, 2013	Mar	CTEC

VORTIOXETINE HYDROBROMIDE

@	ZYDUS PHARMS	EQ 5MG BASE	A211146	001	Sep 17, 2021	Mar	DISC
@		EQ 10MG BASE	A211146	002	Sep 17, 2021	Mar	DISC
@		EQ 20MG BASE	A211146	003	Sep 17, 2021	Mar	DISC

>A>									
>A>									
>A>									
>A>	+	!	ALNYLAM PHARMS INC	25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Jun	NEWA

ZALEPLON

CAPSULE; ORAL

ZALEPLON

AB	CHARTWELL MOLECULAR	5MG	A077505	001	Jun 20, 2008	Mar	CAHN
AB		10MG	A077505	002	Jun 20, 2008	Mar	CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE

@	EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb	DISC	
		ZINC CHLORIDE IN PLASTIC CONTAINER						
+	!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb	CTEC

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AP	+	!	AM REGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Apr	CFTG
AP	+	!		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Apr	CFTG
AP			GLAND PHARMA LTD	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216249	001	May 03, 2022	Apr	NFTG
AP				EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216249	002	May 03, 2022	Apr	NFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	!	VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jan	CAHN
AB	+			EQ 40MG BASE	N020825	002	Feb 05, 2001	Jan	CAHN
AB	+			EQ 60MG BASE	N020825	003	Feb 05, 2001	Jan	CAHN
AB	+			EQ 80MG BASE	N020825	004	Feb 05, 2001	Jan	CAHN

ZIPRASIDONE MESYLATEINJECTABLE; INTRAMUSCULAR
GEODON

AP	+	VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CPOT
AP	+		EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jan CAHN
ZIPRASIDONE MESYLATE							
AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CPOT
POWDER; INTRAMUSCULAR GEODON							
AP	+	VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CDFR
ZIPRASIDONE MESYLATE							
AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CDFR

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

AP		AMNEAL	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN
----	--	--------	-------------------	---------	-----	--------------	----------

ZOLPIDEM TARTRATETABLET; ORAL
ZOLPIDEM TARTRATE

AB		CHARTWELL MOLECULAR	5MG	A077388	001	Jul 30, 2012	Mar CAHN
AB			10MG	A077388	002	Jul 30, 2012	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

AUROBINDO PHARMA LTD 250MG;250MG;65MG

A211695 001 Feb 02, 2022 Jan NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

TARO PHARMS 0.1%

A215940 001 Jan 14, 2022 Jan NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

GAVISCON

+ @ CHATTEM SANOFI 80MG;20MG

N018685 001 Dec 09, 1983 May DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A> BAJAJ 5MG/5ML A091327 001 Oct 17, 2011 Jun CAHN

@ CHARTWELL RX 5MG/5ML A090378 002 May 09, 2008 Mar CAHN

>D> MICRO LABS 5MG/5ML A091327 001 Oct 17, 2011 Jun CAHN

@ TRIS PHARMA INC 5MG/5ML A090572 001 Nov 16, 2012 May DISC

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A> BAJAJ 5MG/5ML A091327 002 Oct 17, 2011 Jun CAHN

@ CHARTWELL RX 5MG/5ML A090378 001 May 09, 2008 Mar CAHN

>D> MICRO LABS 5MG/5ML A091327 002 Oct 17, 2011 Jun CAHN

@ TRIS PHARMA INC 5MG/5ML A090572 002 Nov 16, 2012 May DISC

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

GLENMARK PHARMS INC 5MG A078427 003 Dec 28, 2007 May CAHN

10MG A078427 004 Dec 28, 2007 May CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S ZYRTEC ALLERGY

>D> + @ J AND J CONSUMER INC 2.5MG N021621 007 Nov 30, 2020 Jun CMFD

>A> + 2.5MG N021621 007 Nov 30, 2020 Jun CMFD

>D> + @ 10MG N021621 004 Nov 16, 2007 Jun CMFD

>A> + 10MG N021621 004 Nov 16, 2007 Jun CMFD

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AKORN 1%

A209484 001 Nov 21, 2018 Mar CMKT

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

AUROBINDO PHARMA LTD 38MG;200MG

A216204 001 May 31, 2022 May NEWA

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

ALEOR DERMACEUTICALS 10%

A215839 001 May 03, 2022 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>A> GRAVITI PHARMS EQ 20MG BASE A216349 001 Jun 24, 2022 Jun NEWA

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

+ @ DEXCEL PHARMA EQ 20MG BASE N214278 001 Oct 20, 2020 Jan DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>A> GLENMARK PHARMS INC 10MG A077146 001 Mar 07, 2005 Jun CAHN

20MG A090837 001 Aug 04, 2010 May CAHN

VKT PHARMA 10MG A215822 001 Jan 28, 2022 Jan NEWA

20MG A215822 002 Jan 28, 2022 Jan NEWA

>D> WOCHKHARDT 10MG A077146 001 Mar 07, 2005 Jun CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	ATLANTIDE	30MG	A 079112	002	Feb 08, 2012	Apr	CAHN
>D>	SUN PHARM INDS	30MG	A 091567	002	Feb 06, 2012	Jun	DISC
>A>	@	30MG	A 091567	002	Feb 06, 2012	Jun	DISC

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	ATLANTIDE	30MG	A 079112	001	Feb 08, 2012	Apr	CAHN
>D>	SUN PHARM INDS	30MG	A 091567	001	Feb 06, 2012	Jun	DISC
>A>	@	30MG	A 091567	001	Feb 06, 2012	Jun	DISC

FEXOFENADINE HYDROCHLORIDE ALLERGY

	ATLANTIDE	60MG	A 079112	004	Feb 08, 2012	Apr	CAHN
		180MG	A 079112	006	Feb 08, 2012	Apr	CAHN
>D>	SUN PHARM INDS	60MG	A 091567	004	Feb 06, 2012	Jun	DISC
>A>	@	60MG	A 091567	004	Feb 06, 2012	Jun	DISC

FEXOFENADINE HYDROCHLORIDE HIVES

	ATLANTIDE	60MG	A 079112	003	Feb 08, 2012	Apr	CAHN
		180MG	A 079112	005	Feb 08, 2012	Apr	CAHN
>D>	SUN PHARM INDS	60MG	A 091567	003	Feb 06, 2012	Jun	DISC
>A>	@	60MG	A 091567	003	Feb 06, 2012	Jun	DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	60MG;120MG	N 020786	002	Jan 24, 2011	Jan	CAHN
+!		60MG;120MG	N 020786	002	Jan 24, 2011	Jan	CAHN

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	180MG;240MG	N 021704	002	Jan 24, 2011	Jan	CAHN
+!		180MG;240MG	N 021704	002	Jan 24, 2011	Jan	CAHN

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS	60MG;120MG	A 215434	001	May 31, 2022	May	NEWA
--	-----------	------------	----------	-----	--------------	-----	------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

	DR REDDYS	600MG	A 215932	001	Mar 15, 2022	Mar	NEWA
		1.2GM	A 215932	002	Mar 15, 2022	Mar	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	L PERRIGO CO	600MG;60MG	A 214407	001	Feb 01, 2022	Jan	NEWA
		1.2GM;120MG	A 214407	002	Feb 01, 2022	Jan	NEWA

IBUPROFEN

SUSPENSION/DROPS; ORAL

IBUPROFEN

>A>	STRIDES PHARMA	50MG/1.25ML	A 214071	001	Jun 09, 2022	Jun	NEWA
-----	----------------	-------------	----------	-----	--------------	-----	------

IVERMECTIN

LOTION; TOPICAL

IVERMECTIN

	TEVA PHARMS USA	0.5%	A 212485	001	Mar 21, 2022	Mar	NEWA
--	-----------------	------	----------	-----	--------------	-----	------

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

	BAUSCH	EQ 0.025% BASE	A 208158	001	Sep 24, 2020	Mar	CPOT
	BAUSCH AND LOMB INC	EQ 0.025% BASE	A 208158	001	Sep 24, 2020	Mar	CAHN
	CHILDREN'S ALAWAY						
+	BAUSCH AND LOMB	EQ 0.025% BASE	N 021996	002	Feb 11, 2015	Mar	CPOT
+		EQ 0.035% BASE	N 021996	002	Feb 11, 2015	Mar	CTNA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

	GLENMARK PHARMS INC	15MG	A 202727	001	May 18, 2012	May	CAHN
--	---------------------	------	----------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 2.5MG/5ML N209090 001 Jan 31, 2017 Jan CAHN

TABLET;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 5MG N209089 001 Jan 31, 2017 Jan CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

@ L PERRIGO CO 0.75MG A090740 001 Dec 30, 2010 May DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

>D> AKORN 1MG/5ML A074352 001 Nov 17, 1995 Jun DISC

>A> @ 1MG/5ML A074352 001 Nov 17, 1995 Jun DISC

LORATADINE

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG N021891 001 Aug 23, 2006 Apr CHRS

CLARITIN

+! BAYER HEALTHCARE LLC 10MG N021891 002 Nov 21, 2018 Apr CHRS

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

PERRIGO PHARMA INTL 5% A091344 001 Apr 28, 2011 Jan CAHN

SOLUTION;TOPICAL

THEROXIDIL

>D> EI INC 2% A078176 001 Nov 09, 2007 Jun CAHN

>D> 5% A076239 001 Aug 24, 2004 Jun CAHN

>A> PURE SOURCE 2% A078176 001 Nov 09, 2007 Jun CAHN

>A> 5% A076239 001 Aug 24, 2004 Jun CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL

NASONEX 24HR ALLERGY

+! PERRIGO PHARMA INTL 0.05MG/SPRAY N215712 001 Mar 17, 2022 Mar NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ @ BAYER 220MG;120MG N021076 001 Nov 29, 1999 Jan DISC

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 220MG;120MG A211360 001 Jun 01, 2022 May NEWA

! PERRIGO 220MG;120MG A076518 001 Mar 17, 2004 Jan CHRS

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

AUROBINDO PHARMA LTD EQ 2MG BASE A215357 001 May 13, 2022 May NEWA

EQ 4MG BASE A215357 002 May 13, 2022 May NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>D> @ BAUSCH EQ 0.1% BASE A206046 001 Jul 26, 2017 Jun CAHN

>A> @ BAUSCH AND LOMB INC EQ 0.1% BASE A206046 001 Jul 26, 2017 Jun CAHN

@ GLENMARK PHARMS INC EQ 0.1% BASE A200810 001 Jun 28, 2017 May CAHN

@ MYLAN EQ 0.2% BASE A204620 001 Jun 16, 2020 May DISC

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+! DEXCEL PHARMA 20MG N209400 001 Jul 05, 2017 Feb CHRS

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

L PERRIGO CO EQ 20MG BASE A216096 001 May 24, 2022 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID OTC

+! RILEY CONSUMER 20MG;1.1GM N022281 001 Dec 01, 2009 Mar CAHN

FOR SUSPENSION;ORAL
ZEGERID OTC

+! RILEY CONSUMER 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

POTASSIUM IODIDE

SOLUTION;ORAL
POTASSIUM IODIDE

+ @ ROXANE 1GM/ML N018551 001 Feb 19, 1982 Jan CRLD

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

>D> L PERRIGO CO 120MG A075153 001 Feb 26, 1999 Jun CHRS

>A> ! 120MG A075153 001 Feb 26, 1999 Jun CHRS

SUDAFED 12 HOUR

>D> ! MCNEIL CONS 120MG A073585 001 Oct 31, 1991 Jun DISC

>A> @ 120MG A073585 001 Oct 31, 1991 Jun DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
ZANTAC 150

+ @ CHATTEM SANOFI EQ 150MG BASE N021698 001 Aug 31, 2004 Jan CAHN

+ @ EQ 150MG BASE N021698 002 Mar 13, 2007 Jan CAHN

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020520 001 Dec 19, 1995 Jan CAHN

TABLET, EFFERVESCENT;ORAL
ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020745 001 Feb 26, 1998 Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL
NASACORT ALLERGY 24 HOUR

+! CHATTEM SANOFI 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

+! 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2022

NO JUNE 2022 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2022 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11255842	Jan 10, 2040	U-3322			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	10004743	Jul 05, 2030	DP		>A> M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			>A> PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	10004743	Jul 05, 2030	DP		>A> M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			>A> PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	10004743	Jul 05, 2030	DP		>A> M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			>A> PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	11266796	Feb 22, 2041	DP			
	>A> 11344685	Sep 26, 2039	DP			
	>A> 11351317	Feb 10, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	8357713	Dec 22, 2029	DP U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8357713	Dec 22, 2029	DP U-2104			
<u>ALPELISIB - VIJOICE</u>						
N 215039 001	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - VIJOICE</u>						
N 215039 002	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - VIJOICE</u>						
N 215039 003	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11197835	Dec 02, 2030	U-2106			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11197835	Dec 02, 2030	U-2106			
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	11268128	Jun 29, 2032	U-2956			
	11274331	Jun 29, 2032	U-2956			
	11274332	Jun 29, 2032	U-2956			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11235169	Oct 15, 2040	U-3303			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001 >A>	11364230	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	11253474	Feb 24, 2041	DP U-3309			
	11253474	Feb 24, 2041	DP U-3310			
	11253474	Feb 24, 2041	DP U-3311			
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001					NCE GAIN	May 03, 2027 May 03, 2032
<u>AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK</u>						
N 215153 001					NCE GAIN	May 03, 2027 May 03, 2032
<u>AMPHOTERICIN B - AMPHOTERICIN B</u>						
A 212514 001					CGT	Aug 14, 2022
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE</u>						
A 212025 001					CGT	Aug 24, 2022
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	>A> 11344547	Sep 24, 2033	U-3245			
	>A> 11344547	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	>A> 11344547	Sep 24, 2033	U-3245			
	>A> 11344547	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	>A> 11344547	Sep 24, 2033	U-3245			
	>A> 11344547	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	>A> 11344547	Sep 24, 2033	U-3245			
	>A> 11344547	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	11273158	Apr 06, 2039	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	11273158	Apr 06, 2039	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	11273158	Apr 06, 2039	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	11273158	Apr 06, 2039	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	11273158	Apr 06, 2039	U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	8829195	May 13, 2033	DS U-1374		ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	8829195	May 13, 2033	DS U-1374		ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001					ODE-377	Oct 07, 2028
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					>A> I-889	May 20, 2025
<u>BACLOFEN - FLEOSUVY</u>						
N 215602 001	11324696	Sep 29, 2037	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	11045474	Nov 30, 2032	U-3372		>A> I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		>A> I-891	May 10, 2025
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	11045474	Nov 30, 2032	U-3372		>A> I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		>A> I-891	May 10, 2025
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	11045474	Nov 30, 2032	U-3372		>A> I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		>A> I-891	May 10, 2025
	9089574	Nov 30, 2032	U-3372		NCE	May 31, 2023
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	11311541	Apr 09, 2035	U-3369			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11230530	Mar 09, 2035	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11230530	Mar 09, 2035	U-3300			
<u>BETAINE - BETAINE</u>						
A 214864 001					CGT	Aug 02, 2022
<u>BEXAROTENE - BEXAROTENE</u>						
A 215398 001					CGT	Nov 13, 2022
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002					NCE ODE-378	Feb 07, 2023 Oct 07, 2028
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 002	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Apr 28, 2031	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Apr 28, 2031	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Apr 28, 2031	DS			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					NP	Dec 15, 2024
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	>A> 11331442	May 10, 2038	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	>A> 11357727	Jan 22, 2041	DP U-3380			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	>A> 11357727	Jan 22, 2041	DP U-3380			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	11253504	Mar 13, 2034	U-3118			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11278544	Apr 21, 2024	U-1583			
	11324741	May 29, 2029	U-1583			
<u>CABOTEGRAVIR - APRETUDE</u>						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	8410103	Apr 28, 2026	DS DP U-3061		M-273	Jan 31, 2025
	8410103	Apr 28, 2026	DS DP U-3348		NPP	Mar 29, 2025
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	7125879	Apr 21, 2025	DS DP U-3348		NPP	Mar 29, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	7125879	Apr 21, 2025	DS DP U-3348		NPP	Mar 29, 2025
	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11298349	Feb 10, 2032	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11253528	Mar 14, 2034	DP			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	>A> 10213400	Mar 15, 2033	U-2499			
	>A> 10213400*PED	Sep 15, 2033				
	>A> 10864181	Mar 15, 2033	U-3017			
	>A> 10864181*PED	Sep 15, 2033				
	>A> 11253494	Mar 15, 2033	U-3323			
	>A> 11253494	Mar 15, 2033	U-3324			
	>A> 11253494*PED	Sep 15, 2033				
	>A> 8731963	Dec 17, 2022	U-1110			
	>A> 8731963*PED	Jun 17, 2023				
	>A> 8772306	Mar 15, 2033	U-1532			
	>A> 8772306	Mar 15, 2033	U-3198			
	>A> 8772306*PED	Sep 15, 2033				
	>A> 9050302	Mar 15, 2033	U-1532			
	>A> 9050302*PED	Sep 15, 2033				
	>A> 9486426	Mar 15, 2033	U-1532			
	>A> 9486426*PED	Sep 15, 2033				
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
<u>CARBDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	RE48960	Jun 28, 2025	DS DP U-3087			
	RE48960	Jun 28, 2025	DS DP U-3088			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10420841	Mar 14, 2034	U-1672		NPP	Apr 21, 2025
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			
	8968753	Mar 14, 2034	U-3361			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	11246863	Nov 27, 2038	DP			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2023	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11207332	Nov 20, 2028	DP U-3280			
	>A> 8865690	Jul 24, 2023	U-2942			
	>A> 9211295	Jul 24, 2023	DP			
	>A> 9433628	Feb 28, 2029	DP			
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP GAIN	Dec 07, 2024 Dec 07, 2029
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - CLINDAMYCIN PHOSPHATE AND TRETINOIN</u>						
A 212845 001					CGT	Oct 09, 2022
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11254649	Jun 30, 2036	DS DP U-1776			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 003	10993952	Feb 15, 2036	DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001					>A> M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002					>A> M-238	Feb 22, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003					>A> M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004					>A> M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005					>A> M-238	Feb 22, 2022
<u>DAPSONE - ACZONE</u>						
N 207154 001	11273132	Nov 18, 2033	DP			
<u>DAPTOMYCIN - DAPZURA RT</u>						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11168058	Feb 27, 2038	DS DP			
<u>DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8501238	Dec 19, 2028	DS DP U-1636			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	>A> 11357731	Oct 25, 2038	U-3083			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11236328	Jun 22, 2032	U-3301			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Jun 19, 2031	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7728143	Jun 19, 2031	DS			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	>A> 11357772	Mar 07, 2036	U-1995			
	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	>A> 11357772	Mar 07, 2036	U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	>A> 11357772	Mar 07, 2036	U-3055			
	>A> 11357772*PED	Sep 07, 2036				
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	11304961	Dec 18, 2037	DP U-3344			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	11241414	Mar 27, 2029	DP			
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976 001	>A> 11344520	Feb 20, 2035	U-3393			
	>A> 11351133	Feb 20, 2035	U-3393			
<u>DIGOXIN - DIGOXIN</u>						
A 214982 001					CGT	Aug 16, 2022
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436 001	11266799	Nov 05, 2036	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	11246850	Nov 16, 2035	U-1384			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	11246850	Nov 16, 2035	U-1384			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	11234985	Jan 24, 2031	DP U-257			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
<u>DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE</u>						
A 213796 001					CGT	Oct 29, 2022
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	11234954	Jan 18, 2028	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	11234954	Jan 18, 2028	U-620			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	11253472	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	11202772	Apr 13, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	11312718	Jan 10, 2032	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	11312718	Jan 10, 2032	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	10987341	Nov 01, 2039	DP		>A> NP	May 12, 2025
	11241416	Nov 01, 2039	DP			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11213519	Jan 03, 2028	U-2720			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	>A> 11344551	Mar 14, 2034	U-3388			
	>A> 11344551	Mar 14, 2034	U-3389			
<u>ELBASVIR; GRAZOPREVIR - ZEPATIER</u>						
N 208261 001					NPP	Dec 09, 2024
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034	U-2292		M-82	Feb 24, 2025
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	>A> 7390791	Apr 17, 2025	DS DP			
	>A> 7390791*PED	Oct 17, 2025				
	>A> 8754065	Aug 15, 2032	DS DP U-1663			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 9296769	Aug 15, 2032	DS DP U-1663			
	>A> 9296769*PED	Feb 15, 2033				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11173141	Mar 25, 2036	DP			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	9474754	Aug 05, 2033	U-2802			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	11253515	Jul 18, 2038	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	11253515	Jul 18, 2038	DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11241400	May 16, 2040	U-3183			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	10869845	Jan 22, 2040	DP			
<u>EPINEPHRINE - SYMJEPI</u>						
N 207534 001 >A>	11141540	Oct 20, 2036	DP U-3379			
<u>EPINEPHRINE - SYMJEPI</u>						
N 207534 002 >A>	11141540	Oct 20, 2036	DP U-3379			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVAL</u>						
N 211109 001	10961190	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVAL</u>						
N 211109 002	10961190	Oct 19, 2037	DS			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002					M-275	Sep 17, 2024
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	8785500	Mar 05, 2033	U-2502			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001 >A>	11364247	May 06, 2025	U-2501			
	>A> 11364247	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002 >A>	11364247	May 06, 2025	U-2501			
	>A> 11364247	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003 >A>	11364247	May 06, 2025	U-2501			
	>A> 11364247	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004 >A>	11364247	May 06, 2025	U-2501			
	>A> 11364247	May 06, 2025	U-2831			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10452815	Jun 29, 2038	U-2859		I-887	Mar 25, 2025
	10452815*PED	Dec 29, 2038			NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
	10478441*PED	Nov 03, 2033			PED	Dec 25, 2023
	10478442	May 03, 2033	U-2860		PED	Sep 25, 2025
	10478442*PED	Nov 03, 2033			PED	Dec 25, 2027
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	10950331	Sep 28, 2035	U-3098			
	10950331*PED	Mar 28, 2036				
	11040018	Aug 02, 2037	U-2861			
	11040018	Aug 02, 2037	U-3347			
	11040018*PED	Feb 02, 2038				
	9549909	May 03, 2033	U-2858			
	9549909*PED	Nov 03, 2033				
	9603814	May 03, 2033	U-2858			
	9603814*PED	Nov 03, 2033				
	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			
	9610260*PED	Nov 03, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11291645	Oct 20, 2023	DS DP U-3352			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028		U-3312		
	7754702	Feb 15, 2028		U-3313		
	7754702	Feb 15, 2028		U-3314		
	8895612	Jan 08, 2027		U-3115		
	8895612	Jan 08, 2027		U-3116		
	8895612	Jan 08, 2027		U-3315		
	8895612	Jan 08, 2027		U-3316		
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	11234938	Nov 26, 2034	DP			
<u>FINAFLXACIN - XTORO</u>						
N 206307 001	9993483	Jul 02, 2030	DP			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 004					NPP	Mar 22, 2025
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
>A>	11344685	Sep 26, 2039	DP			
>A>	11344685*PED	Mar 26, 2040				
>A>	11351317	Feb 10, 2038	DP			
>A>	11351317*PED	Aug 10, 2038				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
>A>	11344685	Sep 26, 2039	DP			
>A>	11344685*PED	Mar 26, 2040				
>A>	11351317	Feb 10, 2038	DP			
>A>	11351317*PED	Aug 10, 2038				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
>A>	11344685	Sep 26, 2039	DP			
>A>	11344685*PED	Mar 26, 2040				
>A>	11351317	Feb 10, 2038	DP			
>A>	11351317*PED	Aug 10, 2038				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
>A>	11344685	Sep 26, 2039	DP			
>A>	11344685*PED	Mar 26, 2040				
>A>	11351317	Feb 10, 2038	DP			
>A>	11351317*PED	Aug 10, 2038				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030	DP			
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
>A>	11344685	Sep 26, 2039	DP			
>A>	11344685*PED	Mar 26, 2040				
>A>	11351317	Feb 10, 2038	DP			
>A>	11351317*PED	Aug 10, 2038				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
>A>	11344685	Sep 26, 2039	DP			
>A>	11344685*PED	Mar 26, 2040				
>A>	11351317	Feb 10, 2038	DP			
>A>	11351317*PED	Aug 10, 2038				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
>A>	11344685	Sep 26, 2039	DP			
>A>	11344685*PED	Mar 26, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	>A> 11351317	Feb 10, 2038	DP			
	>A> 11351317*PED	Aug 10, 2038				
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001					D-186	May 02, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11312698	May 23, 2032	DS DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11312698	May 23, 2032	DS DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	RE48898	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	RE48898	Jan 19, 2026	DP			
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828 001					ODE-383 W	Aug 21, 2026 Aug 21, 2026
<u>GALLIUM GA-68 GOZETOTIDE - ILLUCCIX</u>						
N 214032 001	11027031	Jul 28, 2035	U-3317			
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001					>A> NP	Mar 23, 2025
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	10603308	Aug 10, 2037	U-3374		>A> NCE	Jun 01, 2027
	7858609	Oct 03, 2027	DP			
	8022054	Nov 01, 2027	DP			
	8318714	Nov 28, 2026	DP			
	8367651	Nov 28, 2026	DP			
	8618087	Nov 28, 2026	U-3374			
	9029355	Nov 28, 2026	DP			
	9056116	Nov 28, 2026	U-3374			
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	11028392	Oct 03, 2034	DS DP U-2672			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	11246866	Jun 24, 2036	DP			
	11246866*PED	Dec 24, 2036				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	11278683	Aug 16, 2026	DP			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001					NPP	Aug 18, 2024
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	11235168	Jan 04, 2038	U-2250			
	11311620	Dec 19, 2036	U-2250			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE</u>						
A 215586 001					CGT	Oct 09, 2022
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	11304962	May 02, 2036	U-2236			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	11318130	Dec 11, 2029	U-68			
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022	U-3272			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			
	8546143	Apr 23, 2022	DS U-3272			
	8809292	May 10, 2027	DS DP U-3272			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	8828956	Dec 04, 2028	DS DP U-3272			
	9074213	Mar 09, 2022	DS U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
<u>ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE</u>						
A 211290 001					CGT	Jun 20, 2022
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11147770	Feb 27, 2033	DP U-3339			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11147770	Feb 27, 2033	DP U-3339			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11147770	Feb 27, 2033	DP U-3339			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	8846718	Jul 02, 2029	U-1908			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	8846718	Jul 02, 2029	U-2375			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	8846718	Jul 02, 2029	U-2375			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	>A> 10610125	Jun 21, 2030	U-2784			
	>A> 10610125	Jun 21, 2030	U-2785			
	>A> 10610125	Jun 21, 2030	U-3385			
	>A> 10653710	Oct 18, 2036	U-3387			
	>A> 10799490	Mar 13, 2035	DP U-2981			
	>A> 10799490	Mar 13, 2035	DP U-2982			
	>A> 10799490	Mar 13, 2035	DP U-3384			
	>A> 10980788	Jun 07, 2039	U-3112			
	>A> 10980788	Jun 07, 2039	U-3113			
	>A> 10980788	Jun 07, 2039	U-3214			
	>A> 10980788	Jun 07, 2039	U-3383			
	>A> 9474779	Aug 19, 2033	DS DP U-2350			
	>A> 9474779	Aug 19, 2033	DS DP U-2533			
	>A> 9474779	Aug 19, 2033	DS DP U-2534			
	>A> 9474779	Aug 19, 2033	DS DP U-3213			
	>A> 9474779	Aug 19, 2033	DS DP U-3386			
	>A> 9850277	Jan 18, 2033	DS DP U-2350			
	>A> 9850277	Jan 18, 2033	DS DP U-2533			
	>A> 9850277	Jan 18, 2033	DS DP U-2534			
	>A> 9850277	Jan 18, 2033	DS DP U-3213			
	>A> 9850277	Jan 18, 2033	DS DP U-3386			
	>A> 9968595	Mar 13, 2035	DP U-2351			
	>A> 9968595	Mar 13, 2035	DP U-2533			
	>A> 9968595	Mar 13, 2035	DP U-2534			
	>A> 9968595	Mar 13, 2035	DP U-3384			
<u>KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN</u>						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001					NPP	Oct 14, 2024
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 001					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 002					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 003					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 004					PC	Aug 30, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					M-272	Dec 19, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					M-272	Dec 19, 2024
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8357713	Dec 22, 2029	DP U-1801			
	8357713	Dec 22, 2029	DP U-1802			
	8357713	Dec 22, 2029	DP U-1803			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	10098877	Jan 10, 2026	U-3283			
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	11278547	Mar 02, 2040	U-3282			
	9918984	Jan 10, 2026	U-3283			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	10537538	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - ERMEZA</u>						
N 215809 001	9345772	Feb 27, 2035	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	11278623	May 10, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	11311679	Jan 20, 2026	DP			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 004	8999393	Jan 08, 2034	DP U-3210			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	11299500	Oct 04, 2038	DS			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	11299500	Oct 04, 2038	DS			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11219596	May 03, 2033	U-2985			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001	11261447	Nov 20, 2038	DS DP U-2995			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	11318121	Aug 15, 2028	DS DP U-3345			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	11229647	Feb 12, 2040		U-3290	ODE-379	Sep 29, 2028
	11260053	May 26, 2031		U-3290		
<u>MARAVIROC - MARAVIROC</u>						
A 203347 001					PC	Aug 06, 2022
<u>MARAVIROC - MARAVIROC</u>						
A 203347 002					PC	Aug 06, 2022
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					NCE	Nov 23, 2026
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034		U-3373		
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034		U-3373		
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034		U-3373		
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034		U-3373		
<u>MELOXICAM - ANJESO</u>						
N 210583 001	11253478	May 26, 2030	DP U-3318			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	>A> 11344622	Apr 25, 2032		U-3093		
	>A> 6992207	Jun 25, 2023	DS DP U-3093			
<u>MESALAMINE - MESALAMINE</u>						
A 214585 001					CGT	Nov 14, 2022
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	11166947	Jan 25, 2038		U-3299		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	11166947	Jan 25, 2038		U-3299		
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	11166947	Jan 25, 2038		U-3299		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11241391	Mar 23, 2032		U-2357		
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11241391	Mar 23, 2032		U-2357		
	11241392	Mar 23, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001					NP	Jun 19, 2023
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 09, 2028	U-2007			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
	>A> 11357761	May 30, 2028	U-2371			
	>A> 11357762	May 30, 2038	U-2371			
	>A> 11357763	May 30, 2038	U-2371			
	>A> 11357764	May 30, 2038	U-2371			
	>A> 11357765	May 30, 2038	U-2371			
	>A> 11357784	Feb 06, 2039	U-2371			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	10016443	Sep 04, 2034	U-3297		NP	Jan 13, 2025
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP			
	10548907	Sep 04, 2034	U-3297			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			
	9937189	Sep 04, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	11135155	Aug 26, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001	11027072	May 24, 2039	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	10143792	May 24, 2031	U-2476			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11207306	Apr 16, 2038	U-2804			
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11291793	Aug 18, 2025	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Feb 21, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Feb 21, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001 >A>	11338011	Feb 03, 2036	U-2857			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11241425	Aug 23, 2031	U-3137			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11241425	Aug 23, 2031	U-3137			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11241425	Aug 23, 2031	U-3137			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11241425	Aug 23, 2031	U-3137			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<u>OTESECONAZOLE - VIVJOA</u>						
N 215888 001	10414751	Mar 17, 2036	DS DP		NCE	Apr 26, 2027
	11247981	May 09, 2033			GAIN	Apr 26, 2032
	8236962	Apr 22, 2031	DS DP			
	8754227	Apr 22, 2031				
	9840492	Mar 17, 2036	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEO</u>						
N 212520 001	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039	U-2849			
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001	8153632	Jan 17, 2029	DS DP U-3331		NCE	Feb 28, 2027
	8153632	Jan 17, 2029	DS DP U-3332			
	8980873	Mar 25, 2030	DS DP U-3331			
	8980873	Mar 25, 2030	DS DP U-3332			
	9573964	May 05, 2028	U-3331			
	9573964	May 05, 2028	U-3332			
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291			
	9061057	Aug 26, 2033	DS DP U-3291			
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11266750	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11266750	Mar 16, 2037	U-665			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 001					CGT	Oct 30, 2022
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 002					CGT	Oct 30, 2022
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	11285134	Apr 24, 2039	U-3252			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	8383150	May 10, 2028	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8383150	May 10, 2028	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8383150	May 10, 2028	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8383150	May 10, 2028	DP U-2361			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	11319346	Mar 01, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					I-881	Jun 17, 2024
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001					I-881	Jun 17, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11273160	Apr 03, 2039	U-2952			
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	8957054	Jan 08, 2030	U-1922			
<u>RANOLAZINE - ASPRUZYO SPRINKLE</u>						
N 216018 002	10898444	Jan 24, 2038	DP			
<u>REMEDESIVIR - VEKLURY</u>						
N 214787 001	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11247969	Mar 10, 2025	DP			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11266635	Aug 12, 2040	U-3330			
	>A> 11344536	Aug 12, 2040	U-3381			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP PED	Dec 20, 2024 Jun 20, 2025
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11219624	May 20, 2031	DP U-3229			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10335390	Sep 04, 2035	DP U-3270			
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	11311679	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	11311679	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP		NCE	Dec 05, 2022
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP	U-3355		
	8536122	Mar 20, 2026	DS DP	U-3355		
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001 >A>	11318191	Feb 17, 2041	DP	U-3162		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002 >A>	11318191	Feb 17, 2041	DP	U-3162		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003 >A>	11318191	Feb 17, 2041	DP	U-3162		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004 >A>	11318191	Feb 17, 2041	DP	U-3162		
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005 >A>	11318191	Feb 17, 2041	DP	U-3162		
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001					M-274	Mar 01, 2025
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002					M-274	Mar 01, 2025
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 003					M-274	Mar 01, 2025
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001					NP	Mar 22, 2025
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001 >A>	9687506	Dec 24, 2031	DS DP	U-3394		
	>A> 9687506	Dec 24, 2031	DS DP	U-3395		
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001 >A>	10479686	Mar 29, 2031	DS DP	U-3390		
	>A> 9687506	Dec 24, 2031	DS DP	U-3394		
	>A> 9687506	Dec 24, 2031	DS DP	U-3395		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	>A> 10213400	Mar 15, 2033	U-2499			
	>A> 10213400*PED	Sep 15, 2033				
	>A> 10864181	Mar 15, 2033	U-1532			
	>A> 10864181*PED	Sep 15, 2033				
	>A> 11253494	Mar 15, 2033	U-3323			
	>A> 11253494	Mar 15, 2033	U-3324			
	>A> 11253494*PED	Sep 15, 2033				
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	>A> 10479686	Mar 29, 2031	DS DP U-3390			
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001					ODE*	Apr 07, 2024
					PED	Oct 07, 2024
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002					ODE*	Apr 07, 2024
					PED	Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	>A> 11338007	Jun 01, 2037	DP U-2039			
	>A> 11338007	Jun 01, 2037	DP U-2040			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	10266523	Mar 30, 2036	DS DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	9895388	Nov 25, 2033	U-3365			
<u>SUCRALFATE - SUCRALFATE</u>						
A 211884 001					CGT	Sep 11, 2022
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	11337962	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	>A> 11364224	Jan 29, 2036	U-72			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	>A> 11344512	Apr 21, 2028	U-3391			
	>A> 11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	>A> 11344512	Apr 21, 2028	U-3391			
	>A> 11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	>A> 11344512	Apr 21, 2028	U-3391			
	>A> 11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	>A> 11344512	Apr 21, 2028	U-3391			
	>A> 11344512	Apr 21, 2028	U-3392			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	>A> 11344512	Apr 21, 2028	U-3391			
	>A> 11344512	Apr 21, 2028	U-3392			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPINAROF - VTAMA</u>						
N 215272 001	>A> 10195160	May 19, 2036	DP		>A> NCE	May 23, 2027
	>A> 10426743	May 19, 2036	U-2625			
	>A> 10647649	Nov 13, 2038	DS			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	>A> 11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	>A> 11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	11311482	May 11, 2038	U-2368			
<u>TECOVIRIMAT - TPOXX</u>						
N 214518 001	>A> 10576165	Aug 02, 2031	DP		>A> NCE	Jul 13, 2023
	>A> 7737168	May 03, 2027	U-3377			
	>A> 8039504	Jul 23, 2027	DP			
	>A> 8124643	Jun 18, 2024	DS DP			
	>A> 8530509	Jun 18, 2024	DP			
	>A> 8802714	Jun 18, 2024	U-3377			
	>A> 9233097	Aug 02, 2031	DP			
	>A> 9907859	Aug 02, 2031	U-3377			
<u>TEDUGLUTIDE RECOMBINANT - GATEX KIT</u>						
N 203441 001	>A> 7847061	Nov 01, 2025	U-1320		Y	
	>A> 7847061*PED	May 01, 2026				
	>A> 9060992	Nov 01, 2025	U-1320		Y	
	>A> 9060992*PED	May 01, 2026				
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u>						
N 216318 001	11311554	Mar 25, 2039	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
	11311555	Nov 30, 2030	U-1500			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 001					CGT	Aug 25, 2022
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592 002					CGT	Aug 25, 2022
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 001	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 8734394	Feb 24, 2031	DP			
	>A> 9402957	Jun 29, 2031	DP			
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 002	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 8734394	Feb 24, 2031	DP			
	>A> 9402957	Jun 29, 2031	DP			
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 003	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 8734394	Feb 24, 2031	DP			
	>A> 9402957	Jun 29, 2031	DP			
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 004	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 8734394	Feb 24, 2031	DP			
	>A> 9402957	Jun 29, 2031	DP			
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 005	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 8734394	Feb 24, 2031	DP			
	>A> 9402957	Jun 29, 2031	DP			
	>A> 9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 006	>A> 11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	>A> 8734394	Feb 24, 2031	DP			
	>A> 9402957	Jun 29, 2031	DP			
	>A> 9474780	Jan 05, 2036	DS DP U-3378			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2023	DS DP U-3100			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2023	DS DP U-3100			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002					I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 206119 001					PC	Sep 06, 2022
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	>A> 10130685	Aug 23, 2025	DP			
	>A> 10421729	Apr 01, 2035	DP			
	>A> 10716793	May 14, 2027	U-1849			
	>A> 10772883	Jun 11, 2030	DP			
	>A> 9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	>A> 10130685	Aug 23, 2025	DP			
	>A> 10421729	Apr 01, 2035	DP			
	>A> 10716793	May 14, 2027	U-1849			
	>A> 10772883	Jun 11, 2030	DP			
	>A> 9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	>A> 10130685	Aug 23, 2025	DP			
	>A> 10421729	Apr 01, 2035	DP			
	>A> 10716793	May 14, 2027	U-1849			
	>A> 10772883	Jun 11, 2030	DP			
	>A> 9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	>A> 10130685	Aug 23, 2025	DP			
	>A> 10421729	Apr 01, 2035	DP			
	>A> 10716793	May 14, 2027	U-1849			
	>A> 10772883	Jun 11, 2030	DP			
	>A> 9593066	Dec 15, 2028	DS			
	>A> 9604901	Dec 15, 2028	DS			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	11324710	Aug 22, 2038	U-2368			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001	10988436	May 03, 2039	DS		NP	Apr 28, 2025
	11072577	May 03, 2039	U-3370			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001					M-271	Jun 24, 2024
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10995095	Oct 17, 2036	U-3298		I-880	Dec 14, 2024
	8962629	Jan 15, 2031	DS U-3255		I-883	Jan 14, 2025
	8962629	Jan 15, 2031	DS U-3275		I-886	Mar 16, 2025
	8962629	Jan 15, 2031	DS U-3341		I-888	Apr 29, 2025
	8962629	Jan 15, 2031	DS U-3371			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036	U-3298		I-886	Mar 16, 2025
	10730883	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11224598	Oct 19, 2035	U-1900			
<u>VASOPRESSIN - VASOPRESSIN</u>						
A 211538 001					PC	Jul 17, 2022
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	9981006	Jan 30, 2035	U-1857			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036		U-3133		
	11020382	Dec 02, 2036		U-3134		
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034		U-2676		
	9248199	Jan 29, 2034		U-2715		
	9447071	Feb 06, 2035	DS DP			
<u>VUTRISIRAN - AMVUTTRA</u>						
N 215515 001					>A> NCE	Jun 13, 2027
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216249 001					>A> CGT	Dec 24, 2022
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216249 002					>A> CGT	Dec 24, 2022
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004					M-232	Jan 28, 2025

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42ND Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm